|
10KT
Crystal structure of A2A adenosine receptor A2AR-bRIL in complex with Compound50
Deposited 2026-01-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
NA SODIUM ION × 1
A1C5S (4%{S})-2-[(3%{R},6%{S})-1-(1-ethyl-1%{H}-pyrazol-4-yl)-6-methylpiperidin-3-yl]-7-methoxy[1,2,4]triazolo[1,5-%{c}]quinazolin-5-amine × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 17
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 6
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；0.1 M sodium citrate buffer pH 5.0, 0.02-0.04 M Na thiocyanate, 27-30% PEG400, and 2% (v/v) 2, 5-Hexanediol
|
Resolution 2.59 Å
R-free 0.243
|
|
11TD
Structure of human CCR4 in apo state
Deposited 2026-03-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.70 Å
|
|
11TF
Structure of human CCR4 in complex with PRT193
Deposited 2026-03-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1DAO (1R,3r)-3-{(3R)-3-[1-(5-chloro-4-{[(1R)-1-(2,4-dichlorophenyl)ethyl]amino}-6-methylpyrimidin-2-yl)azetidin-3-yl]piperidin-1-yl}-1-methylcyclobutane-1-carboxylic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
11TH
Structure of human CCR4 in complex with FLX475
Deposited 2026-03-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1DAP 2-[(3R)-3-(1-{1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-3-(trifluoromethyl)-1H-pyrazolo[3,4-b]pyrazin-6-yl}azetidin-3-yl)piperidin-1-yl]ethan-1-ol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.50 Å
|
|
11TK
Structure of human CCR4 in complex with AZD2098
Deposited 2026-03-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1DAN 2,3-dichloro-N-(3-methoxypyrazin-2-yl)benzene-1-sulfonamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.54 Å
|
|
11TL
Structure of human CCR4 in complex with GSK2239633A
Deposited 2026-03-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1DAM N-[(3-{[3-(5-chlorothiophene-2-sulfonamido)-4-methoxy-1H-indazol-1-yl]methyl}phenyl)methyl]-2-hydroxy-2-methylpropanamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.90 Å
|
|
1APC
SOLUTION STRUCTURE OF APOCYTOCHROME B562
Deposited 1993-10-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
mmCIF provides none of the parsed conditions
|
Resolution not provided
|
|
1LM3
A Multi-generation Analysis of Cytochrome b562 Redox Variants: Evolutionary Strategies for Modulating Redox Potential Revealed Using a Library Approach
Deposited 2002-04-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain B
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：F61I, F65Y, R106L
Mutation：F61I, F65Y, R106L
|
MG MAGNESIUM ION × 3
HEM PROTOPORPHYRIN IX CONTAINING FE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8.5；302 K；30% polyethylene glycol 4000, 0.1M MgCl2, 0.1M Tris HCl, pH 8.5, VAPOR DIFFUSION, HANGING DROP, temperature 302K
|
Resolution 2.70 Å
R-free 0.333
|
|
1M6T
CRYSTAL STRUCTURE OF B562RIL, A REDESIGNED FOUR HELIX BUNDLE
Deposited 2002-07-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M7W,H102I,R106L
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；298 K；3.2 M NH4(SO4), 2.44 mM N-octanoylsucrose, 0.1 M Bicine, pH 9.0, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 1.81 Å
R-free 0.248
|
|
1QPU
SOLUTION STRUCTURE OF OXIDIZED ESCHERICHIA COLI CYTOCHROME B562
Deposited 1999-05-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
|
SOLUTION NMR
NMR measurement conditions
pH 4.8；298 K；Ionic strength (raw mmCIF value) 500 mM PHOSPHATE；Pressure AMBIENT
NMR measurement conditions
pH 4.8；298 K；Ionic strength (raw mmCIF value) 500 mM PHOSPHATE；Pressure AMBIENT
NMR measurement conditions
pH 4.8；298 K；Ionic strength (raw mmCIF value) 500 mM PHOSPHATE；Pressure AMBIENT
NMR sample composition
3 MM CYTOCHROME B562, 500 MM PHOSPHATE BUFFER, PH 4.8
NMR sample composition
3 MM CYTOCHROME B562 U-15N, 500 MM PHOSPHATE BUFFER, PH 4.8
NMR sample composition
3 MM CYTOCHROME B562, 500 MM PHOSPHATE BUFFER, PH 4.8
|
Resolution not provided
|
|
1QQ3
THE SOLUTION STRUCTURE OF THE HEME BINDING VARIANT ARG98CYS OF OXIDIZED ESCHERICHIA COLI CYTOCHROME B562
Deposited 1999-06-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：R98C
|
HEB HEME B/C × 1
|
SOLUTION NMR
NMR measurement conditions
pH 4.8；298 K；Ionic strength (raw mmCIF value) 500mM PHOSPHATE；Pressure AMBIENT
NMR measurement conditions
pH 4.8；298 K；Ionic strength (raw mmCIF value) 500mM PHOSPHATE；Pressure AMBIENT
NMR sample composition
3MM R98C CYTOCHROME B562; 500MM PHOSPHATE BUFFER; 90% H2O, 10% D2O
NMR sample composition
2.5MM R98C CYTOCHROME B562; 500MM PHOSPHATE BUFFER; 90% H2O, 10% D2O
|
Resolution not provided
|
|
22EM
Gi bound kappa-opioid receptor in complex with beta01
Deposited 2026-01-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain F
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.86 Å
|
|
24XY
P2Y13R-Gq complex bound to ADP
Deposited 2026-03-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–128（106 aa）
|
Mutation：mutation
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
mmCIF provides none of the parsed conditions
|
Resolution 3.00 Å
|
|
24XZ
P2Y14R-Gi complex bound to UDP
Deposited 2026-03-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Mutation：mutation
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
mmCIF provides none of the parsed conditions
|
Resolution 2.93 Å
|
|
256B
IMPROVEMENT OF THE 2.5 ANGSTROMS RESOLUTION MODEL OF CYTOCHROME B562 BY REDETERMINING THE PRIMARY STRUCTURE AND USING MOLECULAR GRAPHICS
Deposited 1990-01-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.40 Å
|
|
256B
IMPROVEMENT OF THE 2.5 ANGSTROMS RESOLUTION MODEL OF CYTOCHROME B562 BY REDETERMINING THE PRIMARY STRUCTURE AND USING MOLECULAR GRAPHICS
Deposited 1990-01-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Not recorded
|
SO4 SULFATE ION × 2
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.40 Å
|
|
25IK
Cryo-EM structure of MasR(FL)-Gq
Deposited 2026-04-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
25–127（103 aa）
|
Mutation：M29W/H124I
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
25IL
Cryo-EM structure of MasR(del2-25)-Gq
Deposited 2026-04-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
25–127（103 aa）
|
Mutation：M29W,H124I
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
28VJ
NorA bound to miniprotein I-23
Deposited 2026-02-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
22–128（107 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.79 Å
|
|
2BC5
Crystal structure of E. coli cytochrome b562 with engineered c-type heme linkages
Deposited 2005-10-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：K59W, R98C, Y101C
|
SO4 SULFATE ION × 1
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；298 K；70% ammonium sulfate, pH 5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.25 Å
R-free 0.277
|
|
2BC5
Crystal structure of E. coli cytochrome b562 with engineered c-type heme linkages
Deposited 2005-10-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 10
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain B
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
|
SO4 SULFATE ION × 4
HEC HEME C × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；298 K；70% ammonium sulfate, pH 5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.25 Å
R-free 0.277
|
|
2BC5
Crystal structure of E. coli cytochrome b562 with engineered c-type heme linkages
Deposited 2005-10-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：K59W, R98C, Y101C
|
SO4 SULFATE ION × 3
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；298 K；70% ammonium sulfate, pH 5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.25 Å
R-free 0.277
|
|
2BC5
Crystal structure of E. coli cytochrome b562 with engineered c-type heme linkages
Deposited 2005-10-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Mutation：K59W, R98C, Y101C
|
SO4 SULFATE ION × 4
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；298 K；70% ammonium sulfate, pH 5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.25 Å
R-free 0.277
|
|
2BC5
Crystal structure of E. coli cytochrome b562 with engineered c-type heme linkages
Deposited 2005-10-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
23–128（106 aa）
|
Mutation：K59W, R98C, Y101C
|
SO4 SULFATE ION × 1
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；298 K；70% ammonium sulfate, pH 5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.25 Å
R-free 0.277
|
|
2BC5
Crystal structure of E. coli cytochrome b562 with engineered c-type heme linkages
Deposited 2005-10-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
|
SO4 SULFATE ION × 9
HEC HEME C × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；298 K；70% ammonium sulfate, pH 5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.25 Å
R-free 0.277
|
|
2BC5
Crystal structure of E. coli cytochrome b562 with engineered c-type heme linkages
Deposited 2005-10-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
|
SO4 SULFATE ION × 9
HEC HEME C × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；298 K；70% ammonium sulfate, pH 5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.25 Å
R-free 0.277
|
|
2BC5
Crystal structure of E. coli cytochrome b562 with engineered c-type heme linkages
Deposited 2005-10-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 7
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
|
SO4 SULFATE ION × 9
HEC HEME C × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；298 K；70% ammonium sulfate, pH 5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.25 Å
R-free 0.277
|
|
2BC5
Crystal structure of E. coli cytochrome b562 with engineered c-type heme linkages
Deposited 2005-10-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 8
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
|
SO4 SULFATE ION × 9
HEC HEME C × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；298 K；70% ammonium sulfate, pH 5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.25 Å
R-free 0.277
|
|
2BC5
Crystal structure of E. coli cytochrome b562 with engineered c-type heme linkages
Deposited 2005-10-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 9
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：K59W, R98C, Y101C
Mutation：K59W, R98C, Y101C
|
SO4 SULFATE ION × 5
HEC HEME C × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；298 K；70% ammonium sulfate, pH 5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.25 Å
R-free 0.277
|
|
2QLA
Crystal Structure of a 16-Helix Bundle Architecture Produced by the Zinc-Mediated Self Assembly of Four Cytochrome cb562 Molecules
Deposited 2007-07-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：K59H, D73H, K77H, R98C, Y101C
Mutation：K59H, D73H, K77H, R98C, Y101C
Mutation：K59H, D73H, K77H, R98C, Y101C
Mutation：K59H, D73H, K77H, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；100mM Tris, 1.25 mM ZnCl2, 25% PEG 3350, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.90 Å
R-free 0.295
|
|
3C62
Tetrameric Cytochrome cb562 (H59/D62/H63/H73/A74/H77) Assembly Stabilized by Interprotein Zinc Coordination
Deposited 2008-02-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：K59H, R62D, D73H, D74A, K77H, R98C, Y101C
Mutation：K59H, R62D, D73H, D74A, K77H, R98C, Y101C
Mutation：K59H, R62D, D73H, D74A, K77H, R98C, Y101C
Mutation：K59H, R62D, D73H, D74A, K77H, R98C, Y101C
|
ZN ZINC ION × 4
CA CALCIUM ION × 5
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；11% PEG 400, 100 mM CaCl2, 100 mM TRIS, 2 mM ZnCl2,
pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.87 Å
R-free 0.273
|
|
3C63
Tetrameric Cytochrome cb562 (K34/H59/D62/H63/H73/A74/H77) Assembly Stabilized by Interprotein Zinc Coordination
Deposited 2008-02-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R34K, K59H, R62D, D73H, D74A, K77H, R98C, Y101C
Mutation：R34K, K59H, R62D, D73H, D74A, K77H, R98C, Y101C
Mutation：R34K, K59H, R62D, D73H, D74A, K77H, R98C, Y101C
Mutation：R34K, K59H, R62D, D73H, D74A, K77H, R98C, Y101C
|
ZN ZINC ION × 4
CA CALCIUM ION × 5
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；12% PEG 400, 200 mM CaCl2, 100 mM TRIS, 1.25 mM ZnCl2,
pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.75 Å
R-free 0.247
|
|
3DE8
Crystal Structure of a Dimeric Cytochrome cb562 Assembly Induced by Copper Coordination
Deposited 2008-06-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：K59H, D73H, K77H, R98C, Y101C
Mutation：K59H, D73H, K77H, R98C, Y101C
Mutation：K59H, D73H, K77H, R98C, Y101C
Mutation：K59H, D73H, K77H, R98C, Y101C
|
CU COPPER (II) ION × 4
CA CALCIUM ION × 6
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；100 mM Hepes, 25% PEG 3350, 200 mM CaCl2, 17.8 mM CuSO4, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.72 Å
R-free 0.244
|
|
3DE8
Crystal Structure of a Dimeric Cytochrome cb562 Assembly Induced by Copper Coordination
Deposited 2008-06-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：K59H, D73H, K77H, R98C, Y101C
Mutation：K59H, D73H, K77H, R98C, Y101C
|
CU COPPER (II) ION × 2
CA CALCIUM ION × 3
HEM PROTOPORPHYRIN IX CONTAINING FE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；100 mM Hepes, 25% PEG 3350, 200 mM CaCl2, 17.8 mM CuSO4, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.72 Å
R-free 0.244
|
|
3DE8
Crystal Structure of a Dimeric Cytochrome cb562 Assembly Induced by Copper Coordination
Deposited 2008-06-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：K59H, D73H, K77H, R98C, Y101C
Mutation：K59H, D73H, K77H, R98C, Y101C
|
CU COPPER (II) ION × 2
CA CALCIUM ION × 3
HEM PROTOPORPHYRIN IX CONTAINING FE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；100 mM Hepes, 25% PEG 3350, 200 mM CaCl2, 17.8 mM CuSO4, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.72 Å
R-free 0.244
|
|
3DE9
Crystal Structure of a Trimeric Cytochrome cb562 Assembly Induced by Nickel Coordination
Deposited 2008-06-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
|
Mutation：K59H, D73H, K77H, R98C, Y101C
|
NI NICKEL (II) ION × 9
HEM PROTOPORPHYRIN IX CONTAINING FE × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 23% PEG 4000, 4.16 mM NiSO4, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.04 Å
R-free 0.278
|
|
3FOO
A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Monoclinic Form
Deposited 2008-12-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 3
PXX N-1,10-phenanthrolin-5-ylacetamide × 3
NI NICKEL (II) ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；25% PEG2000, 0.2 M NaCl, 0.1 M TRIS, 3.3 mM NiCl2, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.268
|
|
3FOO
A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Monoclinic Form
Deposited 2008-12-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
Chain F
23–128（106 aa）
|
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 3
PXX N-1,10-phenanthrolin-5-ylacetamide × 3
NI NICKEL (II) ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；25% PEG2000, 0.2 M NaCl, 0.1 M TRIS, 3.3 mM NiCl2, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.268
|
|
3FOO
A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Monoclinic Form
Deposited 2008-12-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain G
23–128（106 aa）
Chain H
23–128（106 aa）
Chain I
23–128（106 aa）
|
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 3
PXX N-1,10-phenanthrolin-5-ylacetamide × 3
NI NICKEL (II) ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；25% PEG2000, 0.2 M NaCl, 0.1 M TRIS, 3.3 mM NiCl2, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.268
|
|
3FOO
A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Monoclinic Form
Deposited 2008-12-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain J
23–128（106 aa）
Chain K
23–128（106 aa）
Chain L
23–128（106 aa）
|
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 3
PXX N-1,10-phenanthrolin-5-ylacetamide × 3
NI NICKEL (II) ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；25% PEG2000, 0.2 M NaCl, 0.1 M TRIS, 3.3 mM NiCl2, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.40 Å
R-free 0.268
|
|
3FOP
A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Hexagonal Form
Deposited 2008-12-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
NI NICKEL (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；25% PEG2000, 0.2 M MgCl2, 0.1 M TRIS, 3.3 mM NiCl2, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.00 Å
R-free 0.277
|
|
3FOP
A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Hexagonal Form
Deposited 2008-12-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
NI NICKEL (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；25% PEG2000, 0.2 M MgCl2, 0.1 M TRIS, 3.3 mM NiCl2, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.00 Å
R-free 0.277
|
|
3FOP
A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Hexagonal Form
Deposited 2008-12-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
Mutation：K59C, R62A, H63A, K77H, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 3
PXX N-1,10-phenanthrolin-5-ylacetamide × 3
NI NICKEL (II) ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；25% PEG2000, 0.2 M MgCl2, 0.1 M TRIS, 3.3 mM NiCl2, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 3.00 Å
R-free 0.277
|
|
3HNI
Crystal structure of the Zn-induced tetramer of the engineered cyt cb562 variant RIDC-1
Deposited 2009-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；100 mM HEPES, 30% Jeffamine ED-2001, 1.5 mM zinc chloride, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.35 Å
R-free 0.278
|
|
3HNI
Crystal structure of the Zn-induced tetramer of the engineered cyt cb562 variant RIDC-1
Deposited 2009-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain E
23–128（106 aa）
Chain F
23–128（106 aa）
Chain G
23–128（106 aa）
Chain H
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；100 mM HEPES, 30% Jeffamine ED-2001, 1.5 mM zinc chloride, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.35 Å
R-free 0.278
|
|
3HNJ
Crystal structure of the Zn-induced tetramer of the engineered cyt cb562 variant RIDC-2
Deposited 2009-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, D66W, I67L, V69I, Q71A, A89K, Q93L, T96A, T97I
Mutation：R34A, L38A, Q41W, K42S, D66W, I67L, V69I, Q71A, A89K, Q93L, T96A, T97I
Mutation：R34A, L38A, Q41W, K42S, D66W, I67L, V69I, Q71A, A89K, Q93L, T96A, T97I
Mutation：R34A, L38A, Q41W, K42S, D66W, I67L, V69I, Q71A, A89K, Q93L, T96A, T97I
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；100 mM BIS-TRIS, 25% PEG 3350, 3.4 mM zinc chloride, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.00 Å
R-free 0.272
|
|
3HNK
Crystal structure of the dimeric assembly of the cyt cb562 variant RIDC-1
Deposited 2009-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；26% PEG 2000, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.10 Å
R-free 0.271
|
|
3HNK
Crystal structure of the dimeric assembly of the cyt cb562 variant RIDC-1
Deposited 2009-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；26% PEG 2000, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.10 Å
R-free 0.271
|
|
3HNK
Crystal structure of the dimeric assembly of the cyt cb562 variant RIDC-1
Deposited 2009-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；26% PEG 2000, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.10 Å
R-free 0.271
|
|
3HNL
Crystal structure of the Cu-induced dimer of the engineered cyt cb562 variant RIDC-1
Deposited 2009-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 2
CU COPPER (II) ION × 2
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；100 mM HEPES, 200 mM sodium chloride, 25% PEG 3350, 10.7 mM copper sulfate, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.20 Å
R-free 0.270
|
|
3HNL
Crystal structure of the Cu-induced dimer of the engineered cyt cb562 variant RIDC-1
Deposited 2009-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
Mutation：R34A, L38A, Q41W, K42S, D66W, V69I
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
CU COPPER (II) ION × 4
CL CHLORIDE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；100 mM HEPES, 200 mM sodium chloride, 25% PEG 3350, 10.7 mM copper sulfate, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.20 Å
R-free 0.270
|
|
3IQ5
Crystal structure of an engineered metal-free tetrameric cytochrome cb562 complex templated by Zn-coordination
Deposited 2009-08-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；25% PEG 400, 0.1M Bis-Tris, 0.15M Sodium chloride, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.05 Å
R-free 0.277
|
|
3IQ5
Crystal structure of an engineered metal-free tetrameric cytochrome cb562 complex templated by Zn-coordination
Deposited 2009-08-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain B
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；25% PEG 400, 0.1M Bis-Tris, 0.15M Sodium chloride, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.05 Å
R-free 0.277
|
|
3IQ6
Crystal structure of a tetrameric Zn-bound cytochrome cb562 complex with covalently and non-covalently stabilized interfaces
Deposited 2009-08-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；20% PEG 2000, 0.1M HEPES, 0.15 M Sodium chloride, 1.15 mM Zinc chloride, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.35 Å
R-free 0.296
|
|
3IQ6
Crystal structure of a tetrameric Zn-bound cytochrome cb562 complex with covalently and non-covalently stabilized interfaces
Deposited 2009-08-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain E
23–128（106 aa）
Chain F
23–128（106 aa）
Chain G
23–128（106 aa）
Chain H
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；20% PEG 2000, 0.1M HEPES, 0.15 M Sodium chloride, 1.15 mM Zinc chloride, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.35 Å
R-free 0.296
|
|
3L1M
Crystal Structure of a Ni-directed Dimer of Cytochrome cb562 with a Quinolate-Histidine Hybrid Coordination Motif
Deposited 2009-12-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Fragment：residues 23-128
|
Mutation：K59W, G70C, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 2
HQI N-(8-hydroxyquinolin-5-yl)acetamide × 2
NI NICKEL (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 25% PEG 1500, 1.05 mM nickel(II) sulfate, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.30 Å
R-free 0.314
|
|
3L1M
Crystal Structure of a Ni-directed Dimer of Cytochrome cb562 with a Quinolate-Histidine Hybrid Coordination Motif
Deposited 2009-12-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
Fragment：residues 23-128
|
Mutation：K59W, G70C, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
HQI N-(8-hydroxyquinolin-5-yl)acetamide × 1
NI NICKEL (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；100 mM Tris, 25% PEG 1500, 1.05 mM nickel(II) sulfate, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.30 Å
R-free 0.314
|
|
3M15
A Zn-mediated asymmetric trimer of a cytochrome cb562 variant (D74A-RIDC1)
Deposited 2010-03-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, D74A, K77H, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, D74A, K77H, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, D74A, K77H, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 3
ZN ZINC ION × 2
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.60 Å
R-free 0.313
|
|
3M4B
A Zn-mediated tetrahedral protein lattice cage
Deposited 2010-03-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 12
PDB declaration: dodecameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, I67C, V69I, D73H, D74A, K77H, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, I67C, V69I, D73H, D74A, K77H, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, I67C, V69I, D73H, D74A, K77H, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, I67C, V69I, D73H, D74A, K77H, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 12
ACT ACETATE ION × 12
ZN ZINC ION × 36
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；25% PEG 1500, 0.1 M Bis-Tris, 0.2 M CaCl2 and 5 mM ZnCl2., pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.50 Å
R-free 0.256
|
|
3M4C
A Zn-mediated tetrahedral protein lattice cage encapsulating a microperoxidase
Deposited 2010-03-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 15
PDB declaration: pentadecameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, I67C, V69I, D73H, D74A, K77H, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, I67C, V69I, D73H, D74A, K77H, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, I67C, V69I, D73H, D74A, K77H, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, I67C, V69I, D73H, D74A, K77H, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 15
ACT ACETATE ION × 12
ZN ZINC ION × 30
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；12% PEG 1900 MME , 0.1 M HEPES pH 7.5 , 0.2 M NaCl, 2 mM ZnCl2, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.90 Å
R-free 0.223
|
|
3M79
A tetrameric Zn-bound cytochrome cb562 complex with covalently and non-covalently stabilized interfaces crystallized in the presence of Cu(II) and Zn(II)
Deposited 2010-03-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.10 Å
R-free 0.271
|
|
3M79
A tetrameric Zn-bound cytochrome cb562 complex with covalently and non-covalently stabilized interfaces crystallized in the presence of Cu(II) and Zn(II)
Deposited 2010-03-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain E
23–128（106 aa）
Chain F
23–128（106 aa）
Chain G
23–128（106 aa）
Chain H
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.10 Å
R-free 0.271
|
|
3NMI
Crystal structure of the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；2.8 M sodium acetate, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.01 Å
R-free 0.235
|
|
3NMI
Crystal structure of the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；2.8 M sodium acetate, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.01 Å
R-free 0.235
|
|
3NMI
Crystal structure of the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；2.8 M sodium acetate, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.01 Å
R-free 0.235
|
|
3NMI
Crystal structure of the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；2.8 M sodium acetate, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.01 Å
R-free 0.235
|
|
3NMI
Crystal structure of the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain E
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
ACT ACETATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；2.8 M sodium acetate, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.01 Å
R-free 0.235
|
|
3NMI
Crystal structure of the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain F
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；2.8 M sodium acetate, pH 7, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.01 Å
R-free 0.235
|
|
3NMJ
Crystal structure of a nickel mediated dimer for the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；30% PEG 400, 0.1 M Tris, 0.2 ammonium sulfate, 6.2 mM nickel sulfate, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 3.10 Å
R-free 0.238
|
|
3NMJ
Crystal structure of a nickel mediated dimer for the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
NI NICKEL (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；30% PEG 400, 0.1 M Tris, 0.2 ammonium sulfate, 6.2 mM nickel sulfate, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 3.10 Å
R-free 0.238
|
|
3NMJ
Crystal structure of a nickel mediated dimer for the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
NI NICKEL (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；30% PEG 400, 0.1 M Tris, 0.2 ammonium sulfate, 6.2 mM nickel sulfate, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 3.10 Å
R-free 0.238
|
|
3NMJ
Crystal structure of a nickel mediated dimer for the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；30% PEG 400, 0.1 M Tris, 0.2 ammonium sulfate, 6.2 mM nickel sulfate, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 3.10 Å
R-free 0.238
|
|
3NMK
Crystal structure of a zinc mediated dimer for the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；0.1 M Tris, 0.2 M ammonium sulfate, 30% PEG 400, 12.4 mM zinc chloride, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å
R-free 0.233
|
|
3NMK
Crystal structure of a zinc mediated dimer for the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；0.1 M Tris, 0.2 M ammonium sulfate, 30% PEG 400, 12.4 mM zinc chloride, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å
R-free 0.233
|
|
3NMK
Crystal structure of a zinc mediated dimer for the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；0.1 M Tris, 0.2 M ammonium sulfate, 30% PEG 400, 12.4 mM zinc chloride, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å
R-free 0.233
|
|
3NMK
Crystal structure of a zinc mediated dimer for the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2
Deposited 2010-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
23–128（106 aa）
|
Mutation：W59C, R62A, H63A, D66A, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
PXX N-1,10-phenanthrolin-5-ylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；0.1 M Tris, 0.2 M ammonium sulfate, 30% PEG 400, 12.4 mM zinc chloride, pH 8.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å
R-free 0.233
|
|
3TOL
Crystal structure of an engineered cytochrome cb562 that forms 1D, Zn-mediated coordination polymers
Deposited 2011-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Fragment：Soluble cytochrome b562
Chain B
23–128（106 aa）
Fragment：Soluble cytochrome b562
|
Mutation：D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
Mutation：D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 2
ZN ZINC ION × 2
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；20% PEG 3350, 2.1 mM ZnCl2, 20mM CaCl2 and 100 mM BISTRIS, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.00 Å
R-free 0.245
|
|
3TOL
Crystal structure of an engineered cytochrome cb562 that forms 1D, Zn-mediated coordination polymers
Deposited 2011-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain C
23–128（106 aa）
Fragment：Soluble cytochrome b562
Chain D
23–128（106 aa）
Fragment：Soluble cytochrome b562
|
Mutation：D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
Mutation：D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 2
ZN ZINC ION × 2
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；20% PEG 3350, 2.1 mM ZnCl2, 20mM CaCl2 and 100 mM BISTRIS, pH 6.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.00 Å
R-free 0.245
|
|
3TOM
Crystal structure of an engineered cytochrome cb562 that forms 2D, Zn-mediated sheets
Deposited 2011-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain C
23–128（106 aa）
Fragment：Soluble cytochrome b562
Chain D
23–128（106 aa）
Fragment：Soluble cytochrome b562
|
Mutation：D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
Mutation：D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 2
ZN ZINC ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6；298 K；8 mM ZnCl2 and 200 mM BISTRIS, pH 6, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.30 Å
R-free 0.286
|
|
3TOM
Crystal structure of an engineered cytochrome cb562 that forms 2D, Zn-mediated sheets
Deposited 2011-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Fragment：Soluble cytochrome b562
Chain B
23–128（106 aa）
Fragment：Soluble cytochrome b562
|
Mutation：D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
Mutation：D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 2
ZN ZINC ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6；298 K；8 mM ZnCl2 and 200 mM BISTRIS, pH 6, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.30 Å
R-free 0.286
|
|
3TOM
Crystal structure of an engineered cytochrome cb562 that forms 2D, Zn-mediated sheets
Deposited 2011-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Fragment：Soluble cytochrome b562
Chain B
23–128（106 aa）
Fragment：Soluble cytochrome b562
Chain C
23–128（106 aa）
Fragment：Soluble cytochrome b562
Chain D
23–128（106 aa）
Fragment：Soluble cytochrome b562
|
Mutation：D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
Mutation：D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
Mutation：D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
Mutation：D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6；298 K；8 mM ZnCl2 and 200 mM BISTRIS, pH 6, VAPOR DIFFUSION, temperature 298K
|
Resolution 2.30 Å
R-free 0.286
|
|
3U8P
Cytochrome b562 integral fusion with EGFP
Deposited 2011-10-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：F64L
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.4；0.1 M MES/NAOH, PH 6.4, 200 MM magnesium acetate and 20% (W/V) PEG 8000; for cryoprotection 16% glycerol was added to the reservoir buffer, VAPOR DIFFUSION
|
Resolution 2.75 Å
R-free 0.242
|
|
3U8P
Cytochrome b562 integral fusion with EGFP
Deposited 2011-10-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：F64L
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.4；0.1 M MES/NAOH, PH 6.4, 200 MM magnesium acetate and 20% (W/V) PEG 8000; for cryoprotection 16% glycerol was added to the reservoir buffer, VAPOR DIFFUSION
|
Resolution 2.75 Å
R-free 0.242
|
|
3U8P
Cytochrome b562 integral fusion with EGFP
Deposited 2011-10-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Mutation：F64L
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 6.4；0.1 M MES/NAOH, PH 6.4, 200 MM magnesium acetate and 20% (W/V) PEG 8000; for cryoprotection 16% glycerol was added to the reservoir buffer, VAPOR DIFFUSION
|
Resolution 2.75 Å
R-free 0.242
|
|
4EA3
Structure of the N/OFQ Opioid Receptor in Complex with a Peptide Mimetic
Deposited 2012-03-22
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：M29W, H124I, K128L
Mutation：M29W, H124I, K128L
|
0NN 1-benzyl-N-[3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)propyl]-D-prolinamide × 2
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
OLA OLEIC ACID × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipidic Cubic Phase (LCP)；pH 6.4；293 K；25-30% (v/v) PEG 400,
100 to 200 mM potassium sodium tartrate tetrahydrate,
100 mM BIS-TRIS propane pH 6.4 , Lipidic Cubic Phase (LCP), temperature 293K
|
Resolution 3.01 Å
R-free 0.288
|
|
4EA3
Structure of the N/OFQ Opioid Receptor in Complex with a Peptide Mimetic
Deposited 2012-03-22
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：M29W, H124I, K128L
Mutation：M29W, H124I, K128L
|
0NN 1-benzyl-N-[3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)propyl]-D-prolinamide × 2
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
OLA OLEIC ACID × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipidic Cubic Phase (LCP)；pH 6.4；293 K；25-30% (v/v) PEG 400,
100 to 200 mM potassium sodium tartrate tetrahydrate,
100 mM BIS-TRIS propane pH 6.4 , Lipidic Cubic Phase (LCP), temperature 293K
|
Resolution 3.01 Å
R-free 0.288
|
|
4EA3
Structure of the N/OFQ Opioid Receptor in Complex with a Peptide Mimetic
Deposited 2012-03-22
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：M29W, H124I, K128L
Mutation：M29W, H124I, K128L
|
0NN 1-benzyl-N-[3-(1'H,3H-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)propyl]-D-prolinamide × 2
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
OLA OLEIC ACID × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipidic Cubic Phase (LCP)；pH 6.4；293 K；25-30% (v/v) PEG 400,
100 to 200 mM potassium sodium tartrate tetrahydrate,
100 mM BIS-TRIS propane pH 6.4 , Lipidic Cubic Phase (LCP), temperature 293K
|
Resolution 3.01 Å
R-free 0.288
|
|
4EIY
Crystal structure of the chimeric protein of A2aAR-BRIL in complex with ZM241385 at 1.8A resolution
Deposited 2012-04-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M215W, H310I, R314L
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 16
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 6
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5；293 K；25-28% (v/v) PEG 400, 0.04-0.06M sodium thiocyanate, 2% (v/v) 2,5-hexanediol, 100mM sodium citrate, pH 5.0, Lipid Cubic Phase (LCP), temperature 293K
|
Resolution 1.80 Å
R-free 0.213
|
|
4IAQ
Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with dihydroergotamine (PSI Community Target)
Deposited 2012-12-07
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
|
Mutation：L138W, M29W, H124I, R128L
|
2GM Dihydroergotamine × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipid Cubic Phase (LCP)；pH 8.7；293 K；100 mM Tris pH 8.7, 32-36% (v/v) PEG400, 90 mM sodium citrate tribasic dihydrate, 120 mM ammonium sulfate
, Lipid Cubic Phase (LCP), temperature 293K
|
Resolution 2.80 Å
R-free 0.257
|
|
4IAR
Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with ergotamine (PSI Community Target)
Deposited 2012-12-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：L138W, M29W, H124I, R128L
|
ERM Ergotamine × 1
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipid Cubic Phase (LCP)；pH 7.5；293 K；100 mM Tris pH 7.5, 30% (v/v) PEG400, 400 mM lithium chloride
, Lipid Cubic Phase (LCP), temperature 293K
|
Resolution 2.70 Å
R-free 0.261
|
|
4IB4
Crystal structure of the chimeric protein of 5-HT2B-BRIL in complex with ergotamine
Deposited 2012-12-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M144W, M29W, H124I, R128L
|
ERM Ergotamine × 1
PLM PALMITIC ACID × 1
CLR CHOLESTEROL × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
OLA OLEIC ACID × 2
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipid Cubic Phase (LCP)；pH 8；293 K；100 mM Tris/HCl pH 8.0, 100 mM magnesium sulfate and 30% (v/v) PEG400, Lipid Cubic Phase (LCP) , temperature 293K
|
Resolution 2.70 Å
R-free 0.266
|
|
4JE9
Crystal structure of an engineered metal-free RIDC1 construct with four interfacial disulfide bonds
Deposited 2013-02-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Fragment：UNP residues 23-128
Chain B
23–128（106 aa）
Fragment：UNP residues 23-128
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, E81C, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, E81C, T96C, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；293 K；30% methyl-pentanediol, 0.1M Tris pH 8.5, 0.2M sodium chloride, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.12 Å
R-free 0.302
|
|
4JEA
Crystal structure of an engineered Zn-RIDC1 construct with four interfacial disulfide bonds
Deposited 2013-02-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Fragment：UNP residues 23-128
Chain B
23–128（106 aa）
Fragment：UNP residues 23-128
Chain C
23–128（106 aa）
Fragment：UNP residues 23-128
Chain D
23–128（106 aa）
Fragment：UNP residues 23-128
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, E81C, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, E81C, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, E81C, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, E81C, T96C, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 4
SO4 SULFATE ION × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5；293 K；35% methyl-pentanediol, 0.1M Tris pH 8.5, 0.2M ammonium sulfate, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.22 Å
R-free 0.179
|
|
4JEB
Crystal structure of an engineered RIDC1 tetramer with four interfacial disulfide bonds and four three-coordinate Zn(II) sites
Deposited 2013-02-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Fragment：UNP residues 23-128
Chain B
23–128（106 aa）
Fragment：UNP residues 23-128
|
Mutation：R34A, L38A, Q41W, K42S, K59A, D66W, V69I, D73H, D74A, K77H, E81C, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59A, D66W, V69I, D73H, D74A, K77H, E81C, T96C, R98C, Y101C
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；35% methyl-pentandiol, 0.1M HEPES pH 7.5, 0.2M NaCl, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.30 Å
R-free 0.309
|
|
4JKV
Structure of the human smoothened 7TM receptor in complex with an antitumor agent
Deposited 2013-03-11
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
Fragment：BRIL
Chain B
23–127（105 aa）
Fragment：BRIL
|
Mutation：M7W, H101I, R107L
Mutation：M7W, H101I, R107L
|
1KS 4-fluoro-N-methyl-N-{1-[4-(1-methyl-1H-pyrazol-5-yl)phthalazin-1-yl]piperidin-4-yl}-2-(trifluoromethyl)benzamide × 2
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 5
OLA OLEIC ACID × 3
PEG DI(HYDROXYETHYL)ETHER × 2
PGE TRIETHYLENE GLYCOL × 1
PG4 TETRAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipidic Cubic Phase (LCP)；pH 7.8；293 K；100 mM HEPES, pH 7.8, 70 mM ammonium fluoride, 32% (v/v) PEG400, 4% 8% (v/v) P400, Lipidic Cubic Phase (LCP), temperature 293K
|
Resolution 2.45 Å
R-free 0.231
|
|
4L6R
Structure of the class B human glucagon G protein coupled receptor
Deposited 2013-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
Fragment：UNP residues 23-128 and 123-434
|
Mutation：M7W, H102I, R106L
|
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6；293 K；100 mM MES pH 6.0, 140-200 mM NaK tartrate tetrahydrate, 9-17% (v/v) PEG 400, 0.35-0.55% (v/v) Jeffamine M-600 pH 7.0, 200 uM NNC0640, Lipidic Cubic Phase (LCP), temperature 293K
|
Resolution 3.30 Å
R-free 0.339
|
|
4N6H
1.8 A Structure of the human delta opioid 7TM receptor (PSI Community Target)
Deposited 2013-10-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
Fragment：UNP P0ABE7 residues 23-128, UNP P41143 residues 36-338
|
Mutation：M1007W, H1102I, R1106L, P37S
|
OLA OLEIC ACID × 12
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 5
PGE TRIETHYLENE GLYCOL × 3
TLA L(+)-TARTARIC ACID × 1
EJ4 (4bS,8R,8aS,14bR)-7-(cyclopropylmethyl)-5,6,7,8,14,14b-hexahydro-4,8-methano[1]benzofuro[2,3-a]pyrido[4,3-b]carbazole-1,8a(9H)-diol × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LCP；293 K；31-34% (v/v) PEG 400, 0.095 to 0.12 M K/Na tartrate, 5% (v/v) ethylene glycol, 100 mM MES buffer at pH 6.1-6.2, LCP, temperature 293K
|
Resolution 1.80 Å
R-free 0.190
|
|
4NC3
Crystal structure of the 5-HT2B receptor solved using serial femtosecond crystallography in lipidic cubic phase.
Deposited 2013-10-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
Fragment：BRIL
|
Mutation：M7W
|
PLM PALMITIC ACID × 1
ERM Ergotamine × 1
CLR CHOLESTEROL × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 4
PEG DI(HYDROXYETHYL)ETHER × 1
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
OLA OLEIC ACID × 3
DGA DIACYL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipidic Cubic Phase (LCP)；pH 8；293 K；100mM Tris/HCl pH8.0, 20-80mM MgCl2 and 30% (v/v) PEG400 , Lipidic Cubic Phase (LCP), temperature 293K
|
Resolution 2.80 Å
R-free 0.270
|
|
4NTJ
Structure of the human P2Y12 receptor in complex with an antithrombotic drug
Deposited 2013-12-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：D294N, M1007W, H1102I, R1106L
|
AZJ ethyl 6-{4-[(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyano-2-methylpyridine-3-carboxylate × 1
CLR CHOLESTEROL × 2
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；0.05-0.15M ammonium formate, 0.1M sodium cacodylate, pH 6.0-6.5, 25-35% PEG 400, 200M AZD1283, Lipidic Cubic Phase, temperature 293K
|
Resolution 2.62 Å
R-free 0.246
|
|
4O9R
Human Smoothened Receptor structure in complex with cyclopamine
Deposited 2014-01-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
Fragment：UNP Q99835 residues 190-433, P0ABE7 residues 23-128, Q99835 residues 441-555
|
Mutation：M1007W, H1102I, R1106L
|
CY8 Cyclopamine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipidic Cubic Phase (LCP)；pH 7；293 K；100 mM Hepes, 30 % (v/v) PEG 400, 100 mM NaCl , pH 7.0, Lipidic Cubic Phase (LCP), temperature 293K
|
Resolution 3.20 Å
R-free 0.278
|
|
4OR2
Human class C G protein-coupled metabotropic glutamate receptor 1 in complex with a negative allosteric modulator
Deposited 2014-02-10
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：M7W, H102I, R106L
Mutation：M7W, H102I, R106L
|
FM9 4-fluoro-N-methyl-N-{4-[6-(propan-2-ylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl}benzamide × 2
CLR CHOLESTEROL × 6
OLA OLEIC ACID × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
PO4 PHOSPHATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipidic Cubic Phase (LCP)；pH 7；293 K；100mM HEPES (pH 7.0), 27-30% (v/v) PEG 400, 80-120mM (NH4)2HPO4, 4-8mM TCEP, Lipidic Cubic Phase (LCP), temperature 293K
|
Resolution 2.80 Å
R-free 0.268
|
|
4PXZ
Crystal structure of P2Y12 receptor in complex with 2MeSADP
Deposited 2014-03-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M1007W/H1102I/R1106L/D294N
|
6AD 2-(methylsulfanyl)adenosine 5'-(trihydrogen diphosphate) × 1
CLR CHOLESTEROL × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipidic cubic phase (LCP)；pH 5；293 K；30-40% PEG 400, 0.30-0.45M ammonium acetate, citrate, 3% v/v 1-Propanol, 0.1 M sodium citrate, pH 5.0, Lipidic cubic phase (LCP), temperature 293.0K
|
Resolution 2.50 Å
R-free 0.230
|
|
4PY0
Crystal structure of P2Y12 receptor in complex with 2MeSATP
Deposited 2014-03-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：D294N, M1007W, H1102I, R1106L
|
6AT 2-(methylsulfanyl)adenosine 5'-(tetrahydrogen triphosphate) × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipidic cubic phase (LCP)；pH 6；293 K；35-40% PEG 400, 0.15-0.20M ammonium tartrate, 4% v/v MPD, 0.1M sodium citrate, pH 6.0, Lipidic cubic phase (LCP), temperature 293.0K
|
Resolution 3.10 Å
R-free 0.265
|
|
4QIM
Structure of the human smoothened receptor in complex with ANTA XV
Deposited 2014-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
Fragment：UNP Q99835 residues 190-433, P0ABE7 residues 23-128, Q99835 residues 441-555
|
Mutation：M1007W, H1102I, R1106L
|
A8T 2-{6-[4-(4-benzylphthalazin-1-yl)piperazin-1-yl]pyridin-3-yl}propan-2-ol × 1
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipidic Cubic Phase (LCP)；pH 7.2；293 K；100-115mM NH4Cl, 100mM HEPES pH7.2, 36% PEG400, Lipidic Cubic Phase (LCP), temperature 293K
|
Resolution 2.61 Å
R-free 0.263
|
|
4QIN
Structure of the human smoothened receptor in complex with SAG1.5
Deposited 2014-05-31
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Fragment：UNP Q99835 residues 190-433, P0ABE7 residues 23-128, Q99835 residues 441-555
|
Mutation：M1007W, H1102I, R1106L
|
SG8 3-chloro-4,7-difluoro-N-[trans-4-(methylamino)cyclohexyl]-N-[3-(pyridin-4-yl)benzyl]-1-benzothiophene-2-carboxamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
Lipidic Cubic Phase (LCP)；pH 6；293 K；100mM MgSO4, 100mM MES pH6.0, 30% PEG400, 2-3% Polypropylene glycol P 400, Lipidic Cubic Phase (LCP), temperature 293K
|
Resolution 2.60 Å
R-free 0.260
|
|
4RWA
Synchrotron structure of the human delta opioid receptor in complex with a bifunctional peptide (PSI community target)
Deposited 2014-12-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
|
Mutation：M29W, H124I, R138L,M29W, H124I, R138L
|
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；25-28% (v/v) PEG 400, 0.12 to 0.2 M NaCl, 100 mM MES buffer at pH 6.0, 1 mM DIPP-NH2 and 5% (v/v) of either one of the following additives: 30% glycerol, 1.0 M glycine or 0.01M L-glutathione reduced/0.01M L-glutathione oxidized, Lipidic cubic phase, temperature 293K
|
Resolution 3.28 Å
R-free 0.273
|
|
4RWA
Synchrotron structure of the human delta opioid receptor in complex with a bifunctional peptide (PSI community target)
Deposited 2014-12-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
23–128（106 aa）
|
Mutation：M29W, H124I, R138L,M29W, H124I, R138L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；25-28% (v/v) PEG 400, 0.12 to 0.2 M NaCl, 100 mM MES buffer at pH 6.0, 1 mM DIPP-NH2 and 5% (v/v) of either one of the following additives: 30% glycerol, 1.0 M glycine or 0.01M L-glutathione reduced/0.01M L-glutathione oxidized, Lipidic cubic phase, temperature 293K
|
Resolution 3.28 Å
R-free 0.273
|
|
4RWD
XFEL structure of the human delta opioid receptor in complex with a bifunctional peptide
Deposited 2014-12-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
|
Mutation：M29W, H124I, R138L,M29W, H124I, R138L
|
OLA OLEIC ACID × 3
NA SODIUM ION × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；0.1M MES pH 6.0, 10-180mM Lithium citrate, 30-32% (v/v) PEG400, Lipidic cubic phase, temperature 293K
|
Resolution 2.70 Å
R-free 0.238
|
|
4RWD
XFEL structure of the human delta opioid receptor in complex with a bifunctional peptide
Deposited 2014-12-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
23–128（106 aa）
|
Mutation：M29W, H124I, R138L,M29W, H124I, R138L
|
OLA OLEIC ACID × 4
NA SODIUM ION × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；0.1M MES pH 6.0, 10-180mM Lithium citrate, 30-32% (v/v) PEG400, Lipidic cubic phase, temperature 293K
|
Resolution 2.70 Å
R-free 0.238
|
|
4U9D
Crystal Structure of the Zn-directed tetramer of the engineered cyt cb562 variant, AB3
Deposited 2014-08-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Fragment：UNP residues 23-128
Chain B
23–128（106 aa）
Fragment：UNP residues 23-128
Chain C
23–128（106 aa）
Fragment：UNP residues 23-128
Chain D
23–128（106 aa）
Fragment：UNP residues 23-128
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, A89H, T96C, R98C, A100H, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, A89H, T96C, R98C, A100H, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, A89H, T96C, R98C, A100H, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, A89H, T96C, R98C, A100H, Y101C
|
HEC HEME C × 4
ZN ZINC ION × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；18% PEG 400 in 20 mM Tris (pH 8.5) and 0.2 M MgCl2
|
Resolution 2.50 Å
R-free 0.296
|
|
4U9E
Crystal structure of the Zn-directed tetramer of the engineered cyt cb562 variant, A104/57G AB3
Deposited 2014-08-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Fragment：UNP residues 23-128
|
Mutation：R34A, L38A, Q41W, K42S, E57G, K59H, D66W, V69I, D73H, K77H, A89H, T96C, R98C, A100H, Y101C, K104A,
|
HEC HEME C × 4
CA CALCIUM ION × 20
ZN ZINC ION × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；27% (+/-)-2-methyl-2,4-pentanediol 400 in 100 mM Bis-Tris (pH 6.5) with 0.2M CaCl2 and 20 mM ampicillin
|
Resolution 2.80 Å
R-free 0.285
|
|
4YAY
XFEL structure of human Angiotensin Receptor
Deposited 2015-02-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M1007W, H1102I, R1106L
|
ZD7 5,7-diethyl-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-3,4-dihydro-1,6-naphthyridin-2(1H)-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；294 K；100 mM sodium citrate, pH 5.0, 450 mM NH4H2PO4, 28% (v/v) PEG400 and 4% (v/v) DMSO
|
Resolution 2.90 Å
R-free 0.274
|
|
4Z34
Crystal Structure of Human Lysophosphatidic Acid Receptor 1 in complex with ONO9780307
Deposited 2015-03-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–64（42 aa）
Fragment：unp residues 2-232; unp residues 23-64; unp residues 73-127; unp residues 248-326
Chain A
73–127（55 aa）
Fragment：unp residues 2-232; unp residues 23-64; unp residues 73-127; unp residues 248-326
|
Mutation：M1007W, H1102I, R1106L
Mutation：M1007W, H1102I, R1106L
|
ON7 {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]-4-(methoxycarbonyl)-1 H-pyrrol-3-yl}acetic acid × 1
1WV (2S)-2,3-dihydroxypropyl (7Z)-tetradec-7-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1 M sodium citrate (pH 5.5),
34 - 38% (v/v) PEG400 and
200 mM ammonium acetate
|
Resolution 3.00 Å
R-free 0.281
|
|
4Z35
Crystal Structure of Human Lysophosphatidic Acid Receptor 1 in complex with ONO-9910539
Deposited 2015-03-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–64（42 aa）
Chain A
73–127（55 aa）
|
Mutation：M1007W, H1102I, R1106L
Mutation：M1007W, H1102I, R1106L
|
ON9 3-{1-[(2S,3S)-3-(4-acetyl-3,5-dimethoxyphenyl)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-hydroxypropyl]-4-(methoxycarbonyl)-1H-pyrrol-3-yl}propanoic acid × 1
1WV (2S)-2,3-dihydroxypropyl (7Z)-tetradec-7-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1 M sodium citrate
(pH 5.5), 34 - 38% (v/v) PEG400 and 200 mM ammonium acetate
|
Resolution 2.90 Å
R-free 0.279
|
|
4Z36
Crystal Structure of Human Lysophosphatidic Acid Receptor 1 in complex with ONO-3080573
Deposited 2015-03-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–64（42 aa）
Fragment：unp residues 2-232; unp residues 23-64; unp residues 78-127; unp residues 249-327
Chain A
78–127（50 aa）
Fragment：unp residues 2-232; unp residues 23-64; unp residues 78-127; unp residues 249-327
|
Mutation：M1007W, H1102I, R1106L
Mutation：M1007W, H1102I, R1106L
|
ON3 1-(4-{[(2S,3R)-2-(2,3-dihydro-1H-inden-2-yloxy)-3-(3,5-dimethoxy-4-methylphenyl)-3-hydroxypropyl]oxy}phenyl)cyclopropan ecarboxylic acid × 1
1WV (2S)-2,3-dihydroxypropyl (7Z)-tetradec-7-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1 M sodium citrate
(pH 5.5), 34 - 38% (v/v) PEG400 and 200 mM ammonium acetate
|
Resolution 2.90 Å
R-free 0.292
|
|
4ZUD
Crystal Structure of Human Angiotensin Receptor in Complex with Inverse Agonist Olmesartan at 2.8A resolution.
Deposited 2015-05-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M1007W, H1102I, R1106L
|
OLM Olmesartan × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；100 mM sodium citrate, pH 5.0, 400 mM KH2PO4, 25% (v/v) PEG400, and 6% (v/v) DMSO
|
Resolution 2.80 Å
R-free 0.234
|
|
5AWI
Domain-swapped cytochrome cb562 dimer
Deposited 2015-07-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Fragment：UNP residues 23-128
Chain B
23–128（106 aa）
Fragment：UNP residues 23-128
|
Mutation：R98C, Y101C
Mutation：R98C, Y101C
|
HEC HEME C × 2
ZN ZINC ION × 7
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；277 K；25% PEG MME 350, 6 mM ZnSO4, 750 mM MES buffer
|
Resolution 1.85 Å
R-free 0.205
|
|
5BU7
Crystal structure of an engineered protein that forms nanotubes with tunable diameters
Deposited 2015-06-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：T96C, D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
Mutation：T96C, D73H, K77H, R98C, Y101C, K27E, D28K, T31E, R34L, L38A, Q41L, H59R, D66A, V69M, L76A
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 14
|
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；pH 7.5；298 K；50-fold excess of zinc chloride
|
Resolution 2.46 Å
R-free 0.292
|
|
5DHG
The crystal structure of nociceptin/orphanin FQ peptide receptor (NOP) in complex with C-35 (PSI Community Target)
Deposited 2015-08-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M1007W, H1102I, R1106L
|
DGV 1-benzyl-N-{3-[4-(2,6-dichlorophenyl)piperidin-1-yl]propyl}-D-prolinamide × 1
OLA OLEIC ACID × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7.5；293 K；25-35% (V/V) PEG400, 130-200 MM POTASSIM SODIUM TARTRATE TETRAHYDRATE, 100 MM BIS-TRIS PROPANE, PH 6.4, LIPIDIC CUBIC PHASE, TEMPERATURE 293K
|
Resolution 3.00 Å
R-free 0.275
|
|
5DHG
The crystal structure of nociceptin/orphanin FQ peptide receptor (NOP) in complex with C-35 (PSI Community Target)
Deposited 2015-08-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：M1007W, H1102I, R1106L
|
DGV 1-benzyl-N-{3-[4-(2,6-dichlorophenyl)piperidin-1-yl]propyl}-D-prolinamide × 1
OLA OLEIC ACID × 2
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7.5；293 K；25-35% (V/V) PEG400, 130-200 MM POTASSIM SODIUM TARTRATE TETRAHYDRATE, 100 MM BIS-TRIS PROPANE, PH 6.4, LIPIDIC CUBIC PHASE, TEMPERATURE 293K
|
Resolution 3.00 Å
R-free 0.275
|
|
5DHG
The crystal structure of nociceptin/orphanin FQ peptide receptor (NOP) in complex with C-35 (PSI Community Target)
Deposited 2015-08-30
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：M1007W, H1102I, R1106L
Mutation：M1007W, H1102I, R1106L
|
DGV 1-benzyl-N-{3-[4-(2,6-dichlorophenyl)piperidin-1-yl]propyl}-D-prolinamide × 2
OLA OLEIC ACID × 5
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7.5；293 K；25-35% (V/V) PEG400, 130-200 MM POTASSIM SODIUM TARTRATE TETRAHYDRATE, 100 MM BIS-TRIS PROPANE, PH 6.4, LIPIDIC CUBIC PHASE, TEMPERATURE 293K
|
Resolution 3.00 Å
R-free 0.275
|
|
5DHH
The crystal structure of nociceptin/orphanin FQ peptide receptor (NOP) in complex with SB-612111 (PSI Community Target)
Deposited 2015-08-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M1007W, H1102I, R1106L
|
OLA OLEIC ACID × 5
DGW (5S,7S)-7-{[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl}-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6.4；293 K；25-35% (V/V) PEG400, 130-200 MM POTASSIM SODIUM TARTRATE TETRAHYDRATE, 100 MM BIS-TRIS PROPANE, PH 6.4, LIPIDIC CUBIC PHASE, TEMPERATURE 293K
|
Resolution 3.00 Å
R-free 0.279
|
|
5DHH
The crystal structure of nociceptin/orphanin FQ peptide receptor (NOP) in complex with SB-612111 (PSI Community Target)
Deposited 2015-08-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：M1007W, H1102I, R1106L
|
OLA OLEIC ACID × 2
DGW (5S,7S)-7-{[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl}-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ol × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6.4；293 K；25-35% (V/V) PEG400, 130-200 MM POTASSIM SODIUM TARTRATE TETRAHYDRATE, 100 MM BIS-TRIS PROPANE, PH 6.4, LIPIDIC CUBIC PHASE, TEMPERATURE 293K
|
Resolution 3.00 Å
R-free 0.279
|
|
5DHH
The crystal structure of nociceptin/orphanin FQ peptide receptor (NOP) in complex with SB-612111 (PSI Community Target)
Deposited 2015-08-31
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：M1007W, H1102I, R1106L
Mutation：M1007W, H1102I, R1106L
|
OLA OLEIC ACID × 7
DGW (5S,7S)-7-{[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl}-1-methyl-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-ol × 2
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6.4；293 K；25-35% (V/V) PEG400, 130-200 MM POTASSIM SODIUM TARTRATE TETRAHYDRATE, 100 MM BIS-TRIS PROPANE, PH 6.4, LIPIDIC CUBIC PHASE, TEMPERATURE 293K
|
Resolution 3.00 Å
R-free 0.279
|
|
5IU4
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with ZM241385 at 1.7A resolution
Deposited 2016-03-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：;A54L, T88A, R107A, K122A, N154A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, N154A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, N154A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, N154A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, N154A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, N154A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, N154A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, N154A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, N154A, L202A, L235A, V239A, S277A
;
|
NA SODIUM ION × 1
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
CLR CHOLESTEROL × 4
OLA OLEIC ACID × 20
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES pH 5.5, 0.2M K/Na tartrate, 27.5-40% PEG400, 0.5-1% (v/v) (+/-)-2-methyl-2,4-pentanediol
|
Resolution 1.72 Å
R-free 0.200
|
|
5IU7
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12c at 1.9A resolution
Deposited 2016-03-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：;A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A
;
|
NA SODIUM ION × 1
6DY 2-(furan-2-yl)-N~5~-[2-(4-phenylpiperidin-1-yl)ethyl][1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine × 1
CLR CHOLESTEROL × 4
OLA OLEIC ACID × 18
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；0.lM tri-sodium citrate pH 5.3-5.4, 0.05M sodium thiocyanate, 29-32% PEG400, 2% (v/v) 2,5-hexanediol
|
Resolution 1.90 Å
R-free 0.198
|
|
5IU8
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12f at 2.0A resolution
Deposited 2016-03-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：;A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A
;
|
NA SODIUM ION × 1
6DZ 2-(furan-2-yl)-N~5~-[2-(4-methylpiperazin-1-yl)ethyl][1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine × 1
HTO HEPTANE-1,2,3-TRIOL × 1
CLR CHOLESTEROL × 4
OLA OLEIC ACID × 19
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES pH 5.5, 0.2M K/Na tartrate, 33.5% PEG400, 0.5% (v/v) 1,2,3-heptanetriol
|
Resolution 2.00 Å
R-free 0.200
|
|
5IUA
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12b at 2.2A resolution
Deposited 2016-03-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：;A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A
;
|
NA SODIUM ION × 1
6DX 2-(furan-2-yl)-N~5~-[3-(4-phenylpiperazin-1-yl)propyl][1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine × 1
CLR CHOLESTEROL × 4
OLA OLEIC ACID × 17
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；0.lM tri-sodium citrate pH 5.3-5.4, 0.05M sodium thiocyanate, 29-32% PEG400, 2% (v/v) 2,5-hexanediol
|
Resolution 2.20 Å
R-free 0.233
|
|
5IUB
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12x at 2.1A resolution
Deposited 2016-03-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：;A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A,A54L, T88A, R107A, K122A, L202A, L235A, V239A, S277A
;
|
NA SODIUM ION × 1
6DV N~5~-{2-[4-(2,4-difluorophenyl)piperazin-1-yl]ethyl}-2-(furan-2-yl)[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 16
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES pH 5.5, 0.2M K/Na tartrate, 27.5-40% PEG400, 0.5-1% (v/v) (+/-)-2-methyl-2,4-pentanediol
|
Resolution 2.10 Å
R-free 0.218
|
|
5JTB
Crystal structure of the chimeric protein of A2aAR-BRIL with bound iodide ions
Deposited 2016-05-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
Fragment：;UNP Residues 2-208,UNP Residues 23-217,UNP Residues 219-316,UNP Residues 2-208,UNP Residues 23-217,UNP Residues 219-316,UNP Residues 2-208,UNP Residues 23-217,UNP Residues 219-316
;
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
CLR CHOLESTEROL × 3
IOD IODIDE ION × 6
PEG DI(HYDROXYETHYL)ETHER × 2
OLA OLEIC ACID × 4
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 6
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；in meso lipidic cubic phase crystallization
|
Resolution 2.80 Å
R-free 0.294
|
|
5K2A
2.5 angstrom A2a adenosine receptor structure with sulfur SAD phasing using XFEL data
Deposited 2016-05-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 10
OLA OLEIC ACID × 10
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；28 % (v/v) PEG 400, 40 mM sodium thiocyanate and 100 mM sodium citrate buffer pH 5.0
|
Resolution 2.50 Å
R-free 0.228
|
|
5K2B
2.5 angstrom A2a adenosine receptor structure with MR phasing using XFEL data
Deposited 2016-05-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 9
OLA OLEIC ACID × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；28 % (v/v) PEG 400, 40 mM sodium thiocyanate and 100 mM sodium citrate buffer pH 5.0
|
Resolution 2.50 Å
R-free 0.219
|
|
5K2C
1.9 angstrom A2a adenosine receptor structure with sulfur SAD phasing and phase extension using XFEL data
Deposited 2016-05-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 10
OLA OLEIC ACID × 11
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；28 % (v/v) PEG 400, 40 mM sodium thiocyanate and 100 mM sodium citrate buffer pH 5.0
|
Resolution 1.90 Å
R-free 0.208
|
|
5K2D
1.9A angstrom A2a adenosine receptor structure with MR phasing using XFEL data
Deposited 2016-05-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 8
OLA OLEIC ACID × 11
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；28 % (v/v) PEG 400, 40 mM sodium thiocyanate and 100 mM sodium citrate buffer pH 5.0
|
Resolution 1.90 Å
R-free 0.207
|
|
5L31
Crystal structure of an engineered metal-free RIDC1 variant containing five disulfide bonds.
Deposited 2016-08-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Fragment：UNP residues 23-128
Chain B
23–128（106 aa）
Fragment：UNP residues 23-128
Chain C
23–128（106 aa）
Fragment：UNP residues 23-128
Chain D
23–128（106 aa）
Fragment：UNP residues 23-128
|
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
HEC HEME C × 4
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；Drop consists of 1 uL of 45% MPD, and 0.1 M Bis Tris (pH 6.5) mixed with 1.5 uL of 2.8 mM protein
|
Resolution 2.40 Å
R-free 0.267
|
|
5L32
Crystal structure of the Zn-RIDC1 complex bearing six interfacial disulfide bonds
Deposited 2016-08-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Fragment：UNP residues 23-128
Chain B
23–128（106 aa）
Fragment：UNP residues 23-128
Chain C
23–128（106 aa）
Fragment：UNP residues 23-128
Chain D
23–128（106 aa）
Fragment：UNP residues 23-128
|
Not recorded
|
HEC HEME C × 4
P6G HEXAETHYLENE GLYCOL × 1
ZN ZINC ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；294 K；0.2 M magnesium chloride, 0.1 M Bis-Tris (pH 6.5), 35% PEG 400
|
Resolution 2.10 Å
R-free 0.250
|
|
5L7D
Structure of human Smoothened in complex with cholesterol
Deposited 2016-06-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
Fragment：UNP residues 32-428,UNP residues 23-127,UNP residues 443-555
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 2
CLR CHOLESTEROL × 1
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；0.1 M MES pH 6, 30% (v/v) PEG500 DME, 0.1 M sodium acetate, 0.5 mM zinc chloride, 0.1 M ammonium fluoride
|
Resolution 3.20 Å
R-free 0.264
|
|
5L7D
Structure of human Smoothened in complex with cholesterol
Deposited 2016-06-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–127（105 aa）
Fragment：UNP residues 32-428,UNP residues 23-127,UNP residues 443-555
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；0.1 M MES pH 6, 30% (v/v) PEG500 DME, 0.1 M sodium acetate, 0.5 mM zinc chloride, 0.1 M ammonium fluoride
|
Resolution 3.20 Å
R-free 0.264
|
|
5L7I
Structure of human Smoothened in complex with Vismodegib
Deposited 2016-06-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
VIS 2-chloranyl-~{N}-(4-chloranyl-3-pyridin-2-yl-phenyl)-4-methylsulfonyl-benzamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 4；293 K；0.09 M sodium acetate pH4, 0.09 M sodium malonate, 27% (v/v) PEG500 DME, 0.1 M sodium acetate, 0.5 mM zinc chloride, 0.1 M ammonium fluoride.
|
Resolution 3.30 Å
R-free 0.257
|
|
5L7I
Structure of human Smoothened in complex with Vismodegib
Deposited 2016-06-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–127（105 aa）
|
Not recorded
|
VIS 2-chloranyl-~{N}-(4-chloranyl-3-pyridin-2-yl-phenyl)-4-methylsulfonyl-benzamide × 1
NA SODIUM ION × 1
MPG [(Z)-octadec-9-enyl] (2R)-2,3-bis(oxidanyl)propanoate × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 4；293 K；0.09 M sodium acetate pH4, 0.09 M sodium malonate, 27% (v/v) PEG500 DME, 0.1 M sodium acetate, 0.5 mM zinc chloride, 0.1 M ammonium fluoride.
|
Resolution 3.30 Å
R-free 0.257
|
|
5MZJ
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with theophylline at 2.0A resolution
Deposited 2017-01-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：A54L, T88A, R107A, K122A, N154A, L202A,M1007W,L235A, V239A, S277A, G318A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE,
27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.00 Å
R-free 0.204
|
|
5MZP
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with caffeine at 2.1A resolution
Deposited 2017-02-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：;A54L, T88A, R107A, K122A, N154A, L202A, M1007W, L235A, V239A, S277A, G318A,A54L, T88A, R107A, K122A, N154A, L202A, M1007W, L235A, V239A, S277A, G318A,A54L, T88A, R107A, K122A, N154A, L202A, M1007W, L235A, V239A, S277A, G318A
;
|
NA SODIUM ION × 1
CFF CAFFEINE × 1
CLR CHOLESTEROL × 4
OLA OLEIC ACID × 18
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
TAR D(-)-TARTARIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE,
27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.10 Å
R-free 0.220
|
|
5N2R
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with PSB36 at 2.8A resolution
Deposited 2017-02-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Mutation：;A54L, T88A, R107A, K122A, N154A, L202A, M1007W, L235A, V239A, S277A, G318A,A54L, T88A, R107A, K122A, N154A, L202A, M1007W, L235A, V239A, S277A, G318A,A54L, T88A, R107A, K122A, N154A, L202A, M1007W, L235A, V239A, S277A, G318A,A54L, T88A, R107A, K122A, N154A, L202A, M1007W, L235A, V239A, S277A, G318A
;
|
NA SODIUM ION × 1
8JN 1-butyl-3-[(~{E})-3-oxidanylprop-1-enyl]-8-[(1~{R},5~{S})-3-tricyclo[3.3.1.0^{3,7}]nonanyl]-7~{H}-purine-2,6-dione × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 21
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 5
TAR D(-)-TARTARIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.80 Å
R-free 0.229
|
|
5N2S
Crystal structure of stabilized A1 receptor in complex with PSB36 at 3.3A resolution
Deposited 2017-02-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
22–127（106 aa）
|
Mutation：A57L, T91A, N159A, Y205A, L236A, L240A, T277A, C309S,A57L, T91A, N159A, Y205A, L236A, L240A, T277A, C309S
|
8K8 1-butyl-3-(3-oxidanylpropyl)-8-[(1~{R},5~{S})-3-tricyclo[3.3.1.0^{3,7}]nonanyl]-7~{H}-purine-2,6-dione × 1
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7.5；293 K；0.1M SODIUM / POTASSIUM PHOSPHATE PH 7.5, 0.2M LITHIUM SULPHATE, 37.5% (W/V) PEG400
|
Resolution 3.30 Å
R-free 0.278
|
|
5NDD
Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with AZ8838 at 2.8 angstrom resolution
Deposited 2017-03-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Mutation：G89A, H108A, G157A, M166L, Y174A, V176E, N222Q, M268A,I289A, L293A
|
8TZ (~{S})-(4-fluoranyl-2-propyl-phenyl)-(1~{H}-imidazol-2-yl)methanol × 1
NA SODIUM ION × 1
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.8；293 K；0.1 M sodium citrate/citrate acid pH 5.5-6.2, 0.2 M ammonium phosphate dibasic, 38-43 % (w/v) PEG400 and 1 mM AZ8838
|
Resolution 2.80 Å
R-free 0.264
|
|
5NDZ
Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with AZ3451 at 3.6 angstrom resolution
Deposited 2017-03-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Mutation：;G89A, H108A, G157A, M166L, Y174A, V176E, N222Q, M268A, I289A, L293A,G89A, H108A, G157A, M166L, Y174A, V176E, N222Q, M268A, I289A, L293A,G89A, H108A, G157A, M166L, Y174A, V176E, N222Q, M268A, I289A, L293A,G89A, H108A, G157A, M166L, Y174A, V176E, N222Q, M268A, I289A, L293A
;
|
8UN 2-(6-bromanyl-1,3-benzodioxol-5-yl)-~{N}-(4-cyanophenyl)-1-[(1~{S})-1-cyclohexylethyl]benzimidazole-5-carboxamide × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.8；293 K；0.1 M sodium citrate/citrate acid pH 5.5-6.2, 0.2 M ammonium phosphate dibasic, 38-43 % (w/v) PEG400
|
Resolution 3.60 Å
R-free 0.291
|
|
5NJ6
Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in ternary complex with Fab3949 and AZ7188 at 4.0 angstrom resolution
Deposited 2017-03-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–127（105 aa）
|
Mutation：;G89A, H108A, G157A, M166L, Y174A, V176E, N222Q, M268A, I289A, L293A,G89A, H108A, G157A, M166L, Y174A, V176E, N222Q, M268A, I289A, L293A,G89A, H108A, G157A, M166L, Y174A, V176E, N222Q, M268A, I289A, L293A
;
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.7；293 K；0.1M MES pH 5.5-6.2, 0.2M POTASSIUM / SODIUM TARTRATE, 30-35% (W/V) PEG400, 2% (W/V) 2,5-HEXANEDIOL
|
Resolution 4.00 Å
R-free 0.319
|
|
5NLX
A2A Adenosine receptor room-temperature structure determined by serial millisecond crystallography
Deposited 2017-04-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
OLA OLEIC ACID × 3
NA SODIUM ION × 1
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
CLR CHOLESTEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；291 K；0.1M sodium citrate pH 5.0, 0.05M sodium thiocyanate, 28-34% PEG400, 5 mM ZM241385, 2% (v/v) 1,6-hexanediol
|
Resolution 2.14 Å
R-free 0.229
|
|
5NM2
A2A Adenosine receptor cryo structure
Deposited 2017-04-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
NA SODIUM ION × 1
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
OLA OLEIC ACID × 15
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
CLR CHOLESTEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；291 K；0.1M sodium citrate pH 5.0, 0.05M sodium thiocyanate, 28-34% PEG400, 5 mM ZM241385, 2% (v/v) 1,6-hexanedio
|
Resolution 1.95 Å
R-free 0.212
|
|
5NM4
A2A Adenosine receptor room-temperature structure determined by serial femtosecond crystallography
Deposited 2017-04-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
OLA OLEIC ACID × 5
NA SODIUM ION × 1
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
CLR CHOLESTEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；291 K；0.1M sodium citrate pH 5.0, 0.05M sodium thiocyanate, 28-34% PEG400, 5 mM ZM241385, 2% (v/v) 1,6-hexanediol
|
Resolution 1.70 Å
R-free 0.235
|
|
5OLG
Structure of the A2A-StaR2-bRIL562-ZM241385 complex at 1.86A obtained from in meso soaking experiments.
Deposited 2017-07-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Mutation：;A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A
;
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
CLR CHOLESTEROL × 4
OLA OLEIC ACID × 17
SCN THIOCYANATE ION × 4
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
CIT CITRIC ACID × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293.15 K；Crystal growth: 0.l M tri-sodium citrate pH 5.3-5.4, 0.05 M sodium thiocyanate, 29-32% PEG400, 2% (v/v) 2,5-hexanediol, 0.5 mM theophylline.
ZM241385 was subsequently added to motherliquor for the soaking experiment at a final concentration of 0.005 mM.
|
Resolution 1.87 Å
R-free 0.224
|
|
5OLH
Structure of the A2A-StaR2-bRIL562-Vipadenant complex at 2.6A obtained from in meso soaking experiments.
Deposited 2017-07-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：;A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A
;
|
9XT 3-[(4-azanyl-3-methyl-phenyl)methyl]-7-(furan-2-yl)-[1,2,3]triazolo[4,5-d]pyrimidin-5-amine × 1
OLA OLEIC ACID × 15
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293.15 K；Crystal growth: 0.l M tri-sodium citrate pH 5.3-5.4, 0.05 M sodium thiocyanate, 29-32% PEG400, 2% (v/v) 2,5-hexanediol and 0.5 mM theophylline
Vipadenant was added to the mother liquor to a concentration of 0.005 mM for the soaking experiments.
|
Resolution 2.60 Å
R-free 0.249
|
|
5OLO
Structure of the A2A-StaR2-bRIL562-Tozadenant complex at 3.1A obtained from in meso soaking experiments.
Deposited 2017-07-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Mutation：A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A
|
9XW ~{N}-(4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-yl)-4-methyl-4-oxidanyl-piperidine-1-carboxamide × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 10
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 8
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293.15 K；Crystal growth: 0.l M tri-sodium citrate pH 5.3-5.4, 0.05 M sodium thiocyanate, 29-32% PEG400, 2% (v/v) 2,5-hexanediol and 0.5 mM theophylline
Tozadenant was added to the mother liquor to a concentration of 0.005 mM for the soaking experiments.
|
Resolution 3.10 Å
R-free 0.245
|
|
5OLV
Structure of the A2A-StaR2-bRIL562-LUAA47070 complex at 2.0A obtained from in meso soaking experiments.
Deposited 2017-07-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：;A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A
;
|
9Y2 4-(3,3-dimethylbutanoylamino)-3,5-bis(fluoranyl)-~{N}-(1,3-thiazol-2-yl)benzamide × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 4
OLA OLEIC ACID × 13
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 10
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293.15 K；Crystal growth: 0.l M tri-sodium citrate pH 5.3-5.4, 0.05 M sodium thiocyanate, 29-32% PEG400, 2% (v/v) 2,5-hexanediol and 0.5 mM theophylline
LUAA47070 was added to the mother liquor to a concentration of 0.005 mM for the soaking experiments.
|
Resolution 2.00 Å
R-free 0.208
|
|
5OLZ
Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 1.9A obtained from bespoke co-crystallisation experiments.
Deposited 2017-07-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：;A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A
;
|
T4E 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-chlorophenol × 1
CLR CHOLESTEROL × 4
OLA OLEIC ACID × 15
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 11
TAR D(-)-TARTARIC ACID × 1
PGE TRIETHYLENE GLYCOL × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293.15 K；0.l M tri-sodium citrate pH 5.3-5.4, 0.05 M sodium thiocyanate, 29-32% PEG400, 2% (v/v) 2,5-hexanediol and 0.005 mM Compound 4e.
|
Resolution 1.90 Å
R-free 0.196
|
|
5OM1
Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 2.1A obtained from in meso soaking experiments (1 hour soak).
Deposited 2017-07-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：;A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A
;
|
T4E 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-chlorophenol × 1
NA SODIUM ION × 1
OLA OLEIC ACID × 14
CLR CHOLESTEROL × 4
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 12
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293.15 K；Crystal growth: 0.l M tri-sodium citrate pH 5.3-5.4, 0.05 M sodium thiocyanate, 29-32% PEG400, 2% (v/v) 2,5-hexanediol and 0.5 mM theophylline
Compound 4e was added to the mother liquor to a concentration of 0.005 mM for the soaking experiments.
|
Resolution 2.10 Å
R-free 0.210
|
|
5OM4
Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 1.86A obtained from in meso soaking experiments (24 hour soak).
Deposited 2017-07-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：;A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A,A54L; T88A; R107A; K122A; L202A; L235A; V239A; S277A; N154A
;
|
T4E 4-(3-amino-5-phenyl-1,2,4-triazin-6-yl)-2-chlorophenol × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 4
OLA OLEIC ACID × 16
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 11
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293.15 K；Crystal growth: 0.l M tri-sodium citrate pH 5.3-5.4, 0.05 M sodium thiocyanate, 29-32% PEG400, 2% (v/v) 2,5-hexanediol and 0.5 mM theophylline
Compound 4e was added to the mother liquor to a concentration of 0.005 mM for the soaking experiments.
|
Resolution 2.00 Å
R-free 0.205
|
|
5TUD
Structural Insights into the Extracellular Recognition of the Human Serotonin 2B Receptor by an Antibody
Deposited 2016-11-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Fragment：UNP P41595 residues 36-248 and 314-405 linked by UNP P0ABE7 residues 23-128
|
Mutation：M144W, M1007W, H1102I, R1106L
|
ERM Ergotamine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7.7；293 K；Tris/HCL pH 7.7, 60 mM Sodium/Potassium Tartrate, 25% PEG400.
|
Resolution 3.00 Å
R-free 0.247
|
|
5TUD
Structural Insights into the Extracellular Recognition of the Human Serotonin 2B Receptor by an Antibody
Deposited 2016-11-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
23–128（106 aa）
Fragment：UNP P41595 residues 36-248 and 314-405 linked by UNP P0ABE7 residues 23-128
|
Mutation：M144W, M1007W, H1102I, R1106L
|
ERM Ergotamine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7.7；293 K；Tris/HCL pH 7.7, 60 mM Sodium/Potassium Tartrate, 25% PEG400.
|
Resolution 3.00 Å
R-free 0.247
|
|
5TVN
Crystal structure of the LSD-bound 5-HT2B receptor
Deposited 2016-11-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M144W, M1007W, H1102I, R1106L
|
7LD (8alpha)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide × 1
CLR CHOLESTEROL × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
PEG DI(HYDROXYETHYL)ETHER × 1
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM Tris/HCl pH 7.5-8.0, 90-130 mM potassium phosphate monobasic, 28-30% PEG400
|
Resolution 2.90 Å
R-free 0.263
|
|
5UEN
Crystal structure of the human adenosine A1 receptor A1AR-bRIL in complex with the covalent antagonist DU172 at 3.2A resolution
Deposited 2017-01-03
|
Different construct
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
Fragment：;UNP P30542 reisues 2-210, UNP P0ABE7 residues 23-127, UNP P30542 residues 228-31,UNP P30542 reisues 2-210, UNP P0ABE7 residues 23-127, UNP P30542 residues 228-31,UNP P30542 reisues 2-210, UNP P0ABE7 residues 23-127, UNP P30542 residues 228-31
;
Chain B
23–127（105 aa）
Fragment：;UNP P30542 reisues 2-210, UNP P0ABE7 residues 23-127, UNP P30542 residues 228-31,UNP P30542 reisues 2-210, UNP P0ABE7 residues 23-127, UNP P30542 residues 228-31,UNP P30542 reisues 2-210, UNP P0ABE7 residues 23-127, UNP P30542 residues 228-31
;
|
Not recorded
|
DU1 4-{[3-(8-cyclohexyl-2,6-dioxo-1-propyl-1,2,6,7-tetrahydro-3H-purin-3-yl)propyl]carbamoyl}benzene-1-sulfonyl fluoride × 2
OLA OLEIC ACID × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM Hepes pH 7.0-8.0, 28-38% PEG 300 and 500-700 mM NH4F
|
Resolution 3.20 Å
R-free 0.316
|
|
5UIG
Crystal structure of adenosine A2A receptor bound to a novel triazole-carboximidamide antagonist
Deposited 2017-01-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M1007W, H1102I, R1106L,M1007W, H1102I, R1106L,M1007W, H1102I, R1106L
|
EDT {[-(BIS-CARBOXYMETHYL-AMINO)-ETHYL]-CARBOXYMETHYL-AMINO}-ACETIC ACID × 1
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1
8D1 5-amino-N-[(2-methoxyphenyl)methyl]-2-(3-methylphenyl)-2H-1,2,3-triazole-4-carboximidamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.045 M MES, 0.045 M MgCl2, 28% PEG400, 5% Jeffamine M-600 (pH 7.0)
|
Resolution 3.50 Å
R-free 0.299
|
|
5UIG
Crystal structure of adenosine A2A receptor bound to a novel triazole-carboximidamide antagonist
Deposited 2017-01-13
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
|
Mutation：M1007W, H1102I, R1106L,M1007W, H1102I, R1106L,M1007W, H1102I, R1106L
|
EDT {[-(BIS-CARBOXYMETHYL-AMINO)-ETHYL]-CARBOXYMETHYL-AMINO}-ACETIC ACID × 2
MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 2
8D1 5-amino-N-[(2-methoxyphenyl)methyl]-2-(3-methylphenyl)-2H-1,2,3-triazole-4-carboximidamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；0.045 M MES, 0.045 M MgCl2, 28% PEG400, 5% Jeffamine M-600 (pH 7.0)
|
Resolution 3.50 Å
R-free 0.299
|
|
5UNF
XFEL structure of human angiotensin II type 2 receptor (Monoclinic form) in complex with compound 1 (N-benzyl-N-(2-ethyl-4-oxo-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl])
Deposited 2017-01-30
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Fragment：UNP P0ABE7 residues 23-128 and UNP P50052 35-335 linked via LINKER resdiues GSGS
Chain B
23–128（106 aa）
Fragment：UNP P0ABE7 residues 23-128 and UNP P50052 35-335 linked via LINKER resdiues GSGS
|
Mutation：M1007W, H1102I, R1106L
Mutation：M1007W, H1102I, R1106L
|
8ES N-benzyl-N-(2-ethyl-4-oxo-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-3,4-dihydroquinazolin-6-yl)thiophene-2-carboxamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 8；293 K；100 mM Tris-HCl, pH 8.0, 25 mM potassium formate, 25% (v/v) PEG400, and 0.3% (v/v) (+/-)-2-Methyl-2,4-pentanediol
|
Resolution 2.80 Å
R-free 0.256
|
|
5UNG
XFEL structure of human angiotensin II type 2 receptor (Orthorhombic form) in complex with compound 1 (N-benzyl-N-(2-ethyl-4-oxo-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl] methyl}-3,4-dihydroquinazolin-6-yl)thiophene-2-carboxamide)
Deposited 2017-01-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
Fragment：UNP P0ABE7 residues 23-128 and UNP P50052 35-335 linked via LINKER resdiues GSGS
|
Mutation：M1007W, H1102I, R1106L
|
8ES N-benzyl-N-(2-ethyl-4-oxo-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-3,4-dihydroquinazolin-6-yl)thiophene-2-carboxamide × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
OLA OLEIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 8；293 K；100 mM Tris-HCl, pH 8.0, 25 mM potassium formate, 25% (v/v) PEG400, and 0.3% (v/v) (+/-)-2-Methyl-2,4-pentanediol
|
Resolution 2.80 Å
R-free 0.262
|
|
5UNH
Synchrotron structure of human angiotensin II type 2 receptor in complex with compound 2 (N-[(furan-2-yl)methyl]-N-(4-oxo-2-propyl-3-{[2'-(2H-tetrazol-5-yl)[1,1'- biphenyl]-4-yl]methyl}-3,4-dihydroquinazolin-6-yl)benzamide)
Deposited 2017-01-30
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Fragment：;UNP P0ABE7 residues 23-128 and UNP P50052 35-335 linked via LINKER resdiues GSGS,UNP P0ABE7 residues 23-128 and UNP P50052 35-335 linked via LINKER resdiues GSGS
;
Chain B
23–128（106 aa）
Fragment：;UNP P0ABE7 residues 23-128 and UNP P50052 35-335 linked via LINKER resdiues GSGS,UNP P0ABE7 residues 23-128 and UNP P50052 35-335 linked via LINKER resdiues GSGS
;
|
Mutation：M1007W, H1102I, R1106L,M1007W, H1102I, R1106L
Mutation：M1007W, H1102I, R1106L,M1007W, H1102I, R1106L
|
8EM N-[(furan-2-yl)methyl]-N-(4-oxo-2-propyl-3-{[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-3,4-dihydroquinazolin-6-yl)benzamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 8；293 K；100 mM Tris-HCl, pH 8.0, 25 mM potassium formate, 25% (v/v) PEG400, and 0.3% (v/v) (+/-)-2-Methyl-2,4-pentanediol
|
Resolution 2.90 Å
R-free 0.259
|
|
5UVI
Serial Millisecond Crystallography of Membrane and Soluble Protein Micro-crystals using Synchrotron Radiation
Deposited 2017-02-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
CLR CHOLESTEROL × 3
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
OLA OLEIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；0.1 M sodium citrate pH 5.0, 32 % PEG 400, 75 mM sodium thocyanate
|
Resolution 3.20 Å
R-free 0.287
|
|
5VRA
2.35-Angstrom In situ Mylar structure of human A2A adenosine receptor at 100 K
Deposited 2017-05-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
Fragment：UNP P29274 residues 2-208 and 219-316 linked by UNP P0ABE7 residues 23-128
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 6
OLA OLEIC ACID × 10
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；25-28% PEG400, 0.04-0.06 M sodium thiocyanate, 2% 2,5-hexanediol, and 100 mM sodium citrate pH 5.0
|
Resolution 2.35 Å
R-free 0.223
|
|
5WIU
Structure of the human D4 Dopamine receptor in complex with Nemonapride
Deposited 2017-07-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
24–128（105 aa）
|
Not recorded
|
AQD Nemonapride × 1
PO4 PHOSPHATE ION × 3
OLA OLEIC ACID × 9
PEG DI(HYDROXYETHYL)ETHER × 9
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；298 K；100 mM Tris-HCl, pH 5.8-6.2, 160-200 mM ammonium phosphate dibasic, 34% PEG400
|
Resolution 1.96 Å
R-free 0.236
|
|
5WIV
Structure of the sodium-bound human D4 Dopamine receptor in complex with Nemonapride
Deposited 2017-07-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
24–128（105 aa）
|
Not recorded
|
AQD Nemonapride × 1
PO4 PHOSPHATE ION × 5
OLA OLEIC ACID × 8
PEG DI(HYDROXYETHYL)ETHER × 9
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM Tris-HCl, pH 5.9-6.2, 100-140 mM ammonium phosphate dibasic, 180-200 mM sodium chloride, 34% PEG400
|
Resolution 2.14 Å
R-free 0.227
|
|
5XJM
Complex structure of angiotensin II type 2 receptor with Fab
Deposited 2017-05-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Fragment：UNP residues 35-242,UNP residues 246-346
|
Mutation：M1007W, H1102I, R1106L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293 K；34%(v/v) PEG 300, 0.1 M HEPES pH 7.0, 0.5%(v/v) Tacsimate (pH7.0)
|
Resolution 3.20 Å
R-free 0.275
|
|
5XZI
Crystal structure of the Zn-directed tetramer of the engineered cyt cb562 variant, AB5
Deposited 2017-07-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, E86D, A89E, Q93H, T96C, R98C, A100H, Y101C
|
HEC HEME C × 4
ZN ZINC ION × 8
CL CHLORIDE ION × 12
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；31.5% 2-methyl-2,4-pentanediol 400, 0.1M HEPES, pH 7.5, 0.2M MgCl2
|
Resolution 2.65 Å
R-free 0.263
|
|
5XZJ
Crystal structure of the Zn-directed tetramer of the engineered cyt cb562 variant, C96T/AB5
Deposited 2017-07-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, E86D, A89E, Q93H, R98C, A100H, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, E86D, A89E, Q93H, R98C, A100H, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, E86D, A89E, Q93H, R98C, A100H, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, E86D, A89E, Q93H, R98C, A100H, Y101C
|
HEC HEME C × 4
ZN ZINC ION × 14
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；45% 2-methyl-2,4-pentanediol 400,
0.1M HEPES, pH 6.5
|
Resolution 1.98 Å
R-free 0.217
|
|
5YM7
Crystal Structure of B562RIL without disulfide bond
Deposited 2017-10-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M7W, H102I, R106L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；NH4(SO4), Bicine , N-octanoylsucrose
|
Resolution 1.56 Å
R-free 0.238
|
|
5YM7
Crystal Structure of B562RIL without disulfide bond
Deposited 2017-10-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
|
Mutation：M7W, H102I, R106L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；NH4(SO4), Bicine , N-octanoylsucrose
|
Resolution 1.56 Å
R-free 0.238
|
|
5YO3
Crystal Structure of B562RIL with engineered disulfide bond V16C-A29C
Deposited 2017-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M7W, V16C, A29C, H102I, R106L
|
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9；292 K；NH4(SO4), Bicine, N-octanoylsucrose
|
Resolution 1.70 Å
R-free 0.188
|
|
5YO3
Crystal Structure of B562RIL with engineered disulfide bond V16C-A29C
Deposited 2017-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
|
Mutation：M7W, V16C, A29C, H102I, R106L
|
SO4 SULFATE ION × 8
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 9；292 K；NH4(SO4), Bicine, N-octanoylsucrose
|
Resolution 1.70 Å
R-free 0.188
|
|
5YO4
Crystal Structure of B562RIL with engineered disulfide bond K27C-A79C
Deposited 2017-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M7W, H102I, R106L, K27C, A79C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；3.2M NH4(SO4),
0.1M Bicine
2.44mM N-octanoylsucrose
|
Resolution 1.37 Å
R-free 0.212
|
|
5YO5
Crystal Structure of B562RIL with engineered disulfide bond A20C-Q25C
Deposited 2017-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M7W, H102I, R106L, A20C, Q25C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；3.2M NH4(SO4),
0.1M Bicine
2.44mM N-octanoylsucrose
|
Resolution 2.20 Å
R-free 0.267
|
|
5YO5
Crystal Structure of B562RIL with engineered disulfide bond A20C-Q25C
Deposited 2017-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：M7W, H102I, R106L, A20C, Q25C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；3.2M NH4(SO4),
0.1M Bicine
2.44mM N-octanoylsucrose
|
Resolution 2.20 Å
R-free 0.267
|
|
5YO5
Crystal Structure of B562RIL with engineered disulfide bond A20C-Q25C
Deposited 2017-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Mutation：M7W, H102I, R106L, A20C, Q25C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；3.2M NH4(SO4),
0.1M Bicine
2.44mM N-octanoylsucrose
|
Resolution 2.20 Å
R-free 0.267
|
|
5YO5
Crystal Structure of B562RIL with engineered disulfide bond A20C-Q25C
Deposited 2017-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
23–128（106 aa）
|
Mutation：M7W, H102I, R106L, A20C, Q25C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；3.2M NH4(SO4),
0.1M Bicine
2.44mM N-octanoylsucrose
|
Resolution 2.20 Å
R-free 0.267
|
|
5YO5
Crystal Structure of B562RIL with engineered disulfide bond A20C-Q25C
Deposited 2017-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain E
23–128（106 aa）
|
Mutation：M7W, H102I, R106L, A20C, Q25C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；3.2M NH4(SO4),
0.1M Bicine
2.44mM N-octanoylsucrose
|
Resolution 2.20 Å
R-free 0.267
|
|
5YO5
Crystal Structure of B562RIL with engineered disulfide bond A20C-Q25C
Deposited 2017-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain F
23–128（106 aa）
|
Mutation：M7W, H102I, R106L, A20C, Q25C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；3.2M NH4(SO4),
0.1M Bicine
2.44mM N-octanoylsucrose
|
Resolution 2.20 Å
R-free 0.267
|
|
5YO5
Crystal Structure of B562RIL with engineered disulfide bond A20C-Q25C
Deposited 2017-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 7
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain G
23–128（106 aa）
|
Mutation：M7W, H102I, R106L, A20C, Q25C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；3.2M NH4(SO4),
0.1M Bicine
2.44mM N-octanoylsucrose
|
Resolution 2.20 Å
R-free 0.267
|
|
5YO5
Crystal Structure of B562RIL with engineered disulfide bond A20C-Q25C
Deposited 2017-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 8
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain H
23–128（106 aa）
|
Mutation：M7W, H102I, R106L, A20C, Q25C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；3.2M NH4(SO4),
0.1M Bicine
2.44mM N-octanoylsucrose
|
Resolution 2.20 Å
R-free 0.267
|
|
5YO6
Crystal Structure of B562RIL with engineered disulfide bond T9C-A36C
Deposited 2017-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M7W, H102L. R106L, T9C, A36C
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；292 K；3.2M NH4(SO4),
0.1M Bicine
2.44mM N-octanoylsucrose
|
Resolution 1.20 Å
R-free 0.237
|
|
6A93
Crystal structure of 5-HT2AR in complex with risperidone
Deposited 2018-07-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–62（40 aa）
Chain A
88–128（41 aa）
|
Mutation：S162K, M164W, R120I, H124I, R128G, M29W
Mutation：S162K, M164W, R120I, H124I, R128G, M29W
|
8NU 3-[2-[4-(6-fluoranyl-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one × 1
CLR CHOLESTEROL × 1
ZN ZINC ION × 1
1PE PENTAETHYLENE GLYCOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM MES, pH 6.0-6.5, 28-31% (v/v) PEG 400, 120-200 mM Am-formate, 1-2% (v/v) DMSO
|
Resolution 3.00 Å
R-free 0.275
|
|
6A93
Crystal structure of 5-HT2AR in complex with risperidone
Deposited 2018-07-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–62（40 aa）
Chain B
88–128（41 aa）
|
Mutation：S162K, M164W, R120I, H124I, R128G, M29W
Mutation：S162K, M164W, R120I, H124I, R128G, M29W
|
8NU 3-[2-[4-(6-fluoranyl-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one × 1
CLR CHOLESTEROL × 1
PLM PALMITIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM MES, pH 6.0-6.5, 28-31% (v/v) PEG 400, 120-200 mM Am-formate, 1-2% (v/v) DMSO
|
Resolution 3.00 Å
R-free 0.275
|
|
6A94
Crystal structure of 5-HT2AR in complex with zotepine
Deposited 2018-07-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–62（40 aa）
Chain A
88–128（41 aa）
|
Mutation：S162K, M164W,R120I, H124I, R128G, M29W
Mutation：S162K, M164W,R120I, H124I, R128G, M29W
|
ZOT 2-(3-chloranylbenzo[b][1]benzothiepin-5-yl)oxy-N,N-dimethyl-ethanamine × 1
CLR CHOLESTEROL × 1
1PE PENTAETHYLENE GLYCOL × 1
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM MES, pH 6.0, or HEPES, pH 7.0, 30% (v/v) PEG400, 100 mM Li-chloride, Na-acetate, or 14 other various salts from StockOptions Salt (Hampton Research)
|
Resolution 2.90 Å
R-free 0.269
|
|
6A94
Crystal structure of 5-HT2AR in complex with zotepine
Deposited 2018-07-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–62（40 aa）
Chain B
88–128（41 aa）
|
Mutation：S162K, M164W,R120I, H124I, R128G, M29W
Mutation：S162K, M164W,R120I, H124I, R128G, M29W
|
ZOT 2-(3-chloranylbenzo[b][1]benzothiepin-5-yl)oxy-N,N-dimethyl-ethanamine × 1
CLR CHOLESTEROL × 1
PLM PALMITIC ACID × 1
A6L 2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM MES, pH 6.0, or HEPES, pH 7.0, 30% (v/v) PEG400, 100 mM Li-chloride, Na-acetate, or 14 other various salts from StockOptions Salt (Hampton Research)
|
Resolution 2.90 Å
R-free 0.269
|
|
6AI5
Disulfide-free, Zn-directed tetramer of the engineered cyt cb562 variant, C96T/A104AB3
Deposited 2018-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
Chain E
23–128（106 aa）
Chain G
23–128（106 aa）
|
Mutation：C96T/A104AB3
Mutation：C96T/A104AB3
Mutation：C96T/A104AB3
Mutation：C96T/A104AB3
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
ZN ZINC ION × 8
CL CHLORIDE ION × 5
MG MAGNESIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；12.5% PEG 3350, pH 7.5, 0.2 M MgCl2
|
Resolution 1.81 Å
R-free 0.209
|
|
6AK3
Crystal structure of the human prostaglandin E receptor EP3 bound to prostaglandin E2
Deposited 2018-08-29
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–62（40 aa）
Chain A
85–127（43 aa）
Chain B
23–62（40 aa）
Chain B
85–127（43 aa）
|
Mutation：A173I,V185S,N217Q,S258D,C289L,N308Q,M1007W,R1098I,H1102I
Mutation：A173I,V185S,N217Q,S258D,C289L,N308Q,M1007W,R1098I,H1102I
Mutation：A173I,V185S,N217Q,S258D,C289L,N308Q,M1007W,R1098I,H1102I
Mutation：A173I,V185S,N217Q,S258D,C289L,N308Q,M1007W,R1098I,H1102I
|
P2E (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxo-cyclopentyl]hept-5-enoic acid × 2
POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；buffer A (0.1 M MES-NaOH (pH 6.0), 35 % PEG300, 400 mM Na2SO4, 1% 1,2,3-heptanetriol, 0.2 mM ONO-AE3-240),
buffer B (0.1 M MES-NaOH (pH 5.5-6.0), 30-40 % PEG300, 100 mM NaCl, 100 mM Li2SO4, 1% 1,2,3-heptanetriol, 0.2 mM ONO-AE3-240),
buffer C (0.1 M MES-NaOH (pH 6.1) or 0.1 M Tris-HCl (pH 7.5-8.0), 30 % PEG500MME, 200 mM (NH4)2SO4, 1% 1,2,3-heptanetriol, 0.2 mM ONO-AE3-240), buffer D (0.1 M MES-NaOH (pH 5.8-6.1), 30 % PEG300, 100 mM MgSO4, 1% 1,2,3-heptanetriol, 0.2 mM ONO-AE3-240), buffer E (0.1 M MES-NaOH (pH 5.5), 30 % PEG300, 100 mM K2SO4, 1% 1,2,3-heptanetriol, 0.2 mM ONO-AE3-240)
|
Resolution 2.90 Å
R-free 0.295
|
|
6AQF
Crystal structure of A2AAR-BRIL in complex with the antagonist ZM241385 produced from Pichia pastoris
Deposited 2017-08-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
Fragment：;UNP P29274 residues 2-208 and 219-316 linked via UNP P0ABE7 residues 23-128,UNP P29274 residues 2-208 and 219-316 linked via UNP P0ABE7 residues 23-128,UNP P29274 residues 2-208 and 219-316 linked via UNP P0ABE7 residues 23-128
;
|
Mutation：M1007W, H1102I, R1106L,M1007W, H1102I, R1106L,M1007W, H1102I, R1106L
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
CLR CHOLESTEROL × 3
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
OLA OLEIC ACID × 7
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；26-28 % (v/v) PEG400
40-60 mM sodium thiocyanate
2% (v/v) 2,5-hexanediol
100mM sodium citrate pH 5.0
|
Resolution 2.51 Å
R-free 0.256
|
|
6B73
Crystal Structure of a nanobody-stabilized active state of the kappa-opioid receptor
Deposited 2017-10-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Fragment：unp residues 23-128; unp residues 54-358
|
Mutation：M29W, H124I, L51R, I135L
|
CVV N-[(5alpha,6beta)-17-(cyclopropylmethyl)-3-hydroxy-7,8-didehydro-4,5-epoxymorphinan-6-yl]-3-iodobenzamide × 1
CLR CHOLESTEROL × 1
OLA OLEIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM Bis-tris pH 6.5-7.0, 140-200 mM magnesium sulfate hydrate, 100 mM sodium citrate tribasic dehydrate, 10 mM Manganese(II) chloride tetrahydrate, 28-30% PEG400
|
Resolution 3.10 Å
R-free 0.275
|
|
6B73
Crystal Structure of a nanobody-stabilized active state of the kappa-opioid receptor
Deposited 2017-10-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
23–128（106 aa）
Fragment：unp residues 23-128; unp residues 54-358
|
Mutation：M29W, H124I, L51R, I135L
|
CVV N-[(5alpha,6beta)-17-(cyclopropylmethyl)-3-hydroxy-7,8-didehydro-4,5-epoxymorphinan-6-yl]-3-iodobenzamide × 1
CLR CHOLESTEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM Bis-tris pH 6.5-7.0, 140-200 mM magnesium sulfate hydrate, 100 mM sodium citrate tribasic dehydrate, 10 mM Manganese(II) chloride tetrahydrate, 28-30% PEG400
|
Resolution 3.10 Å
R-free 0.275
|
|
6BQG
Crystal structure of 5-HT2C in complex with ergotamine
Deposited 2017-11-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M29W, H124I, R128L, C360N
|
ERM Ergotamine × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；0.1 M sodium citrate pH 6.0, 100mM (NH4)2SO4, 30% PEG400
|
Resolution 3.00 Å
R-free 0.291
|
|
6BQH
Crystal structure of 5-HT2C in complex with ritanserin
Deposited 2017-11-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
E2J 6-(2-{4-[bis(4-fluorophenyl)methylidene]piperidin-1-yl}ethyl)-7-methyl-5H-[1,3]thiazolo[3,2-a]pyrimidin-5-one × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 6
PEG DI(HYDROXYETHYL)ETHER × 1
OLA OLEIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；0.1 M sodium citrate pH 6.0, 100mM (NH4)2SO4, 30% PEG400
|
Resolution 2.70 Å
R-free 0.275
|
|
6C1Q
Crystal structure of human C5a receptor in complex with an orthosteric antagonist PMX53 and an allosteric antagonist NDT9513727
Deposited 2018-01-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
23–128（106 aa）
Fragment：cytochrome (UNP residues 23-127) + C5a receptor (UNP residues 30-331)
|
Mutation：M29W, H124I, R128L
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
9P2 1-(1,3-benzodioxol-5-yl)-~{N}-(1,3-benzodioxol-5-ylmethyl)-~{N}-[(3-butyl-2,5-diphenyl-imidazol-4-yl)methyl]methanamine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6.5；283 K；25-35% PEG300, 100 mM MES, pH 6.5, 80-150 mM sodium malonate, 0.5% P400, 5 uM NDT, 5 uM PMX53
|
Resolution 2.90 Å
R-free 0.286
|
|
6C1R
Crystal structure of human C5a receptor in complex with an orthosteric antagonist PMX53 and an allosteric antagonist avacopan
Deposited 2018-01-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
23–128（106 aa）
Fragment：cytochrome (UNP residues 23-127) + C5a receptor (UNP residues 30-331)
|
Mutation：M29W, H124I, R128L
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
EFD avacopan × 1
MLI MALONATE ION × 2
NA SODIUM ION × 1
PGE TRIETHYLENE GLYCOL × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
OLA OLEIC ACID × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6.5；283 K；25-32% PEG300, 100 mM MES, pH6.5, 90-120 mM sodium malonate, 1% P400, 5 uM avacopan, 5 uM PMX53
|
Resolution 2.20 Å
R-free 0.224
|
|
6CBV
Crystal structure of BRIL bound to an affinity matured synthetic antibody.
Deposited 2018-02-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain B
23–128（106 aa）
|
Mutation：M7W, H102I, R106L
|
GOL GLYCEROL × 2
FMT FORMIC ACID × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；0.2 M Sodium formate, 20 % w/v PEG 3350
|
Resolution 1.87 Å
R-free 0.225
|
|
6CC4
Structure of MurJ from Escherichia coli
Deposited 2018-02-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；100 mM MES, pH 6.0, 100 mM potassium phosphate dibasic, 28% PEG300, 1% 1,2,3-heptanetriol, lipid stock used for reconstitution was 10:1 w/w monoolein:cholesterol
|
Resolution 3.50 Å
R-free 0.301
|
|
6CMO
Rhodopsin-Gi complex
Deposited 2018-03-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.50 Å
|
|
6D32
Crystal structure of Xenopus Smoothened in complex with cyclopamine
Deposited 2018-04-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
CY8 Cyclopamine × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；Reconstituted in 10:1 monoolein:cholesterol mix. Precipitant solution: 35-45% PEG 300, 300-500 mM LiSO4, 0.1 M MES pH 6-6.5
|
Resolution 3.75 Å
R-free 0.260
|
|
6D35
Crystal structure of Xenopus Smoothened in complex with cholesterol
Deposited 2018-04-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；Reconstituted in 10:1 monoolein:cholesterol mix. Precipitant solution: 35-45% PEG 300, 300-500 mM LiSO4, 0.1 M MES pH 6-6.5
|
Resolution 3.90 Å
R-free 0.304
|
|
6DHY
Crystallogrpahic tetramer of Zn-bound RIDC1 variant bearing two disulfide bonded cysteines
Deposited 2018-05-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R34A, A38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, A38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, A38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, A38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
|
HEC HEME C × 4
CA CALCIUM ION × 3
ZN ZINC ION × 10
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；8% PEG 1900 MME (w/v), 40 mM CaCl2, 33.3 mM Tris (pH 7.5)
|
Resolution 2.22 Å
R-free 0.258
|
|
6DHZ
Crystallographic octamer of a metal-free RIDC1 variant bearing two disulfide bonded cysteines
Deposited 2018-05-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 8
PDB declaration: octameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R34A, A38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, A38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, A38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
Mutation：R34A, A38A, Q41W, K42S, K59H, D66W, V69I, D73H, K77H, T96C, R98C, Y101C
|
HEC HEME C × 8
CA CALCIUM ION × 14
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；15% 2-methyl-2,4-pentane diol (v/v), 33.3 mM Bis-Tris (pH 6.5), 66.7 mM CaCl2
|
Resolution 2.80 Å
R-free 0.277
|
|
6DO1
Structure of nanobody-stabilized angiotensin II type 1 receptor bound to S1I8
Deposited 2018-06-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
24–122（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
CL CHLORIDE ION × 3
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 8；293.15 K；Protein was reconstituted with a 10:1 (w:w) mix of monoolein and cholesterol. Crystals were grown in cubic phase sandwich plates with using 100 mM Tris pH 8.0, 15-25 mM MgCl2, and 28-29% PEG 300
|
Resolution 2.90 Å
R-free 0.359
|
|
6DO1
Structure of nanobody-stabilized angiotensin II type 1 receptor bound to S1I8
Deposited 2018-06-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain B
24–122（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
CL CHLORIDE ION × 2
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 8；293.15 K；Protein was reconstituted with a 10:1 (w:w) mix of monoolein and cholesterol. Crystals were grown in cubic phase sandwich plates with using 100 mM Tris pH 8.0, 15-25 mM MgCl2, and 28-29% PEG 300
|
Resolution 2.90 Å
R-free 0.359
|
|
6DRX
Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor
Deposited 2018-06-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Not recorded
|
H8G N,N-diethyl-N'-[(8alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea × 1
CLR CHOLESTEROL × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM Tris/HCl pH 7.4-7.7, 30-50 mM
Ammonium tartrate dibasic, 30% v/v PEG400
|
Resolution 3.10 Å
R-free 0.286
|
|
6DRY
Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor
Deposited 2018-06-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Not recorded
|
H8D (8beta)-N-[(2S)-1-hydroxybutan-2-yl]-6-methyl-9,10-didehydroergoline-8-carboxamide × 1
CLR CHOLESTEROL × 1
OLA OLEIC ACID × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
PEG DI(HYDROXYETHYL)ETHER × 1
PO4 PHOSPHATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM Tris/HCl pH 7.2-8.0, 170-190 mM Potassium phosphate monobasic, 30% v/v PEG400
|
Resolution 2.92 Å
R-free 0.272
|
|
6DRZ
Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor
Deposited 2018-06-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Not recorded
|
CLR CHOLESTEROL × 1
OLA OLEIC ACID × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
PEG DI(HYDROXYETHYL)ETHER × 1
PO4 PHOSPHATE ION × 1
H8J (8alpha)-N-[(2S)-1-hydroxybutan-2-yl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM Tris/HCl pH 7.3-7.5, 40-100 mM MgCl2, 30% v/v PEG400
|
Resolution 3.10 Å
R-free 0.263
|
|
6DS0
Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor
Deposited 2018-06-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
CLR CHOLESTEROL × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
PEG DI(HYDROXYETHYL)ETHER × 1
H8M (1S)-1-[(2-chloro-3,4-dimethoxyphenyl)methyl]-6-methyl-2,3,4,9-tetrahydro-1H-beta-carboline × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM Tris/HCl pH 8.0, 100 mM Sodium Formate, 30% v/v PEG400
|
Resolution 3.19 Å
R-free 0.264
|
|
6DY4
Fe(II)-bound structure of the engineered cyt cb562 variant, CH2E
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97E, R98C, Y101C
|
FE FE (III) ION × 1
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Drop consists of 2 uL of 25% PEG 1500, and 0.1 M Tris (pH 8.5) mixed with 2 uL of 4 mM protein and 2.5 mM Iron(II) Sulfate (Anaerobic crystal growth)
|
Resolution 1.90 Å
R-free 0.254
|
|
6DY4
Fe(II)-bound structure of the engineered cyt cb562 variant, CH2E
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97E, R98C, Y101C
|
FE FE (III) ION × 1
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Drop consists of 2 uL of 25% PEG 1500, and 0.1 M Tris (pH 8.5) mixed with 2 uL of 4 mM protein and 2.5 mM Iron(II) Sulfate (Anaerobic crystal growth)
|
Resolution 1.90 Å
R-free 0.254
|
|
6DY6
Mn(II)-bound structure of the engineered cyt cb562 variant, CH2E
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97E, R98C, Y101C
|
MN MANGANESE (II) ION × 2
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Drop consists of 1 uL of 30% PEG 400, 200 mM Ammonium Acetate and 0.1 M Tris (pH 8.5) mixed with 1 uL of 2.5 mM protein and 2 mM Manganese(II) Chloride
|
Resolution 1.80 Å
R-free 0.260
|
|
6DY6
Mn(II)-bound structure of the engineered cyt cb562 variant, CH2E
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97E, R98C, Y101C
|
HEC HEME C × 1
1PE PENTAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Drop consists of 1 uL of 30% PEG 400, 200 mM Ammonium Acetate and 0.1 M Tris (pH 8.5) mixed with 1 uL of 2.5 mM protein and 2 mM Manganese(II) Chloride
|
Resolution 1.80 Å
R-free 0.260
|
|
6DY8
Mn(II)-bound structure of the engineered cyt cb562 variant, CH2EY
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97E, R98C, Y101C
|
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Drop consists of 1 uL of 25% PEG 1500, 200 mM Calcium Chloride, and 0.1 M Tris (pH 8.5) mixed with 1 uL of 3.5 mM protein and 3.5 mM Manganese(II)Chloride
|
Resolution 1.90 Å
R-free 0.278
|
|
6DY8
Mn(II)-bound structure of the engineered cyt cb562 variant, CH2EY
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97E, R98C, Y101C
|
HEC HEME C × 1
MN MANGANESE (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Drop consists of 1 uL of 25% PEG 1500, 200 mM Calcium Chloride, and 0.1 M Tris (pH 8.5) mixed with 1 uL of 3.5 mM protein and 3.5 mM Manganese(II)Chloride
|
Resolution 1.90 Å
R-free 0.278
|
|
6DY8
Mn(II)-bound structure of the engineered cyt cb562 variant, CH2EY
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97E, R98C, Y101C
|
HEC HEME C × 1
MN MANGANESE (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Drop consists of 1 uL of 25% PEG 1500, 200 mM Calcium Chloride, and 0.1 M Tris (pH 8.5) mixed with 1 uL of 3.5 mM protein and 3.5 mM Manganese(II)Chloride
|
Resolution 1.90 Å
R-free 0.278
|
|
6DY8
Mn(II)-bound structure of the engineered cyt cb562 variant, CH2EY
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97E, R98C, Y101C
|
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Drop consists of 1 uL of 25% PEG 1500, 200 mM Calcium Chloride, and 0.1 M Tris (pH 8.5) mixed with 1 uL of 3.5 mM protein and 3.5 mM Manganese(II)Chloride
|
Resolution 1.90 Å
R-free 0.278
|
|
6DYB
Metal-free structure of the engineered cyt cb562 variant, CH3
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：K59W, I67H, Q71H, T96C, T97H, R98C, Y101C
|
HEC HEME C × 1
CA CALCIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；Drop consists of 1 uL of 30% PEG 400, 200 mM calcium chloride and 0.1 M Hepes (pH 7.5) mixed with 1 uL of 2.5 mM protein
|
Resolution 2.75 Å
R-free 0.309
|
|
6DYB
Metal-free structure of the engineered cyt cb562 variant, CH3
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Mutation：K59W, I67H, Q71H, T96C, T97H, R98C, Y101C
|
HEC HEME C × 1
CA CALCIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；Drop consists of 1 uL of 30% PEG 400, 200 mM calcium chloride and 0.1 M Hepes (pH 7.5) mixed with 1 uL of 2.5 mM protein
|
Resolution 2.75 Å
R-free 0.309
|
|
6DYC
Co(II)-bound structure of the engineered cyt cb562 variant, CH3
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：K59W, I67H, Q71H, T96C, T97H, R98C, Y101C
|
CO COBALT (II) ION × 1
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Drop consists of 2 uL of 25% PEG 3350, 200 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 5.5) mixed with 2 uL of 3 mM protein and 3 mM Cobalt(II) Chloride
|
Resolution 1.33 Å
R-free 0.192
|
|
6DYC
Co(II)-bound structure of the engineered cyt cb562 variant, CH3
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：K59W, I67H, Q71H, T96C, T97H, R98C, Y101C
|
HEC HEME C × 1
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Drop consists of 2 uL of 25% PEG 3350, 200 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 5.5) mixed with 2 uL of 3 mM protein and 3 mM Cobalt(II) Chloride
|
Resolution 1.33 Å
R-free 0.192
|
|
6DYD
Cu(II)-bound structure of the engineered cyt cb562 variant, CH3
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：K59W, I67H, Q71H, T96C, T97H, R98C, Y101C
|
CA CALCIUM ION × 2
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Drop consists of 2 uL of 45% MPD, 200 mM calcium chloride and 0.1 M Bis-Tris (pH 5.5) mixed with 2 uL of 2 mM protein and 2 mM Copper(II) sulfate
|
Resolution 1.72 Å
R-free 0.247
|
|
6DYD
Cu(II)-bound structure of the engineered cyt cb562 variant, CH3
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Mutation：K59W, I67H, Q71H, T96C, T97H, R98C, Y101C
|
CA CALCIUM ION × 3
HEC HEME C × 1
CU COPPER (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Drop consists of 2 uL of 45% MPD, 200 mM calcium chloride and 0.1 M Bis-Tris (pH 5.5) mixed with 2 uL of 2 mM protein and 2 mM Copper(II) sulfate
|
Resolution 1.72 Å
R-free 0.247
|
|
6DYE
Fe(II)-bound structure of the engineered cyt cb562 variant, CH3
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：K59W, I67H, Q71H, T96C, T97H, R98C, Y101C
|
FE FE (III) ION × 1
HEC HEME C × 1
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；Drop consists of 2 uL of 25% PEG 1500, 200 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 6.5) mixed with 2 uL of 3 mM protein and 2 mM Iron(II) Sulfate (Anaerobic crystal growth)
|
Resolution 2.25 Å
R-free 0.270
|
|
6DYE
Fe(II)-bound structure of the engineered cyt cb562 variant, CH3
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：K59W, I67H, Q71H, T96C, T97H, R98C, Y101C
|
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；Drop consists of 2 uL of 25% PEG 1500, 200 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 6.5) mixed with 2 uL of 3 mM protein and 2 mM Iron(II) Sulfate (Anaerobic crystal growth)
|
Resolution 2.25 Å
R-free 0.270
|
|
6DYF
Cu(II)-bound structure of the engineered cyt cb562 variant, CH3Y
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97H, R98C, Y101C
|
HEC HEME C × 1
CU COPPER (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Drop consists of 2 uL of 30% PEG 400, 200 mM Magnesium Choride and 0.1 M Bis-Tris (pH 5.5) mixed with 1 uL of 2.7 mM protein and 1.5 mM Copper(II) Sulfate
|
Resolution 1.10 Å
R-free 0.165
|
|
6DYF
Cu(II)-bound structure of the engineered cyt cb562 variant, CH3Y
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97H, R98C, Y101C
|
HEC HEME C × 1
PEG DI(HYDROXYETHYL)ETHER × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Drop consists of 2 uL of 30% PEG 400, 200 mM Magnesium Choride and 0.1 M Bis-Tris (pH 5.5) mixed with 1 uL of 2.7 mM protein and 1.5 mM Copper(II) Sulfate
|
Resolution 1.10 Å
R-free 0.165
|
|
6DYG
Fe(II)-bound structure of the engineered cyt cb562 variant, CH3Y
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97H, R98C, Y101C
|
HEC HEME C × 1
FE FE (III) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；Drop consists of 2 uL of 25% PEG 1500, 200 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 6.5) mixed with 1 uL of 2.7 mM protein and 1.5 mM Iron(II) Sulfate (Anaerobic crystal growth)
|
Resolution 1.49 Å
R-free 0.217
|
|
6DYG
Fe(II)-bound structure of the engineered cyt cb562 variant, CH3Y
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97H, R98C, Y101C
|
HEC HEME C × 1
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；293 K；Drop consists of 2 uL of 25% PEG 1500, 200 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 6.5) mixed with 1 uL of 2.7 mM protein and 1.5 mM Iron(II) Sulfate (Anaerobic crystal growth)
|
Resolution 1.49 Å
R-free 0.217
|
|
6DYH
Vanadyl-bound structure of the engineered cyt cb562 variant, CH3Y
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97H, R98C, Y101C
|
V VANADIUM ION × 1
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Drop consists of 1 uL of 40% PPG, 200 mM calcium chloride and 0.1 M Bis-Tris (pH 5.5) mixed with 1 uL of 3.5 mM protein and 2 mM Vanadyl Sulfate (Anaerobic crystal growth)
|
Resolution 1.83 Å
R-free 0.234
|
|
6DYH
Vanadyl-bound structure of the engineered cyt cb562 variant, CH3Y
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain D
23–128（106 aa）
|
Mutation：K59W, I67H, G70Y, Q71H, T96C, T97H, R98C, Y101C
|
HEC HEME C × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Drop consists of 1 uL of 40% PPG, 200 mM calcium chloride and 0.1 M Bis-Tris (pH 5.5) mixed with 1 uL of 3.5 mM protein and 2 mM Vanadyl Sulfate (Anaerobic crystal growth)
|
Resolution 1.83 Å
R-free 0.234
|
|
6DYI
Co(II)-bound structure of the engineered cyt cb562 variant, H3
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：K59W, I67H, Q71H, T97H, R98C, Y101C
|
CO COBALT (II) ION × 1
HEC HEME C × 1
CL CHLORIDE ION × 1
CA CALCIUM ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；Drop consists of 1 uL of 25% PEG 5000 MME, 200 mM Calcium Chloride and 0.1 M Tris (pH 8.5) mixed with 1 uL of 5 mM protein and 10 mM Cobalt(II) Chloride
|
Resolution 1.96 Å
R-free 0.255
|
|
6DYJ
Iron-bound structure of the engineered cyt b562 variant, CH3Y*
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M7W, K59W, I67H, G70Y, Q71H, T96C, T97H, Y101A, H102I, R106L
|
FE FE (III) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；Drop consists of 2 uL of 25% PEP 426, 100 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 6.0) mixed with 1 uL of 2 mM protein and 1.1 mM Iron(II) Sulfate (Anaerobic crystal growth)
|
Resolution 1.96 Å
R-free 0.252
|
|
6DYJ
Iron-bound structure of the engineered cyt b562 variant, CH3Y*
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Mutation：M7W, K59W, I67H, G70Y, Q71H, T96C, T97H, Y101A, H102I, R106L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；Drop consists of 2 uL of 25% PEP 426, 100 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 6.0) mixed with 1 uL of 2 mM protein and 1.1 mM Iron(II) Sulfate (Anaerobic crystal growth)
|
Resolution 1.96 Å
R-free 0.252
|
|
6DYJ
Iron-bound structure of the engineered cyt b562 variant, CH3Y*
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain E
23–128（106 aa）
|
Mutation：M7W, K59W, I67H, G70Y, Q71H, T96C, T97H, Y101A, H102I, R106L
|
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；Drop consists of 2 uL of 25% PEP 426, 100 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 6.0) mixed with 1 uL of 2 mM protein and 1.1 mM Iron(II) Sulfate (Anaerobic crystal growth)
|
Resolution 1.96 Å
R-free 0.252
|
|
6DYJ
Iron-bound structure of the engineered cyt b562 variant, CH3Y*
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain G
23–128（106 aa）
|
Mutation：M7W, K59W, I67H, G70Y, Q71H, T96C, T97H, Y101A, H102I, R106L
|
FE FE (III) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；Drop consists of 2 uL of 25% PEP 426, 100 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 6.0) mixed with 1 uL of 2 mM protein and 1.1 mM Iron(II) Sulfate (Anaerobic crystal growth)
|
Resolution 1.96 Å
R-free 0.252
|
|
6DYK
Iron- and Nitric Oxide-bound structure of the engineered cyt b562 variant, CH3Y*
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M7W, K59W, I67H, G70Y, Q71H, T96C, T97H, Y101A, H102I, R106L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；Drop consists of 2 uL of 25% PEP 426, 50 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 6.0) mixed with 1 uL of 4 mM protein and 2.2 mM Iron(II) Sulfate (Anaerobic crystal growth). Diethylamine NONOate (5 mM) was added to mother liquor prior to crystal harvest
|
Resolution 1.96 Å
R-free 0.249
|
|
6DYK
Iron- and Nitric Oxide-bound structure of the engineered cyt b562 variant, CH3Y*
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Mutation：M7W, K59W, I67H, G70Y, Q71H, T96C, T97H, Y101A, H102I, R106L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；Drop consists of 2 uL of 25% PEP 426, 50 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 6.0) mixed with 1 uL of 4 mM protein and 2.2 mM Iron(II) Sulfate (Anaerobic crystal growth). Diethylamine NONOate (5 mM) was added to mother liquor prior to crystal harvest
|
Resolution 1.96 Å
R-free 0.249
|
|
6DYK
Iron- and Nitric Oxide-bound structure of the engineered cyt b562 variant, CH3Y*
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain E
23–128（106 aa）
|
Mutation：M7W, K59W, I67H, G70Y, Q71H, T96C, T97H, Y101A, H102I, R106L
|
FE FE (III) ION × 1
NO NITRIC OXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；Drop consists of 2 uL of 25% PEP 426, 50 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 6.0) mixed with 1 uL of 4 mM protein and 2.2 mM Iron(II) Sulfate (Anaerobic crystal growth). Diethylamine NONOate (5 mM) was added to mother liquor prior to crystal harvest
|
Resolution 1.96 Å
R-free 0.249
|
|
6DYK
Iron- and Nitric Oxide-bound structure of the engineered cyt b562 variant, CH3Y*
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain G
23–128（106 aa）
|
Mutation：M7W, K59W, I67H, G70Y, Q71H, T96C, T97H, Y101A, H102I, R106L
|
FE FE (III) ION × 1
NO NITRIC OXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；Drop consists of 2 uL of 25% PEP 426, 50 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 6.0) mixed with 1 uL of 4 mM protein and 2.2 mM Iron(II) Sulfate (Anaerobic crystal growth). Diethylamine NONOate (5 mM) was added to mother liquor prior to crystal harvest
|
Resolution 1.96 Å
R-free 0.249
|
|
6DYL
Vanadyl-bound structure of the engineered cyt b562 variant, CH3Y*
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M7W, K59W, I67H, G70Y, Q71H, T96C, T97H, Y101A, H102I, R106L
|
V VANADIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Drop consists of 1 uL of 35% PEP 426, 50 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 5.5) mixed with 1 uL of 4 mM protein and 2.2 mM Vanadyl Sulfate (Anaerobic crystal growth)
|
Resolution 1.69 Å
R-free 0.226
|
|
6DYL
Vanadyl-bound structure of the engineered cyt b562 variant, CH3Y*
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Mutation：M7W, K59W, I67H, G70Y, Q71H, T96C, T97H, Y101A, H102I, R106L
|
V VANADIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Drop consists of 1 uL of 35% PEP 426, 50 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 5.5) mixed with 1 uL of 4 mM protein and 2.2 mM Vanadyl Sulfate (Anaerobic crystal growth)
|
Resolution 1.69 Å
R-free 0.226
|
|
6DYL
Vanadyl-bound structure of the engineered cyt b562 variant, CH3Y*
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain E
23–128（106 aa）
|
Mutation：M7W, K59W, I67H, G70Y, Q71H, T96C, T97H, Y101A, H102I, R106L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Drop consists of 1 uL of 35% PEP 426, 50 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 5.5) mixed with 1 uL of 4 mM protein and 2.2 mM Vanadyl Sulfate (Anaerobic crystal growth)
|
Resolution 1.69 Å
R-free 0.226
|
|
6DYL
Vanadyl-bound structure of the engineered cyt b562 variant, CH3Y*
Deposited 2018-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain G
23–128（106 aa）
|
Mutation：M7W, K59W, I67H, G70Y, Q71H, T96C, T97H, Y101A, H102I, R106L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；Drop consists of 1 uL of 35% PEP 426, 50 mM Magnesium Chloride and 0.1 M Bis-Tris (pH 5.5) mixed with 1 uL of 4 mM protein and 2.2 mM Vanadyl Sulfate (Anaerobic crystal growth)
|
Resolution 1.69 Å
R-free 0.226
|
|
6G7O
Crystal structure of human alkaline ceramidase 3 (ACER3) at 2.7 Angstrom resolution
Deposited 2018-04-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
ZN ZINC ION × 1
SO4 SULFATE ION × 6
NA SODIUM ION × 3
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
CA CALCIUM ION × 1
MG MAGNESIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7.5；293.15 K；75mM MgSO4, 34-40% PEG400, 5% DMSO
|
Resolution 2.70 Å
R-free 0.270
|
|
6GT3
Crystal Structure of the A2A-StaR2-bRIL562 in complex with AZD4635 at 2.0A resolution
Deposited 2018-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Mutation：;A54L, T88A, R107A, K122A, N154A, L202A, M1007W, H1102I, L235A, V239A, S277A,A54L, T88A, R107A, K122A, N154A, L202A, M1007W, H1102I, L235A, V239A, S277A,A54L, T88A, R107A, K122A, N154A, L202A, M1007W, H1102I, L235A, V239A, S277A
;
|
NA SODIUM ION × 1
F9Q 6-(2-chloranyl-6-methyl-pyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 15
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 10
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.3；293.15 K；0.1 M TRI-SODIUM CITRATE PH 5.3-5.4, 0.05 M SODIUM THIOCYANATE, 29-32% PEG400, 2%(V/V) 2,5-HEXANEDIOL
|
Resolution 2.00 Å
R-free 0.201
|
|
6IIU
Crystal structure of the human thromboxane A2 receptor bound to ramatroban
Deposited 2018-10-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M1007W/H1102I/R1106L/L247A
|
A8X 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid × 1
ZN ZINC ION × 1
CLR CHOLESTEROL × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；Magnesium acetate, PEG 500 DME
|
Resolution 2.50 Å
R-free 0.218
|
|
6IIV
Crystal structure of the human thromboxane A2 receptor bound to daltroban
Deposited 2018-10-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M1007W/H1102I/R1106L/L247A
|
A90 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethyl]phenyl]ethanoic acid × 1
ZN ZINC ION × 1
CLR CHOLESTEROL × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；Magnesium acetate, PEG 400
|
Resolution 3.00 Å
R-free 0.237
|
|
6IQL
Crystal structure of dopamine receptor D4 bound to the subtype-selective ligand, L745870
Deposited 2018-11-08
|
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
|
Mutation：F121W,C181R,P201I,M1007W,H1106L,P317A,G307A
Mutation：F121W,C181R,P201I,M1007W,H1106L,P317A,G307A
|
L74 3-{[4-(4-chlorophenyl)piperazin-1-yl]methyl}-1H-pyrrolo[2,3-b]pyridine × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；100 mM MES (pH 6.0), 50 mM ammonium citrate, 30% PEG 400
|
Resolution 3.50 Å
R-free 0.336
|
|
6JOD
Angiotensin II type 2 receptor with ligand
Deposited 2019-03-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain C
23–62（40 aa）
Chain C
89–128（40 aa）
|
Mutation：M1007W,R1098I,H1102I,R1106G
Mutation：M1007W,R1098I,H1102I,R1106G
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；30% (v/v) PEG 300
0.1 M HEPES (pH 7.0)
100 mM Sodium phosphate dibasic dihydrate
|
Resolution 3.20 Å
R-free 0.287
|
|
6JZH
Structure of human A2A adenosine receptor in complex with ZM241385 obtained from SFX experiments under atmospheric pressure
Deposited 2019-05-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：N154Q,M29W,H124I,R128L
|
NA SODIUM ION × 1
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
OLA OLEIC ACID × 19
CLR CHOLESTEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；27% (v/v) PEG400, 50-mM sodium thiocyanate, 2% (v/v) 2,5-hexanediol, 100-mM sodium citrate (pH 5.0)
|
Resolution 2.25 Å
R-free 0.218
|
|
6KO5
Complex structure of Ghrelin receptor with Fab
Deposited 2019-08-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
8QX 6-(4-bromanyl-2-fluoranyl-phenoxy)-2-methyl-3-[[(3~{S})-1-propan-2-ylpiperidin-3-yl]methyl]pyrido[3,2-d]pyrimidin-4-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM MES (pH6.6-7.0), 400 mM potassium acetate and 36-40% polyethylene glycol (PEG) 300.
|
Resolution 3.30 Å
R-free 0.258
|
|
6LPJ
A2AR crystallized in EROCOC17+4, LCP-SFX at 277 K
Deposited 2020-01-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M29W, H124I, R128L
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
D12 DODECANE × 1
MYS PENTADECANE × 6
HEX HEXANE × 1
8K6 Octadecane × 3
D10 DECANE × 1
OCT N-OCTANE × 3
UND UNDECANE × 1
ER0 [(2~{R},3~{S})-2,3,4-tris(oxidanyl)butyl] (5~{R},9~{R},13~{R})-5,9,13,17-tetramethyloctadecanoate × 2
TRD TRIDECANE × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM sodium citrate pH5.5, 37% PEG300, 50 mM NaSCN, and 2% 2,5-hexanediol
|
Resolution 1.80 Å
R-free 0.207
|
|
6LPK
A2AR crystallized in EROCOC17+4, LCP-SFX at 293 K
Deposited 2020-01-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M29W, H124I, R128L
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
D12 DODECANE × 1
MYS PENTADECANE × 6
HEX HEXANE × 1
8K6 Octadecane × 3
D10 DECANE × 1
OCT N-OCTANE × 3
UND UNDECANE × 1
ER0 [(2~{R},3~{S})-2,3,4-tris(oxidanyl)butyl] (5~{R},9~{R},13~{R})-5,9,13,17-tetramethyloctadecanoate × 2
TRD TRIDECANE × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM sodium citrate pH5.5, 37% PEG300, 50 mM NaSCN, and 2% 2,5-hexanediol
|
Resolution 1.80 Å
R-free 0.209
|
|
6LPL
A2AR crystallized in EROCOC17+4, SS-ROX at 100 K
Deposited 2020-01-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
D12 DODECANE × 1
MYS PENTADECANE × 6
HEX HEXANE × 1
8K6 Octadecane × 3
D10 DECANE × 1
OCT N-OCTANE × 3
UND UNDECANE × 1
ER0 [(2~{R},3~{S})-2,3,4-tris(oxidanyl)butyl] (5~{R},9~{R},13~{R})-5,9,13,17-tetramethyloctadecanoate × 2
TRD TRIDECANE × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100 mM sodium citrate pH5.5, 35-40% PEG400, 50 mM NaSCN, and 2% 2,5-hexanediol
|
Resolution 2.00 Å
R-free 0.208
|
|
6LW5
Crystal structure of the human formyl peptide receptor 2 in complex with WKYMVm
Deposited 2020-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
|
Mutation：M1007W, H1102I, R1106L, S211L
|
CLR CHOLESTEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；0.1 M Tris, pH 7.5, 35% PEG500 DME, 3% PPG400, 100 mM CH3COOLi
|
Resolution 2.80 Å
R-free 0.289
|
|
6M97
Crystal structure of the high-affinity copper transporter Ctr1
Deposited 2018-08-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
TBR HEXATANTALUM DODECABROMIDE × 6
ZN ZINC ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；50 mM zinc acetate, 50 mM sodium cacodylate pH 5.9, and 26% PEG 400.
|
Resolution 3.03 Å
R-free 0.332
|
|
6M98
Crystal structure of the high-affinity copper transporter Ctr1 in complex with Cu(I)
Deposited 2018-08-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
CU1 COPPER (I) ION × 6
ZN ZINC ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；293 K；50 mM zinc acetate, 50 mM sodium cacodylate pH 5.9, and 28% PEG 400.
|
Resolution 3.21 Å
R-free 0.340
|
|
6ME6
XFEL crystal structure of human melatonin receptor MT2 in complex with 2-phenylmelatonin
Deposited 2018-09-05
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：M2007W, H2102I, R2106L, P37S, D86N, L108F, F129W, N137D, C140L, W246F, A305P
Mutation：M2007W, H2102I, R2106L, P37S, D86N, L108F, F129W, N137D, C140L, W246F, A305P
|
JEY N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide × 2
ZN ZINC ION × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；N-(2-Acetamido)iminodiacetic acid, PEG 400, ammonium acetate
|
Resolution 2.80 Å
R-free 0.249
|
|
6ME7
XFEL crystal structure of human melatonin receptor MT2 (H208A) in complex with 2-phenylmelatonin
Deposited 2018-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M2007W, H2102I, R2106L, P37S, D86N, L108F, F129W, N137D, C140L, W246F, A305P
|
JEY N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide × 1
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；N-(2-Acetamido)iminodiacetic acid, PEG 400, ammonium acetate
|
Resolution 3.20 Å
R-free 0.250
|
|
6ME7
XFEL crystal structure of human melatonin receptor MT2 (H208A) in complex with 2-phenylmelatonin
Deposited 2018-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：M2007W, H2102I, R2106L, P37S, D86N, L108F, F129W, N137D, C140L, W246F, A305P
|
JEY N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；N-(2-Acetamido)iminodiacetic acid, PEG 400, ammonium acetate
|
Resolution 3.20 Å
R-free 0.250
|
|
6ME8
XFEL crystal structure of human melatonin receptor MT2 (N86D) in complex with 2-phenylmelatonin
Deposited 2018-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M2007W, H2102I, R2106L, P37S, D86N, L108F, F129W, N137D, C140L, W246F, A305P
|
JEY N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide × 1
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；N-(2-Acetamido)iminodiacetic acid, PEG 400, ammonium acetate
|
Resolution 3.10 Å
R-free 0.262
|
|
6ME8
XFEL crystal structure of human melatonin receptor MT2 (N86D) in complex with 2-phenylmelatonin
Deposited 2018-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：M2007W, H2102I, R2106L, P37S, D86N, L108F, F129W, N137D, C140L, W246F, A305P
|
JEY N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；N-(2-Acetamido)iminodiacetic acid, PEG 400, ammonium acetate
|
Resolution 3.10 Å
R-free 0.262
|
|
6ME9
XFEL crystal structure of human melatonin receptor MT2 in complex with ramelteon
Deposited 2018-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M2007W, H2102I, R2106L, P37S, D86N, L108F, F129W, N137D, C140L, W246F, A305P
|
JEV N-{2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl}propanamide × 1
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；N-(2-Acetamido)iminodiacetic acid, PEG 400, ammonium acetate
|
Resolution 3.30 Å
R-free 0.270
|
|
6ME9
XFEL crystal structure of human melatonin receptor MT2 in complex with ramelteon
Deposited 2018-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：M2007W, H2102I, R2106L, P37S, D86N, L108F, F129W, N137D, C140L, W246F, A305P
|
JEV N-{2-[(8S)-1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl]ethyl}propanamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；N-(2-Acetamido)iminodiacetic acid, PEG 400, ammonium acetate
|
Resolution 3.30 Å
R-free 0.270
|
|
6MH8
High-viscosity injector-based Pink Beam Serial Crystallography of Micro-crystals at a Synchrotron Radiation Source
Deposited 2018-09-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；298 K；sodium citrate pH 5.0, PEG 400, sodium thiocyanate
|
Resolution 4.20 Å
R-free 0.288
|
|
6OS0
Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to angiotensin II
Deposited 2019-05-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
24–122（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
CL CHLORIDE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7.6；293 K；Protein complex was reconstituted with a 10:1 (w/w) mixture of monoolein and cholesterol. Crystals were grown in 100 mM Tris pH 7.6, 10 mM MgCl2, 25-26% PEG 300
|
Resolution 2.90 Å
R-free 0.318
|
|
6OS1
Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to TRV023
Deposited 2019-05-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
24–122（99 aa）
|
Not recorded
|
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 6
CLR CHOLESTEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 8；293 K；Protein complex was reconstituted with a 10:1 (w/w) mixture of monoolein and cholesterol. Crystals were grown in 100 mM Tris pH 8, 50-70 mM MgCl2, 30% PEG 300, 2-4% 1,3-butanediol
|
Resolution 2.79 Å
R-free 0.282
|
|
6OS2
Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to TRV026
Deposited 2019-05-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
24–122（99 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 6
CLR CHOLESTEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 8；293 K；Protein complex was reconstituted with a 10:1 (w/w) mixture of monoolein and cholesterol. Crystals were grown in 100 mM Tris pH 8, 65 mM MgCl2, 26-28% PEG 300, 4.5% 1,3-butanediol
|
Resolution 2.70 Å
R-free 0.285
|
|
6OT4
Bimetallic dodecameric cage design 2 (BMC2) from cytochrome cb562
Deposited 2019-05-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 12
PDB declaration: dodecameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：E8H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：E8H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：E8H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：E8H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
|
HEC HEME C × 12
HAE ACETOHYDROXAMIC ACID × 24
FE FE (III) ION × 12
ZN ZINC ION × 18
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；Protein solution:
2.2 mM protein with 1.65 mM Fe and 2 mM Zn added 1 hour before crystallisation.
1 ul to 1 ul drops with following mother liquor:
30% PEG400, 0.1 M TrisHCl pH 8.5, 0.2 M NaCl
|
Resolution 1.40 Å
R-free 0.191
|
|
6OT7
Bimetallic dodecameric cage design 3 (BMC3) from cytochrome cb562
Deposited 2019-05-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 12
PDB declaration: dodecameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
|
HEC HEME C × 12
ZN ZINC ION × 21
FE FE (III) ION × 12
HAE ACETOHYDROXAMIC ACID × 24
1PE PENTAETHYLENE GLYCOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；Protein solution of:
2.2 mM protein with 1.65 mM Fe and 3 mM Zn premixed briefly prior to crystallisation.
Drops were 1ul + 1 ul of protein solution and the following mother liquor:
30% PEG400, 0.1 M HEPES pH 7.5, 0.2 M (NH4)2SO4
|
Resolution 1.85 Å
R-free 0.211
|
|
6OT8
Bimetallic hexameric cage design 4 (BMC4) from cytochrome cb562
Deposited 2019-05-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–128（106 aa）
|
Mutation：D2E,D5E,E8H,V16H,Q25E,R34Q,L38Q,Q41W,K42S,K59S,H63S,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
|
HEC HEME C × 6
ZN ZINC ION × 18
FE FE (III) ION × 6
HAE ACETOHYDROXAMIC ACID × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；Protein solution of:
2.2 mM protein with 1.05 mM Fe and 3 mM Zn premixed 1 hour prior to crystallisation.
Drops were 1ul + 1 ul of protein solution and the following mother liquor:
30% PEG400, 0.1 M HEPES pH 7.5, 0.2 M MgCl2
|
Resolution 1.50 Å
R-free 0.218
|
|
6OT9
Bimetallic dodecameric cage design 1 (BMC1) from cytochrome cb562
Deposited 2019-05-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 12
PDB declaration: dodecameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：E8H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,R98C,Y101C
Mutation：E8H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,R98C,Y101C
Mutation：E8H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,R98C,Y101C
Mutation：E8H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,R98C,Y101C
|
ZN ZINC ION × 18
HAE ACETOHYDROXAMIC ACID × 12
HEC HEME C × 12
FE FE (III) ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；Protein solution:
2.1 mM protein, 1.05 mM Fe, 2 mM Zn added 1 hour prior to crystallisation.
1 ul + 1ul drops from protein solution and following mother liquor;
22.5% PEG400, 0.1 M HEPES pH 7.5, 0.2 M NaCl
|
Resolution 2.40 Å
R-free 0.272
|
|
6OVH
Cryo-EM structure of Bimetallic dodecameric cage design 3 (BMC3) from cytochrome cb562
Deposited 2019-05-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 12
PDB declaration: dodecameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
Chain F
23–128（106 aa）
Chain G
23–128（106 aa）
Chain H
23–128（106 aa）
Chain I
23–128（106 aa）
Chain J
23–128（106 aa）
Chain K
23–128（106 aa）
Chain L
23–128（106 aa）
|
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
Mutation：D5H,E8H,V16H,A24T,Q25T,R34Q,L38Q,Q41W,K42S,K59S,H63C,D66W,I67E,V69I,D73N,D74A,K77H,N80K,E81Q,G82C,R98C,Y101C
|
HEC HEME C × 12
HAE ACETOHYDROXAMIC ACID × 24
ZN ZINC ION × 24
FE FE (III) ION × 8
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.60 Å
|
|
6PS7
XFEL A2aR structure by ligand exchange from LUF5843 to ZM241385.
Deposited 2019-07-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 9
CLR CHOLESTEROL × 3
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
OLA OLEIC ACID × 13
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；50mM sodium thiocyanate, 100 mM sodium citrate pH 4.8, and 28% PEG 400, 2 mM of target ligand ZM241385
|
Resolution 1.85 Å
R-free 0.201
|
|
6RZ4
Crystal structure of cysteinyl leukotriene receptor 1 in complex with pranlukast
Deposited 2019-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
KNT pranlukast × 1
NA SODIUM ION × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 9
OLA OLEIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；100 mM sodium citrate pH 6
200-600 mM lithium nitrate
30-38% v/v PEG400
|
Resolution 2.70 Å
R-free 0.254
|
|
6RZ5
XFEL crystal structure of the human cysteinyl leukotriene receptor 1 in complex with zafirlukast
Deposited 2019-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
ZLK zafirlukast × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 8
OLA OLEIC ACID × 11
1PE PENTAETHYLENE GLYCOL × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293 K；75-175 mM sodium phosphate
24-34% v/v PEG400
100 mM HEPES pH 7.0
1 uM zafirlukast
|
Resolution 2.53 Å
R-free 0.223
|
|
6RZ5
XFEL crystal structure of the human cysteinyl leukotriene receptor 1 in complex with zafirlukast
Deposited 2019-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–127（105 aa）
|
Not recorded
|
ZLK zafirlukast × 2
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 9
OLA OLEIC ACID × 8
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293 K；75-175 mM sodium phosphate
24-34% v/v PEG400
100 mM HEPES pH 7.0
1 uM zafirlukast
|
Resolution 2.53 Å
R-free 0.223
|
|
6RZ6
Crystal structure of the human cysteinyl leukotriene receptor 2 in complex with ONO-2570366 (C2221 space group)
Deposited 2019-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
KNW (2~{S})-8-[[4-[4-(2-chloranyl-5-fluoranyl-phenyl)butoxy]phenyl]carbonylamino]-4-(4-oxidanyl-4-oxidanylidene-butyl)-2,3- dihydro-1,4-benzoxazine-2-carboxylic acid × 1
CLR CHOLESTEROL × 1
TLA L(+)-TARTARIC ACID × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 16
OLA OLEIC ACID × 10
1PE PENTAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 8；293 K；100-200 mM NH4 Tartrate dibasic
28-32% v/v PEG400
100 mM HEPES pH 8.0
|
Resolution 2.43 Å
R-free 0.232
|
|
6RZ7
Crystal structure of the human cysteinyl leukotriene receptor 2 in complex with ONO-2570366 (F222 space group)
Deposited 2019-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
KNW (2~{S})-8-[[4-[4-(2-chloranyl-5-fluoranyl-phenyl)butoxy]phenyl]carbonylamino]-4-(4-oxidanyl-4-oxidanylidene-butyl)-2,3- dihydro-1,4-benzoxazine-2-carboxylic acid × 1
CLR CHOLESTEROL × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
OLA OLEIC ACID × 21
PGE TRIETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293 K；30 mM NH4 tartrate dibasic
24% PEG400
100 mM HEPES 7.0
|
Resolution 2.43 Å
R-free 0.259
|
|
6RZ8
Crystal structure of the human cysteinyl leukotriene receptor 2 in complex with ONO-2080365
Deposited 2019-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
KNZ (2~{S})-8-[[4-[4-[2,3-bis(fluoranyl)phenoxy]butoxy]-2-fluoranyl-phenyl]carbonylamino]-4-(4-oxidanyl-4-oxidanylidene-but yl)-2,3-dihydro-1,4-benzoxazine-2-carboxylic acid × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 10
OLA OLEIC ACID × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 8；293 K；100 mM K Formate
30% v/v PEG400
100 mM TRIS-HCl pH 8.0
|
Resolution 2.70 Å
R-free 0.246
|
|
6RZ9
Crystal structure of the human cysteinyl leukotriene receptor 2 in complex with ONO-2770372
Deposited 2019-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
KO5 (2~{S})-8-[[4-[4-(5-fluoranyl-2-methyl-phenyl)butoxy]phenyl]carbonylamino]-4-(4-oxidanyl-4-oxidanylidene-butyl)-2,3-dih ydro-1,4-benzoxazine-2-carboxylic acid × 1
CLR CHOLESTEROL × 1
1PE PENTAETHYLENE GLYCOL × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 13
OLA OLEIC ACID × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293 K；210mM NH4 tartrate dibasic
29% PEG400
HEPES 7.0
|
Resolution 2.73 Å
R-free 0.254
|
|
6S0Q
Structure of the A2A adenosine receptor determined at SwissFEL using native-SAD at 4.57 keV from 50,000 diffraction patterns
Deposited 2019-06-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Mutation：ADORA2A,ADORA2A,ADORA2A
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
OLA OLEIC ACID × 7
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
CLR CHOLESTEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；297 K；0.1M sodium citrate pH 5.0, 0.05M sodium thiocyanate, 28-34% PEG400, 5 mM ZM241385, 2% (v/v) 1,6-hexanedio
|
Resolution 2.65 Å
R-free 0.221
|
|
6UR8
CryoEM structure of human alpha4beta2 nicotinic acetylcholine receptor in complex with varenicline
Deposited 2019-10-22
|
Different construct
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–123（101 aa）
Chain D
23–123（101 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 8
QMR VARENICLINE × 2
BMA beta-D-mannopyranose × 3
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.71 Å
|
|
6USF
CryoEM structure of human alpha4beta2 nicotinic acetylcholine receptor with varenicline in complex with anti-BRIL synthetic antibody BAK5
Deposited 2019-10-26
|
Different construct
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 9
PDB declaration: nonameric
|
Chain A
23–123（101 aa）
Chain D
23–123（101 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
QMR VARENICLINE × 2
BMA beta-D-mannopyranose × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.87 Å
|
|
6WGT
Crystal structure of HTR2A with hallucinogenic agonist
Deposited 2020-04-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
7LD (8alpha)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide × 1
CLR CHOLESTEROL × 2
OLA OLEIC ACID × 2
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293.15 K；100 mM Tris (pH7.0)
370-410 mM KPO4-mono
90-120 mM GuHCl
28-34% PEG 400
|
Resolution 3.40 Å
R-free 0.305
|
|
6WGT
Crystal structure of HTR2A with hallucinogenic agonist
Deposited 2020-04-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Not recorded
|
7LD (8alpha)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide × 1
OLA OLEIC ACID × 1
PO4 PHOSPHATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293.15 K；100 mM Tris (pH7.0)
370-410 mM KPO4-mono
90-120 mM GuHCl
28-34% PEG 400
|
Resolution 3.40 Å
R-free 0.305
|
|
6WGT
Crystal structure of HTR2A with hallucinogenic agonist
Deposited 2020-04-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Not recorded
|
7LD (8alpha)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide × 1
PEG DI(HYDROXYETHYL)ETHER × 1
PO4 PHOSPHATE ION × 1
1PE PENTAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293.15 K；100 mM Tris (pH7.0)
370-410 mM KPO4-mono
90-120 mM GuHCl
28-34% PEG 400
|
Resolution 3.40 Å
R-free 0.305
|
|
6WH4
Crystal structure of HTR2A with inverse agonist
Deposited 2020-04-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
89F 1-methyl-4-[(5~{S})-3-methylsulfanyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl]piperazine × 1
OLA OLEIC ACID × 2
CLR CHOLESTEROL × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293.15 K；100 mM Tris (pH7.0)
380 mM potassium phosphate-monobasic
33% PEG 400
100 mM Guanidine HCL
300 mM NDSB-195
|
Resolution 3.40 Å
R-free 0.304
|
|
6WH4
Crystal structure of HTR2A with inverse agonist
Deposited 2020-04-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Not recorded
|
89F 1-methyl-4-[(5~{S})-3-methylsulfanyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl]piperazine × 1
OLA OLEIC ACID × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293.15 K；100 mM Tris (pH7.0)
380 mM potassium phosphate-monobasic
33% PEG 400
100 mM Guanidine HCL
300 mM NDSB-195
|
Resolution 3.40 Å
R-free 0.304
|
|
6WH4
Crystal structure of HTR2A with inverse agonist
Deposited 2020-04-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
|
Not recorded
|
89F 1-methyl-4-[(5~{S})-3-methylsulfanyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl]piperazine × 1
OLA OLEIC ACID × 1
CLR CHOLESTEROL × 1
PEG DI(HYDROXYETHYL)ETHER × 2
NDS ETHYL DIMETHYL AMMONIO PROPANE SULFONATE × 1
1PE PENTAETHYLENE GLYCOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293.15 K；100 mM Tris (pH7.0)
380 mM potassium phosphate-monobasic
33% PEG 400
100 mM Guanidine HCL
300 mM NDSB-195
|
Resolution 3.40 Å
R-free 0.304
|
|
6WHA
HTR2A bound to 25-CN-NBOH in complex with a mini-Galpha-q protein, beta/gamma subunits and an active-state stabilizing single-chain variable fragment (scFv16) obtained by cryo-electron microscopy (cryoEM)
Deposited 2020-04-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–127（105 aa）
Fragment：cybC (UNP residues 23-127) + linker + HTR2A (UNP residues 66-404)
|
Not recorded
|
U0G 4-(2-{[(2-hydroxyphenyl)methyl]amino}ethyl)-2,5-dimethoxybenzonitrile × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.36 Å
|
|
6WQA
2.0A angstrom A2a adenosine receptor structure using XFEL data collected in helium atmosphere.
Deposited 2020-04-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
NA SODIUM ION × 1
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 15
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 5
GOL GLYCEROL × 1
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；PEG400, sodium thiocyanate, sodium citrate
|
Resolution 2.00 Å
R-free 0.216
|
|
6WW2
Structure of human Frizzled5 by fiducial-assisted cryo-EM
Deposited 2020-05-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE；5s blotting
|
Resolution 3.70 Å
|
|
6WYU
Crystallographic trimer of metal-free TriCyt2
Deposited 2020-05-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：Q41K, D54A, K59I, H63V, V69L, G70W, D73H, K77H, R98C, Y101C
Mutation：Q41K, D54A, K59I, H63V, V69L, G70W, D73H, K77H, R98C, Y101C
Mutation：Q41K, D54A, K59I, H63V, V69L, G70W, D73H, K77H, R98C, Y101C
|
HEC HEME C × 3
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 3
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；43% MPD, 0.2 M (NH4)2SO4, 0.1 M Tris (pH 8.5)
|
Resolution 1.76 Å
R-free 0.191
|
|
6WZ0
Fe-bound structure of an engineered metal-dependent protein trimer, TriCyt2
Deposited 2020-05-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：Q41K, D54A, K59I, H63V, V69L, G70W, D73H, K77H, R98C, Y101C
Mutation：Q41K, D54A, K59I, H63V, V69L, G70W, D73H, K77H, R98C, Y101C
Mutation：Q41K, D54A, K59I, H63V, V69L, G70W, D73H, K77H, R98C, Y101C
|
HEC HEME C × 3
FE2 FE (II) ION × 1
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；25% PEG400, 0.2 M (NH4)2SO4, 0.1 M TRIS (pH 8.5)
|
Resolution 1.70 Å
R-free 0.212
|
|
6WZ1
Mn-bound structure of an engineered protein trimer, TriCyt3
Deposited 2020-05-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
|
HEC HEME C × 3
MN MANGANESE (II) ION × 1
CL CHLORIDE ION × 4
CA CALCIUM ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；30% PEG 400, 0.2 M CaCl2, 0.1 M BIS-TRIS (pH 6.5)
|
Resolution 2.00 Å
R-free 0.229
|
|
6WZ2
Co-bound structure of an engineered protein trimer, TriCyt3
Deposited 2020-05-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
|
HEC HEME C × 3
CO COBALT (II) ION × 1
CL CHLORIDE ION × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；25% PEG1500, 0.2 M MgCl2, 0.1 M HEPES (pH 7.5)
|
Resolution 2.00 Å
R-free 0.218
|
|
6WZ3
Cu-bound structure of the engineered protein trimer, TriCyt3
Deposited 2020-05-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
|
HEC HEME C × 3
CL CHLORIDE ION × 7
CU COPPER (II) ION × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；25% PEG1500, 0.2 M MgCl2, 0.1 M BIS-TRIS (pH 5.5)
|
Resolution 1.80 Å
R-free 0.236
|
|
6WZ7
Mn-bound structure of a TriCyt3 variant
Deposited 2020-05-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80E, E81K, R98C, Y101C
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80E, E81K, R98C, Y101C
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80E, E81K, R98C, Y101C
|
HEC HEME C × 3
MN MANGANESE (II) ION × 1
CL CHLORIDE ION × 5
CA CALCIUM ION × 9
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；45% MPD, 0.2 M calcium chloride, 0.1 M HEPES (pH 7.5)
|
Resolution 2.30 Å
R-free 0.219
|
|
6WZA
Ni-bound structure of an engineered metal-dependent protein trimer, TriCyt1
Deposited 2020-05-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：K59H, D66N, G70W, D73H, K77H, R98C, Y101C
Mutation：K59H, D66N, G70W, D73H, K77H, R98C, Y101C
Mutation：K59H, D66N, G70W, D73H, K77H, R98C, Y101C
|
HEC HEME C × 3
NI NICKEL (II) ION × 1
NA SODIUM ION × 5
CL CHLORIDE ION × 6
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；22.5% PEG 400, 0.2 M NaCl, 0.1 M HEPES (pH 7.5)
|
Resolution 2.50 Å
R-free 0.306
|
|
6WZC
Ni-bound structure of an engineered protein trimer, TriCyt3
Deposited 2020-05-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
|
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
|
HEC HEME C × 3
NI NICKEL (II) ION × 6
CA CALCIUM ION × 12
CL CHLORIDE ION × 9
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；25% PEG2000, 0.2 M CaCl2, 0.1 M Bis-Tris (pH 6.5)
|
Resolution 2.19 Å
R-free 0.219
|
|
6X7E
Co-bound structure of an engineered protein trimer, TriCyt3, with delta isomerism at the hexahistidine coordination site
Deposited 2020-05-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
Mutation：T31K, A35K, Q41K, D54A, K59I, H63V, I67E, V69A, G70W, Q71E, D73H, L76A, K77H, N80K, R98C, Y101C
|
HEC HEME C × 3
CO COBALT (II) ION × 1
CL CHLORIDE ION × 2
MG MAGNESIUM ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；25% PEG1500, 200 mM MgCl2, 100 mM TRIS (8.5)
|
Resolution 2.00 Å
R-free 0.213
|
|
6X8X
Cu-bound structure of an engineered metal-dependent protein trimer, TriCyt1
Deposited 2020-06-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
|
Mutation：K59H, D66N, G70W, D73H, K77H, R98C, Y101C
|
HEC HEME C × 3
CU COPPER (II) ION × 3
CA CALCIUM ION × 15
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；25% PEG2000, 200 mM CaCl2, 100 mM TRIS (pH 8.5)
|
Resolution 2.50 Å
R-free 0.342
|
|
6ZDR
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with Chromone 4d
Deposited 2020-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
QGE [3-(4-methyl-1,3-thiazol-2-yl)-4-oxidanylidene-6-propyl-chromen-7-yl] ethanoate × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 11
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；PEG 400; Sodium Citrate; Sodium Thiocyanate; 2,5 Hexanediol
|
Resolution 1.92 Å
R-free 0.218
|
|
6ZDV
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with Chromone 5d
Deposited 2020-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
QGW [2-methyl-3-(4-methyl-1,3-thiazol-2-yl)-4-oxidanylidene-6-propyl-chromen-7-yl] ethanoate × 1
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
OLA OLEIC ACID × 14
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；PEG 400, Sodium Citrate, Sodium Thiocyanate, 2,5 Hexanediol
|
Resolution 2.13 Å
R-free 0.224
|
|
7ARO
Crystal structure of the non-ribose partial agonist LUF5833 bound to the adenosine A2A receptor
Deposited 2020-10-25
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
RVZ 2-azanyl-6-(1~{H}-imidazol-2-ylmethylsulfanyl)-4-phenyl-pyridine-3,5-dicarbonitrile × 2
OLA OLEIC ACID × 8
CLR CHOLESTEROL × 2
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；300 K；29-32% PEG 400, 0.1M tri-sodium Citrate pH = 5.3-5.4, 0.05M Sodium Thiocyanate, 2.5 % 2,5-hexanediol
|
Resolution 3.12 Å
R-free 0.255
|
|
7BW0
Active human TGR5 complex with a synthetic agonist 23H
Deposited 2020-04-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.90 Å
|
|
7C61
Crystal structure of 5-HT1B-BRIL and SRP2070_Fab complex
Deposited 2020-05-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
|
Mutation：L138W,M1007W,H1102I,R1106L
|
ERM Ergotamine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；30% PEG400, 0.4M SODIUM THIOCYANATE, 0.1M SODIUM ACETATE PH 5.5
|
Resolution 3.00 Å
R-free 0.290
|
|
7C6A
Crystal structure of AT2R-BRIL and SRP2070_Fab complex
Deposited 2020-05-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
|
Mutation：L93V, F133W, M1007W, H1102I, R1106L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；0.05M POTASSIUM ACETATE, 0.1M MES PH6.5, 26-36% PEG300
|
Resolution 3.40 Å
R-free 0.285
|
|
7CMU
Dopamine Receptor D3R-Gi-Pramipexole complex
Deposited 2020-07-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Mutation：M35W,H130I,R134L
|
G6L (6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
7CMV
Dopamine Receptor D3R-Gi-PD128907 complex
Deposited 2020-07-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Mutation：M35W,H130I,R134L
|
G6O (4aR,10bR)-4-propyl-3,4a,5,10b-tetrahydro-2H-chromeno[4,3-b][1,4]oxazin-9-ol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.70 Å
|
|
7DFP
Human dopamine D2 receptor in complex with spiperone
Deposited 2020-11-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–62（40 aa）
Chain A
88–128（41 aa）
|
Mutation：S121K,L123W,M1007W,R1098I, H1102I, R1106G
Mutation：S121K,L123W,M1007W,R1098I, H1102I, R1106G
|
SIP 8-[4-(4-fluorophenyl)-4-oxidanylidene-butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 8；293 K；0.1M Tris-HCl pH 8.0, 0.1M Lithium acetate dihydrate, 30% (V/V) polyethylene glycol 400, 5% (v/v) dimethyl sulfoxide, 0.01M Adenosine triphosphate, 1mM spiperone
|
Resolution 3.10 Å
R-free 0.216
|
|
7E2X
Apo serotonin 1A (5-HT1A) receptor-Gi protein complex
Deposited 2021-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–128（106 aa）
|
Mutation：M7W,H102I,R106L,L125W
|
J40 [(2R)-1-[oxidanyl-[(2R,3R,5S,6R)-2,3,5,6-tetrakis(oxidanyl)-4-phosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-3-tetradecanoyloxy-propan-2-yl] (5E,8E)-hexadeca-5,8,11,14-tetraenoate × 1
CLR CHOLESTEROL × 10
PLM PALMITIC ACID × 3
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
7E2Y
Serotonin-bound Serotonin 1A (5-HT1A) receptor-Gi protein complex
Deposited 2021-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–128（106 aa）
|
Mutation：M7W,H102I,R106L,L125W
|
SRO SEROTONIN × 1
J40 [(2R)-1-[oxidanyl-[(2R,3R,5S,6R)-2,3,5,6-tetrakis(oxidanyl)-4-phosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-3-tetradecanoyloxy-propan-2-yl] (5E,8E)-hexadeca-5,8,11,14-tetraenoate × 1
CLR CHOLESTEROL × 4
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
7E2Z
Aripiprazole-bound serotonin 1A (5-HT1A) receptor-Gi protein complex
Deposited 2021-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–128（106 aa）
|
Mutation：M7W,H102I,R106L,L125W
|
9SC 7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one × 1
CLR CHOLESTEROL × 3
J40 [(2R)-1-[oxidanyl-[(2R,3R,5S,6R)-2,3,5,6-tetrakis(oxidanyl)-4-phosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-3-tetradecanoyloxy-propan-2-yl] (5E,8E)-hexadeca-5,8,11,14-tetraenoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å
|
|
7E32
Serotonin 1D (5-HT1D) receptor-Gi protein complex
Deposited 2021-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Mutation：M7W,H102I,R106L,L127W
|
SRO SEROTONIN × 1
CLR CHOLESTEROL × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å
|
|
7E33
Serotonin 1E (5-HT1E) receptor-Gi protein complex
Deposited 2021-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Mutation：M7W,H102I,R106L,L111W
|
HVU 3-(1-methylpiperidin-4-yl)-1H-indol-5-ol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å
|
|
7EXD
Lasmiditan-bound serotonin 1F (5-HT1F) receptor-Gi protein complex
Deposited 2021-05-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
05X 2,4,6-tris(fluoranyl)-N-[6-(1-methylpiperidin-4-yl)carbonylpyridin-2-yl]benzamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 3.40 Å
|
|
7EZC
Adenosine A2a receptor mutant-I92N
Deposited 2021-06-01
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–123（101 aa）
Chain B
23–123（101 aa）
|
Mutation：I92N,M1007W
Mutation：I92N,M1007W
|
UKA 6-(2,2-diphenylethylamino)-9-[(2R,3R,4S,5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-2-yl]-N-[2-[(1-pyridin-2-ylpiperidin-4-yl)carbamoylamino]ethyl]purine-2-carboxamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 8.2；291 K；100 mM Tris pH 8.2, 30% PEG400 and 0.4 M (NH4)2SO4.
|
Resolution 3.80 Å
R-free 0.313
|
|
7F61
Crystal structure of human histamine receptor H3R in complex with antagonist PF03654746
Deposited 2021-06-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain B
23–128（106 aa）
|
Mutation：M7W, H102I, R106L
|
1IB N-ethyl-3-fluoranyl-3-[3-fluoranyl-4-(pyrrolidin-1-ylmethyl)phenyl]cyclobutane-1-carboxamide × 1
CLR CHOLESTEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；294 K；100mM sodium cacodylate trihydrate, pH6.4, 90mM sodium citrate, 34% PEG400, 2% Dichloromethane
|
Resolution 2.60 Å
R-free 0.285
|
|
7F83
Crystal Structure of a receptor in Complex with inverse agonist
Deposited 2021-07-01
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：T130K,N188Q,M1012W,H1107I,R1111L
Mutation：T130K,N188Q,M1012W,H1107I,R1111L
|
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 6
1KQ 2-(2-methylimidazo[2,1-b][1,3]thiazol-6-yl)-1-[2-[(1R)-5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl]-2,7-diazaspiro[3.5]nonan-7-yl]ethanone × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；293.15 K；100mM HEPES, pH 7.0, 25%-36% PEG300, 80mM - 150mM NH4F
|
Resolution 2.94 Å
R-free 0.265
|
|
7IN1
Crystal structure of A2A in complex with TEP for 21h
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.49 Å
R-free 0.279
|
|
7IN2
Crystal structure of A2A in complex with 1 mM ZM241385 for 21h
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.43 Å
R-free 0.267
|
|
7IN3
Crystal structure of A2A in complex with 5 mM ZM241385 for 21h
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.66 Å
R-free 0.262
|
|
7IN4
Crystal structure of A2A in complex with 10 mM ZM241385 for 21h
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.66 Å
R-free 0.308
|
|
7IN5
Crystal structure of A2A in complex with TEP for 3h
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.49 Å
R-free 0.257
|
|
7IN6
Crystal structure of A2A in complex with 1 mM ZM241385 for 3h
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.52 Å
R-free 0.333
|
|
7IN7
Crystal structure of A2A in complex with 5 mM ZM241385 for 3h
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.43 Å
R-free 0.271
|
|
7IN8
Crystal structure of A2A in complex with 10 mM ZM241385 for 3h
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.52 Å
R-free 0.300
|
|
7IN9
Crystal structure of A2A in complex with Fi16
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1COM (3M)-3-(2-methyl-1,3-thiazol-4-yl)pyridine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.54 Å
R-free 0.227
|
|
7INA
Crystal structure of A2A in complex with F2
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CON 2-{[5-(trifluoromethyl)pyridin-2-yl]sulfanyl}acetamide × 1
TEP THEOPHYLLINE × 1
DMS DIMETHYL SULFOXIDE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.15 Å
R-free 0.284
|
|
7INB
Crystal structure of A2A in complex with F4
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
8ZX 4-methoxybenzamide × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.10 Å
R-free 0.266
|
|
7INC
Crystal structure of A2A in complex with F7
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1COP (1R)-1-(1H-1,3-benzimidazol-2-yl)ethan-1-ol × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.18 Å
R-free 0.245
|
|
7IND
Crystal structure of A2A in complex with F12
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1COO 4-fluorobenzene-1-carbothioamide × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.67 Å
R-free 0.258
|
|
7INE
Crystal structure of A2A in complex with F35
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
VN9 3,4-dihydro-1~{H}-quinolin-2-one × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.28 Å
R-free 0.257
|
|
7INF
Crystal structure of A2A in complex with F44
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1COQ 2,4-difluorobenzene-1-carbothioamide × 1
TEP THEOPHYLLINE × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.26 Å
R-free 0.247
|
|
7ING
Crystal structure of A2A in complex with F99
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
ES2 6-chloro-1,3-dihydro-2H-indol-2-one × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.15 Å
R-free 0.238
|
|
7INH
Crystal structure of A2A in complex with F132
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1COR 6-bromo-2-methyl-4H-3,1-benzoxazin-4-one × 1
TEP THEOPHYLLINE × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.30 Å
R-free 0.282
|
|
7INI
Crystal structure of A2A in complex with F135
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1COV 5~{H}-pyrido[2,1-b]quinazolin-11-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.57 Å
R-free 0.259
|
|
7INJ
Crystal structure of A2A in complex with F148
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1COW (4-chlorophenyl)[2-(methylsulfanyl)-1H-imidazol-1-yl]methanone × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.10 Å
R-free 0.271
|
|
7INK
Crystal structure of A2A in complex with F163
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1COX methyl 1H-indole-6-carboxylate × 1
TEP THEOPHYLLINE × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.19 Å
R-free 0.248
|
|
7INL
Crystal structure of A2A in complex with F173
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1COY 5-methyl-1,2-oxazole-3-carbothioamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.20 Å
R-free 0.250
|
|
7INM
Crystal structure of A2A in complex with F178
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
U4D 5-(trifluoromethyl)pyridin-2-one × 1
TEP THEOPHYLLINE × 1
DMS DIMETHYL SULFOXIDE × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.19 Å
R-free 0.241
|
|
7INN
Crystal structure of A2A in complex with F210
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1COZ N-(4-chlorophenyl)thiourea × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.32 Å
R-free 0.234
|
|
7INO
Crystal structure of A2A in complex with F223
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CO0 N-[2-amino-4-(trifluoromethyl)phenyl]acetamide × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.08 Å
R-free 0.228
|
|
7INP
Crystal structure of A2A in complex with F235
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
YPN 2-[(5-CHLORO-2-PYRIDYL)SULFANYL]ETHANOL × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.21 Å
R-free 0.242
|
|
7INQ
Crystal structure of A2A in complex with F242
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
2O8 4-[(trifluoromethyl)sulfanyl]benzamide × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.19 Å
R-free 0.242
|
|
7INR
Crystal structure of A2A in complex with F273
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
LR5 4-(trifluoromethyl)benzamide × 1
TEP THEOPHYLLINE × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.13 Å
R-free 0.234
|
|
7INT
Crystal structure of A2A in complex with F293
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CO1 2-(methylsulfanyl)-1H-1,3-benzimidazole × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.25 Å
R-free 0.253
|
|
7INU
Crystal structure of A2A in complex with F336
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CO2 (2S)-2-methyl-6-(trifluoromethyl)-2H-1,4-benzothiazin-3(4H)-one × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.46 Å
R-free 0.279
|
|
7INV
Crystal structure of A2A in complex with F379
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
Y25 5-chloropyridin-3-ol × 1
TEP THEOPHYLLINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.57 Å
R-free 0.246
|
|
7INW
Crystal structure of A2A in complex with F428
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1BL1 N-[4-(trifluoromethyl)phenyl]acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.59 Å
R-free 0.244
|
|
7INX
Crystal structure of A2A in complex with FU2-57
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CO3 (2S)-3-{methyl[5-(trifluoromethyl)pyridin-2-yl]amino}propane-1,2-diol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.31 Å
R-free 0.246
|
|
7INY
Crystal structure of A2A in complex with FU2-59
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CS6 1-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}ethan-1-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.36 Å
R-free 0.229
|
|
7INZ
Crystal structure of A2A in complex with FU4-40
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CO5 4-(4-methoxyphenyl)-2H-1lambda~4~,3-thiazol-2-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.41 Å
R-free 0.239
|
|
7IO0
Crystal structure of A2A in complex with FU4-54
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CO6 6-(4-methoxyphenyl)pyrimidine-2,4(3H,5H)-dione × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.05 Å
R-free 0.240
|
|
7IO1
Crystal structure of A2A in complex with FU7-1
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CO7 6-methoxy-1H-indole-2-carboxylic acid × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.25 Å
R-free 0.243
|
|
7IO2
Crystal structure of A2A in complex with FU7-15
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CO8 2-(1H-1,3-benzimidazol-2-yl)acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.96 Å
R-free 0.242
|
|
7IO3
Crystal structure of A2A in complex with FU7-29
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CO9 (6-bromo-1H-indol-2-yl)methanol × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.22 Å
R-free 0.246
|
|
7IO4
Crystal structure of A2A in complex with FU12-19
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1IGL (4R)-4-phenyl-1,3-oxazolidin-2-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.10 Å
R-free 0.244
|
|
7IO5
Crystal structure of A2A in complex with FU12-45
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPA 4-chloro-N-hydroxybenzamide × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.84 Å
R-free 0.237
|
|
7IO6
Crystal structure of A2A in complex with FU12-86
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPB 2-phenyl-1H-pyrrolo[2,3-b]pyridine × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.36 Å
R-free 0.236
|
|
7IO7
Crystal structure of A2A in complex with FU18-60
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPC 3-(3-hydroxypropyl)-3,5-dihydro-4H-pyrimido[5,4-b]indol-4-one × 1
PEG DI(HYDROXYETHYL)ETHER × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.23 Å
R-free 0.243
|
|
7IO8
Crystal structure of A2A in complex with FU18-82
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPD 2-{[(R)-methanesulfinyl]methyl}-1H-1,3-benzimidazole × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.27 Å
R-free 0.247
|
|
7IO9
Crystal structure of A2A in complex with FU35-2
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPE (2R)-2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-2-carboxylic acid × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.91 Å
R-free 0.256
|
|
7IOA
Crystal structure of A2A in complex with FU35-5
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPF N-phenyl-1H-tetrazol-5-amine × 1
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.10 Å
R-free 0.236
|
|
7IOB
Crystal structure of A2A in complex with FU35-42
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPH N~5~-phenyl-1,2,4-thiadiazole-3,5-diamine × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.11 Å
R-free 0.237
|
|
7IOC
Crystal structure of A2A in complex with FU18-82
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPI N-phenyl-1,3,4-thiadiazol-2-amine × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.07 Å
R-free 0.256
|
|
7IOD
Crystal structure of A2A in complex with FU35-78
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPJ (3-anilino-1,2,4-oxadiazol-5-yl)methanol × 1
PEG DI(HYDROXYETHYL)ETHER × 1
DMS DIMETHYL SULFOXIDE × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.40 Å
R-free 0.241
|
|
7IOE
Crystal structure of A2A in complex with FU44-18
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPK 4-chloro-N-(2-hydroxyethoxy)benzamide × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.08 Å
R-free 0.225
|
|
7IOF
Crystal structure of A2A in complex with FU99-31
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPL 5-chloro-2-{[3-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]sulfanyl}-1H-1,3-benzimidazole × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.90 Å
R-free 0.244
|
|
7IOG
Crystal structure of A2A in complex with FU99-89
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPM 2-[(5-chloro-1H-1,3-benzimidazol-2-yl)sulfanyl]acetamide × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.98 Å
R-free 0.236
|
|
7IOH
Crystal structure of A2A in complex with FU99-91
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPN 4-[(1H-1,3-benzimidazol-2-yl)sulfanyl]butanamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.07 Å
R-free 0.238
|
|
7IOI
Crystal structure of A2A in complex with FU101-88
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPO N-(3-fluoro-4-methoxyphenyl)-1H-1,2,3-triazole-4-carboxamide × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.04 Å
R-free 0.235
|
|
7IOJ
Crystal structure of A2A in complex with FU113-13
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPP N-[(furan-2-yl)methyl]thiophene-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.26 Å
R-free 0.238
|
|
7IOK
Crystal structure of A2A in complex with FU113-99
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPQ 5-fluoro-N-[(1H-pyrazol-3-yl)methyl]thiophene-2-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.30 Å
R-free 0.242
|
|
7IOL
Crystal structure of A2A in complex with FU132-3
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPR N-(4-bromophenyl)-1H-imidazole-4-carboxamide × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.81 Å
R-free 0.241
|
|
7IOM
Crystal structure of A2A in complex with FU18-82
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPS 2-(4-bromophenyl)-1lambda~6~,2-thiazinane-1,1-dione × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.10 Å
R-free 0.281
|
|
7ION
Crystal structure of A2A in complex with FU132-90
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPT ({2-oxo-2-[4-(trifluoromethyl)anilino]ethyl}sulfanyl)acetic acid × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.14 Å
R-free 0.244
|
|
7IOO
Crystal structure of A2A in complex with FU132,428-27
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPU 5-bromo-2-carbamamidobenzoic acid × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.01 Å
R-free 0.236
|
|
7IOP
Crystal structure of A2A in complex with FU163-33
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPV methyl 6-bromo-1H-indole-2-carboxylate × 1
DMS DIMETHYL SULFOXIDE × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.92 Å
R-free 0.230
|
|
7IOQ
Crystal structure of A2A in complex with FU163-51
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPW N-[2-(1H-imidazol-2-yl)ethyl]-6-(trifluoromethyl)-1H-indole-2-carboxamide × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.26 Å
R-free 0.233
|
|
7IOR
Crystal structure of A2A in complex with FU163-53
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPX 3-hydroxypropyl 6-(trifluoromethyl)-1H-indole-2-carboxylate × 1
PEG DI(HYDROXYETHYL)ETHER × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.89 Å
R-free 0.233
|
|
7IOS
Crystal structure of A2A in complex with FU163-58
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPY 3-[2-(1H-imidazol-4-yl)ethyl]-7-methoxy-3,5-dihydro-4H-pyrimido[5,4-b]indol-4-one × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.38 Å
R-free 0.240
|
|
7IOT
Crystal structure of A2A in complex with FU163-67
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CPZ 6-bromo-1H-indole-2-carboxamide × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.31 Å
R-free 0.245
|
|
7IOU
Crystal structure of A2A in complex with FU163-75
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CP0 N-(2-amino-2-oxoethyl)-6-chloro-1H-indole-2-carboxamide × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.17 Å
R-free 0.234
|
|
7IOV
Crystal structure of A2A in complex with FU163-104
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CP1 7-bromo-3-methyl-3,5-dihydro-4H-pyridazino[4,5-b]indol-4-one × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.30 Å
R-free 0.236
|
|
7IOW
Crystal structure of A2A in complex with FU163-106
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CP2 N-{2-[(furan-2-carbonyl)amino]ethyl}-6-(propan-2-yl)-1H-indole-2-carboxamide × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.17 Å
R-free 0.225
|
|
7IOX
Crystal structure of A2A in complex with FU163-109
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CP3 [(3S)-3-(1H-1,3-benzimidazol-1-yl)pyrrolidin-1-yl](6-methoxy-1H-indol-2-yl)methanone × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.15 Å
R-free 0.250
|
|
7IOY
Crystal structure of A2A in complex with FU210-12
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CP4 N-(4-fluorophenyl)-N'-{2-[3-(pyridin-2-yl)-1H-pyrazol-1-yl]ethyl}urea × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.00 Å
R-free 0.244
|
|
7IOZ
Crystal structure of A2A in complex with FU223-7
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CP5 5-chloro-1,3-benzothiazol-2(3H)-one × 1
PEG DI(HYDROXYETHYL)ETHER × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.88 Å
R-free 0.242
|
|
7IP0
Crystal structure of A2A in complex with FU223-43
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CP6 methyl (3-methylphenyl)carbamate × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.99 Å
R-free 0.259
|
|
7IP1
Crystal structure of A2A in complex with FU235-66
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CP7 (2S)-3-[(5-chloropyridin-2-yl)sulfanyl]propane-1,2-diol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.29 Å
R-free 0.243
|
|
7IP2
Crystal structure of A2A in complex with FU242-98
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CP8 N-[4-(trifluoromethoxy)phenyl]urea × 1
PEG DI(HYDROXYETHYL)ETHER × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.13 Å
R-free 0.232
|
|
7IP3
Crystal structure of A2A in complex with FU273-23
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CP9 N-[2-(methanesulfonamido)ethyl]-4-(trifluoromethyl)benzamide × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.11 Å
R-free 0.238
|
|
7IP4
Crystal structure of A2A in complex with FU273-77
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CQA 3-[(4-bromophenyl)methanesulfonyl]propan-1-ol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.04 Å
R-free 0.222
|
|
7IP5
Crystal structure of A2A in complex with FU293-69
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CQB N-(2-hydroxyethyl)-1H-indole-2-carboxamide × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.95 Å
R-free 0.239
|
|
7IP6
Crystal structure of A2A in complex with FU293-80
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
6N4 2-(1H-BENZIMIDAZOL-2-YLSULFANYL)ETHANOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.07 Å
R-free 0.223
|
|
7IP7
Crystal structure of A2A in complex with FU293-87
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CQC 1-(1H-1,3-benzimidazol-2-yl)ethan-1-one × 1
DMS DIMETHYL SULFOXIDE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.32 Å
R-free 0.238
|
|
7IP8
Crystal structure of A2A in complex with FU300-24
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CQD 3-hydroxy-N-[(1H-pyrrol-2-yl)methyl]-4-(trifluoromethyl)benzamide × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.28 Å
R-free 0.252
|
|
7IP9
Crystal structure of A2A in complex with FU336-22
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CQE N-{[(2S)-3-oxo-6-(trifluoromethyl)-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetyl}glycine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.10 Å
R-free 0.238
|
|
7IPA
Crystal structure of A2A in complex with FU336-32
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CQF 1-{[(2S)-6-chloro-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetyl}azetidine-3-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.32 Å
R-free 0.250
|
|
7IPB
Crystal structure of A2A in complex with FU336-34
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CQG (2S)-3-{2-[(2S)-6-chloro-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]acetamido}-2-hydroxy-2-methylpropanoic acid × 1
DMS DIMETHYL SULFOXIDE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.09 Å
R-free 0.250
|
|
7IPC
Crystal structure of A2A in complex with FU336-61
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CQH 2-[(2S)-6-chloro-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-2-yl]-N-[(2S)-2,3-dihydroxypropyl]acetamide × 1
DMS DIMETHYL SULFOXIDE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.87 Å
R-free 0.226
|
|
7IPD
Crystal structure of A2A in complex with FU379-101
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CQI 7-chloroquinolin-2(1H)-one × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.19 Å
R-free 0.240
|
|
7IPE
Crystal structure of A2A in complex with FU428-8
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CQJ (3R)-3-(4-bromophenyl)-4-[(5S)-2-oxo-2,5-dihydro-1,3-oxazole-5-carbonyl]piperazin-2-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.84 Å
R-free 0.245
|
|
7IPF
Crystal structure of A2A in complex with FU428-16
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CQK N-(4-ethylphenyl)-2-[(6-methyl-2-oxo-2,5-dihydropyrimidin-4-yl)sulfanyl]acetamide × 1
DMS DIMETHYL SULFOXIDE × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 1.90 Å
R-free 0.240
|
|
7IPG
Crystal structure of A2A in complex with FU428-36
Deposited 2025-08-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Mutation：A54L,T88A,R107A,K122A,N154A,L202A,L235A,V239A
|
NA SODIUM ION × 1
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
A1CS8 (3S)-4-[(2R)-2-hydroxybutanoyl]-3-[4-(trifluoromethyl)phenyl]piperazin-2-one × 1
A1CQL (3R)-4-[(2R)-2-hydroxybutanoyl]-3-[4-(trifluoromethyl)phenyl]piperazin-2-one × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.5；293 K；0.1M MES PH 5.5, 0.2M K/NA TARTRATE, 27.5-40% PEG400, 0.5-1% (V/V) (+/-)-2-METHYL-2,4-PENTANEDIOL
|
Resolution 2.06 Å
R-free 0.249
|
|
7JNI
Crystal structure of the angiotensin II type 2 receptoror (AT2R) in complex with EMA401
Deposited 2020-08-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M29W,H124I,R128L in cyt b562
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
VFD Olodanrigan × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
OLA OLEIC ACID × 3
FMT FORMIC ACID × 1
HEZ HEXANE-1,6-DIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；Tris-HCl pH 8.0,
Potassium Formate,
PEG400, and 1,6-hexanediol
|
Resolution 3.00 Å
R-free 0.273
|
|
7JNI
Crystal structure of the angiotensin II type 2 receptoror (AT2R) in complex with EMA401
Deposited 2020-08-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Mutation：M29W,H124I,R128L in cyt b562
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
VFD Olodanrigan × 1
OLA OLEIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；Tris-HCl pH 8.0,
Potassium Formate,
PEG400, and 1,6-hexanediol
|
Resolution 3.00 Å
R-free 0.273
|
|
7JVR
Cryo-EM structure of Bromocriptine-bound dopamine receptor 2 in complex with Gi protein
Deposited 2020-08-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
08Y bromoergocryptine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å
|
|
7KOO
Alpha-7 nicotinic acetylcholine receptor bound to alpha-bungarotoxin in a resting state
Deposited 2020-11-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 10
PDB declaration: decameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
CA CALCIUM ION × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
7KOQ
Alpha-7 nicotinic acetylcholine receptor bound to epibatidine in a desensitized state
Deposited 2020-11-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10
EPJ EPIBATIDINE × 5
CA CALCIUM ION × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.60 Å
|
|
7KOX
Alpha-7 nicotinic acetylcholine receptor bound to epibatidine and PNU-120596 in the activated state
Deposited 2020-11-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10
EPJ EPIBATIDINE × 5
CA CALCIUM ION × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.70 Å
|
|
7LR5
Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presence of Ni(II) (M1) and Cu(II) (M2)
Deposited 2021-02-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：D60H, I67H, Q71H, T97H, A100H, K104H
Mutation：D60H, I67H, Q71H, T97H, A100H, K104H
|
HEC HEME C × 2
NI NICKEL (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；PEG1500 25%, pH 8 EPPS 100 mM, No salt,
|
Resolution 1.70 Å
R-free 0.230
|
|
7LRA
Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presence of Cu(II) (M1) and Ni(II) (M2)
Deposited 2021-02-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：D60H, I67H, Q71H, T97H, A100H, K104H
Mutation：D60H, I67H, Q71H, T97H, A100H, K104H
|
HEC HEME C × 2
NI NICKEL (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.4；293 K；PEG1500 25%, Ammonium acetate 200 mM, pH 8.4 EPPS 100 mM
|
Resolution 1.70 Å
R-free 0.214
|
|
7LRB
Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presence of Ni(II) (M1) and Cu(II) (M2)
Deposited 2021-02-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：D60H, I67H, Q71H, T97H, A100H, K104H
Mutation：D60H, I67H, Q71H, T97H, A100H, K104H
|
HEC HEME C × 2
CO COBALT (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG1500 25%, Ammonium acetate 160 mM, pH 8.4 EPPS 100 mM
|
Resolution 1.78 Å
R-free 0.211
|
|
7LRR
Co-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presence of Cu(II) (M1) and Co(II) (M2)
Deposited 2021-02-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：D60H, I67H, Q71H, T96C, T97H, A100H, K104H
Mutation：D60H, I67H, Q71H, T96C, T97H, A100H, K104H
|
HEC HEME C × 2
CO COBALT (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；PEG1500 25%, NaCl 200 mM, pH 8 EPPS 100 mM
|
Resolution 1.89 Å
R-free 0.229
|
|
7LRV
Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presence of Ni(II)
Deposited 2021-02-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：D60H, I67H, Q71H, T96C, T97H, A100H, K104H
Mutation：D60H, I67H, Q71H, T96C, T97H, A100H, K104H
|
HEC HEME C × 2
NI NICKEL (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；PEG1500 25%, pH 8 EPPS 100 mM
|
Resolution 1.40 Å
R-free 0.216
|
|
7LSJ
Cu-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 - H63A, crystallized in the presence of Cu(II)
Deposited 2021-02-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：D60H, H63A, I67H, Q71H, T96C, T97H, A100H, K104H
Mutation：D60H, H63A, I67H, Q71H, T96C, T97H, A100H, K104H
|
HEC HEME C × 2
CA CALCIUM ION × 5
CU COPPER (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；PEG1500 24%, CaCl2 200 mM, pH 8 EPPS 100 mM
|
Resolution 1.26 Å
R-free 0.192
|
|
7LSL
Cu-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 - H63A, crystallized in the presence of Ni(II)
Deposited 2021-02-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：D60H, H63A, I67H, Q71H, T96C, T97H, A100H, K104H
Mutation：D60H, H63A, I67H, Q71H, T96C, T97H, A100H, K104H
|
HEC HEME C × 2
NI NICKEL (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；PEG1500 25%, NH4Ac 200 mM, pH 7 MOPS 100 mM
|
Resolution 1.64 Å
R-free 0.244
|
|
7LSN
Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 - H63A, crystallized in the presence of Ni(II)
Deposited 2021-02-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：D60H, H63A, I67H, Q71H, T96C, T97H, A100H, K104H
Mutation：D60H, H63A, I67H, Q71H, T96C, T97H, A100H, K104H
|
HEC HEME C × 2
NI NICKEL (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；PEG1500 25%, (NH4)2SO4 120 mM, pH 8 EPPS 100 mM
|
Resolution 1.52 Å
R-free 0.236
|
|
7LV1
Cu-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presence of Cu(II)
Deposited 2021-02-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：D60H, I67H, Q71H, T96C, T97H, A100H, K104H
Mutation：D60H, I67H, Q71H, T96C, T97H, A100H, K104H
|
HEC HEME C × 2
CA CALCIUM ION × 4
CU COPPER (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；293 K；PEG1500 25%, CaCl2 200 mM, pH 6 MES 100 mM
|
Resolution 1.91 Å
R-free 0.237
|
|
7LV4
Cu-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 - H97A, crystallized in the presence of Cu(II)
Deposited 2021-02-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：D60H, I67H, Q71H, T96C, T97A, A100H, K104H
Mutation：D60H, I67H, Q71H, T96C, T97A, A100H, K104H
|
HEC HEME C × 2
CA CALCIUM ION × 3
CU COPPER (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；293 K；PEG1500 25%, CaCl2 200 mM, pH 7 MOPS 100 mM
|
Resolution 1.99 Å
R-free 0.306
|
|
7MK4
Co-bound crystal structure of the engineered cyt cb562 variant, DiCyt2
Deposited 2021-04-21
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Not recorded
|
HEC HEME C × 2
CO COBALT (II) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.6；298 K；PEG1500 25%, NaCl 140 mM, pH 6.6 MES 100 mM
|
Resolution 1.27 Å
R-free 0.213
|
|
7MYZ
Structure of the full length 5-TM receptor CD47 bound to Fab B6H12
Deposited 2021-05-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain C
23–127（105 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；100mM sodium citrate pH 6.0, 450mM ammonium acetate, 32% PEG400
|
Resolution 3.40 Å
R-free 0.277
|
|
7MYZ
Structure of the full length 5-TM receptor CD47 bound to Fab B6H12
Deposited 2021-05-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain D
23–127（105 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；100mM sodium citrate pH 6.0, 450mM ammonium acetate, 32% PEG400
|
Resolution 3.40 Å
R-free 0.277
|
|
7N4F
Ni-bound crystal structure of the engineered cyt cb562 variant, AB2-H100A, crystallized in the presence of Ni(II)
Deposited 2021-06-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：K59W, D60H, I67H, Q71H, T96C, T97H, R98C, Y101C, K104H
Mutation：K59W, D60H, I67H, Q71H, T96C, T97H, R98C, Y101C, K104H
|
HEC HEME C × 2
NI NICKEL (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；298 K；PEG1500 25%, MgCl2 200 mM, pH 7 MOPS 100 mM
|
Resolution 1.80 Å
R-free 0.254
|
|
7N4G
Co-bound crystal structure of the engineered cyt cb562 variant, AB2-H100A, crystallized in the presence of Co(II)
Deposited 2021-06-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：K59W, D60H, I67H, Q71H, T96C, T97H, R98C, Y101C, K104H
Mutation：K59W, D60H, I67H, Q71H, T96C, T97H, R98C, Y101C, K104H
|
HEC HEME C × 2
CO COBALT (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；298 K；PEG1500 25%, MgCl2 200 mM, pH 8 EPPS 100 mM
|
Resolution 1.93 Å
R-free 0.325
|
|
7PP1
Crystal structure of the P2Y12 receptor in complex with the inverse agonist selatogrel.
Deposited 2021-09-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain AAA
23–128（106 aa）
|
Not recorded
|
7Y5 Selatogrel × 1
CLR CHOLESTEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；298 K；0.1 M ammonium formate, 0.1 M sodium cacdylate, pH 6.0-6.5, 25-35% PEG400
|
Resolution 2.78 Å
R-free 0.286
|
|
7PX4
Crystal structure of the adenosine A2A receptor (A2A-PSB1-bRIL) in complex with preladenant conjugate PSB-2113
Deposited 2021-10-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：S91K
|
CLR CHOLESTEROL × 3
8E2 Preladenant conjugate PSB-2113 × 1
OLA OLEIC ACID × 26
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；24% (v/v) PEG-400 (polyethylene glycol 400, average molecular weight 400), 10-30 mM sodium thiocyanate, 100 mM sodium citrate pH 5.2, and 2% (v/v) 2,5-hexanediol
|
Resolution 2.25 Å
R-free 0.240
|
|
7PYR
Crystal structure of the adenosine A2A receptor (A2A-PSB1-bRIL) in complex with preladenant conjugate PSB-2115
Deposited 2021-10-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：S91K
|
CLR CHOLESTEROL × 3
8IM 2-[2-[2-[2-[2-[2-[4-[4-[2-[7-azanyl-4-(furan-2-yl)-3,5,6,8,10,11-hexazatricyclo[7.3.0.0^{2,6}]dodeca-1(9),2,4,7,11-pentaen-10-yl]ethyl]piperazin-1-yl]phenoxy]ethanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]-~{N}-[5-[2,2-bis(fluoranyl)-4,6,10,12-tetramethyl-1,3-diaza-2$l^{4}-boratricyclo[7.3.0.0^{3,7}]dodeca-4,6,9,11-tetraen-8-yl]pentyl]ethanamide × 1
OLA OLEIC ACID × 25
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 4
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；24% (v/v) PEG-400 (polyethylene glycol 400, average molecular weight 400), 10-30 mM sodium thiocyanate, 100 mM sodium citrate pH 5.2, and 2% (v/v) 2,5-hexanediol
|
Resolution 2.60 Å
R-free 0.252
|
|
7RM5
MicroED structure of the human adenosine receptor at 2.8A
Deposited 2021-07-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
CLR CHOLESTEROL × 4
NA SODIUM ION × 1
|
ELECTRON CRYSTALLOGRAPHY
cryo-EM buffer
pH 5；25-28% (v/v) PEG 400, 0.04-0.06M sodium thiocyanate, 2% (v/v) 2,5-hexanediol, 100mM sodium citrate, pH 5.0, Lipid Cubic Phase (LCP), temperature 293K
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.79 Å
R-free 0.288
|
|
7RWU
Crystal structure of Ni-bound RIDC1 variant in the presence of reductant
Deposited 2021-08-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
|
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
|
NI NICKEL (II) ION × 9
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 3
HEC HEME C × 3
CL CHLORIDE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；295 K；45% MPD, 0.1 M Tris, 0.2 M MgCl2
|
Resolution 1.80 Å
R-free 0.189
|
|
7RWV
Crystal structure of a metal-free RIDC1 variant
Deposited 2021-08-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
|
HEC HEME C × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；30% PEG400, 0.1 M HEPES, 0.2 M MgCl2
|
Resolution 2.20 Å
R-free 0.252
|
|
7RWW
Crystal structure of a Zn-bound RIDC1 variant
Deposited 2021-08-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
|
ZN ZINC ION × 5
HEC HEME C × 4
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 3
MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 1
EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；45% MPD, 0.1 M HEPES, 0.2 M MgCl2
|
Resolution 1.70 Å
R-free 0.208
|
|
7RWX
Crystal structure of a Zn-bound RIDC1 variant in the presence of reductant
Deposited 2021-08-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
|
ZN ZINC ION × 4
CA CALCIUM ION × 4
HEC HEME C × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；30% PEG400, 0.1 M HEPES, 0.2 M CaCl2
|
Resolution 1.60 Å
R-free 0.290
|
|
7RWY
Crystal structure of a Fe-bound RIDC1 variant in the presence of reductant
Deposited 2021-08-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
|
HEC HEME C × 3
1PE PENTAETHYLENE GLYCOL × 1
FE FE (III) ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；40% PPG, 0.1 M Bis-Tris
|
Resolution 2.20 Å
R-free 0.259
|
|
7RWY
Crystal structure of a Fe-bound RIDC1 variant in the presence of reductant
Deposited 2021-08-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain F
23–128（106 aa）
|
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
Mutation：R56A, L60A, Q63W, K64S, K81H, D88W, V91I, D95H, D96A, K99H, T118C, R120C, Y123C
|
HEC HEME C × 3
1PE PENTAETHYLENE GLYCOL × 1
FE FE (III) ION × 2
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；295 K；40% PPG, 0.1 M Bis-Tris
|
Resolution 2.20 Å
R-free 0.259
|
|
7S8M
CryoEM structure of Gi-coupled MRGPRX2 with peptide agonist Cortistatin-14
Deposited 2021-09-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 2.54 Å
|
|
7S8O
CryoEM structure of Gi-coupled MRGPRX2 with small molecule agonist (R)-Zinc-3573
Deposited 2021-09-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
8IU (3R)-N,N-dimethyl-1-[(8S)-5-phenylpyrazolo[1,5-a]pyrimidin-7-yl]pyrrolidin-3-amine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 2.58 Å
|
|
7S8P
CryoEM structure of Gq-coupled MRGPRX4 with small molecule agonist MS47134
Deposited 2021-09-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
8IX N-[(1r,3R,5S,7R)-3,5-dimethyltricyclo[3.3.1.1~3,7~]decane-1-carbonyl]-D-phenylalanine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 2.60 Å
|
|
7SBF
PZM21 bound Mu Opioid Receptor-Gi Protein Complex
Deposited 2021-09-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
8QY N-[(2S)-2-(dimethylamino)-3-(4-hydroxyphenyl)propyl]-N'-[(2S)-1-(thiophen-3-yl)propan-2-yl]urea × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å
|
|
7SU2
Crystal structure of a Co-bound RIDC1 variant
Deposited 2021-11-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain G
23–128（106 aa）
|
Mutation：A56, A60, W63, S64, H81, W88, I91, H95, A96, H99, C118, C120, C123
Mutation：A56, A60, W63, S64, H81, W88, I91, H95, A96, H99, C118, C120, C123
Mutation：A56, A60, W63, S64, H81, W88, I91, H95, A96, H99, C118, C120, C123
Mutation：A56, A60, W63, S64, H81, W88, I91, H95, A96, H99, C118, C120, C123
|
HEC HEME C × 4
CO COBALT (II) ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；30% PEG400, 200 mM NaCl, 100 mM HEPES (7.5)
|
Resolution 2.00 Å
R-free 0.232
|
|
7T2G
CryoEM structure of mu-opioid receptor - Gi protein complex bound to mitragynine pseudoindoxyl (MP)
Deposited 2021-12-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
EIG Mitragynine pseudoindoxyl × 1
CLR CHOLESTEROL × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.50 Å
|
|
7T32
CryoEM structure of the adenosine 2A receptor-BRIL/Anti BRIL Fab complex with ZM241385
Deposited 2021-12-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：YES
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen OTHER
|
Resolution 3.40 Å
|
|
7TEP
Crystal structure of a Cu-bound cytochrome cb562 variant in the presence of reductant
Deposited 2022-01-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, D74A, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, D74A, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, D74A, K77H, T96C, R98C, Y101C
Mutation：R34A, L38A, Q41W, K42S, K59H, D66W, V69I, D73H, D74A, K77H, T96C, R98C, Y101C
|
HEC HEME C × 4
CU COPPER (II) ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；25% PEG1500, 0.1 M Bis-Tris, 0.2 M ammonium acetate
|
Resolution 2.70 Å
R-free 0.339
|
|
7TX6
Cryo-EM structure of the human reduced folate carrier in complex with methotrexate
Deposited 2022-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
25–127（103 aa）
|
Mutation：UNP residues 215-241 replaced with engineered epitope
|
MTX METHOTREXATE × 1
AJP Digitonin × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å
|
|
7TX7
Cryo-EM structure of the human reduced folate carrier
Deposited 2022-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
25–127（103 aa）
|
Mutation：UNP residues 215-241 replaced with engineered epitope
|
AJP Digitonin × 4
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.80 Å
|
|
7VOD
Crystal structure of 5-HT2AR in complex with cariprazine
Deposited 2021-10-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–62（40 aa）
Chain A
88–128（41 aa）
|
Mutation：S162K,N164W,M1007W,R1098I,H1102I,R1106G,S372N
Mutation：S162K,N164W,M1007W,R1098I,H1102I,R1106G,S372N
|
MG MAGNESIUM ION × 1
CLR CHOLESTEROL × 3
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
7RU 3-[4-[2-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethyl-urea × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293.15 K；100 mM Tris/HCl, 100 mM Potassium formate, 30% PEG
|
Resolution 3.30 Å
R-free 0.239
|
|
7VOE
Crystal structure of 5-HT2AR in complex with aripiprazole
Deposited 2021-10-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–62（40 aa）
Chain A
88–128（41 aa）
|
Mutation：S162K,N164W,M1007W,R1098I,H1102I,R1106G,S372N
Mutation：S162K,N164W,M1007W,R1098I,H1102I,R1106G,S372N
|
CLR CHOLESTEROL × 3
1PE PENTAETHYLENE GLYCOL × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 4
9SC 7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one × 1
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293.15 K；100 mM Tris/HCl, 50 mM ammonium floride, 28%-30% PEG400,
300 mM NDSB-195 or 3% w/v trimethylamine N-oxide dihydrate
|
Resolution 2.90 Å
R-free 0.244
|
|
7W0L
Cryo-EM structure of a dimeric GPCR-Gi complex with small molecule
Deposited 2021-11-18
|
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain Q
23–127（105 aa）
Chain R
23–127（105 aa）
|
Not recorded
|
8EH (1R,2S)-N-[4-(2,6-dimethoxyphenyl)-5-(6-methylpyridin-2-yl)-1,2,4-triazol-3-yl]-1-(5-methylpyrimidin-2-yl)-1-oxidanyl-propane-2-sulfonamide × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.57 Å
|
|
7W0M
Cryo-EM structure of a monomeric GPCR-Gi complex with small molecule
Deposited 2021-11-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
8EH (1R,2S)-N-[4-(2,6-dimethoxyphenyl)-5-(6-methylpyridin-2-yl)-1,2,4-triazol-3-yl]-1-(5-methylpyrimidin-2-yl)-1-oxidanyl-propane-2-sulfonamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.71 Å
|
|
7W0N
Cryo-EM structure of a dimeric GPCR-Gi complex with peptide
Deposited 2021-11-18
|
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 8
PDB declaration: octameric
|
Chain Q
23–127（105 aa）
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.21 Å
|
|
7W0O
Cryo-EM structure of a monomeric GPCR-Gi complex with peptide
Deposited 2021-11-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.78 Å
|
|
7W0P
Cryo-EM structure of a GPCR-Gi complex with peptide
Deposited 2021-11-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.16 Å
|
|
7WJ5
Cryo-EM structure of human somatostatin receptor 2 complex with its agonist somatostatin delineates the ligand binding specificity
Deposited 2022-01-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.72 Å
|
|
7WVV
Cryo-EM structure of the human formyl peptide receptor 2 in complex with fMLFII and Gi2
Deposited 2022-02-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Mutation：S211L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å
|
|
7WVW
Cryo-EM structure of the human formyl peptide receptor 2 in complex with fMYFINILTL and Gi2
Deposited 2022-02-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Mutation：S211L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å
|
|
7WVX
Cryo-EM structure of the human formyl peptide receptor 2 in complex with fhumanin and Gi2
Deposited 2022-02-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Mutation：S211L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å
|
|
7WVY
Cryo-EM structure of the human formyl peptide receptor 2 in complex with Abeta42 and Gi2
Deposited 2022-02-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Mutation：S211L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
7X5H
Serotonin 5A (5-HT5A) receptor-Gi protein complex
Deposited 2022-03-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
8K3 3-(2-azanylethyl)-1H-indole-5-carboxamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 3.10 Å
|
|
7XAY
Crystal structure of Hat1-Hat2-Asf1-H3-H4
Deposited 2022-03-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–127（105 aa）
|
Not recorded
|
COA COENZYME A × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；289 K；100 mM Bis-Tris propane, pH 6.5, 20% PEG-3350, and 200 mM sodium nitrate
|
Resolution 3.30 Å
R-free 0.256
|
|
7XKI
Human Cx36/GJD2 (N-terminal deletion BRIL-fused mutant) gap junction channel in soybean lipids (D6 symmetry)
Deposited 2022-04-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
|
Assembly 1
Insufficient information
Homooligomer；Protein × 12
PDB declaration: dodecameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
Chain F
23–128（106 aa）
Chain G
23–128（106 aa）
Chain H
23–128（106 aa）
Chain I
23–128（106 aa）
Chain J
23–128（106 aa）
Chain K
23–128（106 aa）
Chain L
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
|
MC3 1,2-DIMYRISTOYL-RAC-GLYCERO-3-PHOSPHOCHOLINE × 48
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
7XKT
Human Cx36/GJD2 (BRIL-fused mutant) gap junction channel in detergents at 2.2 Angstroms resolution
Deposited 2022-04-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 12
PDB declaration: dodecameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
Chain F
23–128（106 aa）
Chain G
23–128（106 aa）
Chain H
23–128（106 aa）
Chain I
23–128（106 aa）
Chain J
23–128（106 aa）
Chain K
23–128（106 aa）
Chain L
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
|
MC3 1,2-DIMYRISTOYL-RAC-GLYCERO-3-PHOSPHOCHOLINE × 72
Y01 CHOLESTEROL HEMISUCCINATE × 24
LHG 1,2-DIPALMITOYL-PHOSPHATIDYL-GLYCEROLE × 12
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.20 Å
|
|
7XRZ
Crystal structure of BRIL and SRP2070_Fab complex
Deposited 2022-05-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain X
24–128（105 aa）
|
Mutation：M29W,H124I,R128L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277.15 K；PEG 6000, Tris-HCl
|
Resolution 2.10 Å
R-free 0.268
|
|
7XRZ
Crystal structure of BRIL and SRP2070_Fab complex
Deposited 2022-05-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain Y
24–128（105 aa）
|
Mutation：M29W,H124I,R128L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；277.15 K；PEG 6000, Tris-HCl
|
Resolution 2.10 Å
R-free 0.268
|
|
7XT8
Serotonin 4 (5-HT4) receptor-Gs-Nb35 complex
Deposited 2022-05-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 5
PLM PALMITIC ACID × 2
SRO SEROTONIN × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 3.10 Å
|
|
7XT9
Serotonin 4 (5-HT4) receptor-Gs complex
Deposited 2022-05-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 4
PLM PALMITIC ACID × 2
SRO SEROTONIN × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 3.20 Å
|
|
7XTA
Serotonin 4 (5-HT4) receptor-Gi-scFv16 complex
Deposited 2022-05-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
SRO SEROTONIN × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 3.20 Å
|
|
7XTB
Serotonin 6 (5-HT6) receptor-Gs-Nb35 complex
Deposited 2022-05-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
SRO SEROTONIN × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 3.30 Å
|
|
7XTC
Serotonin 7 (5-HT7) receptor-Gs-Nb35 complex
Deposited 2022-05-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
8K3 3-(2-azanylethyl)-1H-indole-5-carboxamide × 1
CLR CHOLESTEROL × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 3.20 Å
|
|
7XWO
Neurokinin A bound to active human neurokinin 2 receptor in complex with G324
Deposited 2022-05-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain B
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 2.70 Å
|
|
7XY6
Adenosine receptor bound to an agonist in complex with G protein obtained by cryo-EM
Deposited 2022-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Mutation：M29W, H124I
|
I5D 2-[6-azanyl-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl]sulfanylethanamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.99 Å
|
|
7XY7
Adenosine receptor bound to a non-selective agonist in complex with a G protein obtained by cryo-EM
Deposited 2022-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Mutation：M29W, H124I
|
NEC N-ETHYL-5'-CARBOXAMIDO ADENOSINE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.26 Å
|
|
7XZ5
GPR119-Gs-LPC complex
Deposited 2022-06-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
LSC (4R,7R,18E)-4,7-dihydroxy-N,N,N-trimethyl-10-oxo-3,5,9-trioxa-4-phosphaheptacos-18-en-1-aminium 4-oxide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 3.10 Å
|
|
7XZ6
GPR119-Gs-APD668 complex
Deposited 2022-06-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
I7J propan-2-yl 4-[1-(2-fluoranyl-4-methylsulfonyl-phenyl)pyrazolo[3,4-d]pyrimidin-4-yl]oxypiperidine-1-carboxylate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 2.80 Å
|
|
7Y12
Cryo-EM structure of MrgD-Gi complex with beta-alanine
Deposited 2022-06-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
Fragment：Chimera protein of Cytochrome b-562 (UNP residues 23-127) and MrgD (UNP residues 5-321)
|
Mutation：M29W, H124I
|
BAL BETA-ALANINE × 1
PLM PALMITIC ACID × 3
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE；blot time 3 seconds
blot force 5
|
Resolution 3.10 Å
|
|
7Y13
Cryo-EM structure of apo-state MrgD-Gi complex (local)
Deposited 2022-06-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain R
23–127（105 aa）
Fragment：Chimera protein of Cytochrome b-562 (UNP residues 23-127) and MrgD (UNP residues 5-321)
|
Mutation：M29W, H124I
|
PLM PALMITIC ACID × 7
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE；blot time 3 seconds
blot force 5
|
Resolution 3.10 Å
|
|
7Y14
Cryo-EM structure of MrgD-Gi complex with beta-alanine (local)
Deposited 2022-06-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain R
23–127（105 aa）
Fragment：Chimera protein of Cytochrome b-562 (UNP residues 23-127) and MrgD (UNP residues 5-321)
|
Mutation：M29W ,H124I
|
BAL BETA-ALANINE × 1
PLM PALMITIC ACID × 4
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE；blot time 3 seconds
blot force 5
|
Resolution 3.20 Å
|
|
7Y15
Cryo-EM structure of apo-state MrgD-Gi complex
Deposited 2022-06-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
Fragment：Chimera protein of Cytochrome b-562 (UNP residues 23-127) and MrgD (UNP residues 5-321)
|
Mutation：M29W, H124I
|
PLM PALMITIC ACID × 3
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE；blot time 3 seconds
blot force 5
|
Resolution 2.90 Å
|
|
7YIT
Molecular mechanism of biased signaling at the kappa opioid receptor
Deposited 2022-07-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
23–128（106 aa）
|
Mutation：M1007W,V1084E,H1102I
|
IVB nalfurafine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6.7；293 K；40-200 mM magnesium sulfate hydrate, 100 mM sodium citrate tribasic dehydrate, 10 mM Manganese (II) chloride tetrahydrate
28-30% PEG400
|
Resolution 3.30 Å
R-free 0.335
|
|
7YXA
XFEL crystal structure of the human sphingosine 1 phosphate receptor 5 in complex with ONO-5430608
Deposited 2022-02-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
B2O 4-[6-(2-naphthalen-1-ylethoxy)-2,3,4,5-tetrahydro-1H-3-benzazepin-3-ium-3-yl]butanoic acid × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；295 K；crystallization in syringes in precipitant conditions containing 100-300 mM KH2PO4 monobasic, 28-32% v/v PEG400, and 100 mM HEPES pH 7
|
Resolution 2.20 Å
R-free 0.329
|
|
7YXA
XFEL crystal structure of the human sphingosine 1 phosphate receptor 5 in complex with ONO-5430608
Deposited 2022-02-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–128（106 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
B2O 4-[6-(2-naphthalen-1-ylethoxy)-2,3,4,5-tetrahydro-1H-3-benzazepin-3-ium-3-yl]butanoic acid × 1
OLA OLEIC ACID × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 7；295 K；crystallization in syringes in precipitant conditions containing 100-300 mM KH2PO4 monobasic, 28-32% v/v PEG400, and 100 mM HEPES pH 7
|
Resolution 2.20 Å
R-free 0.329
|
|
7ZI0
Structure of human Smoothened in complex with cholesterol and SAG
Deposited 2022-04-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
V0S 3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-{[3-(pyridin-4-yl)phenyl]methyl}-1-benzothiophene-2-carboxamide × 1
CLR CHOLESTEROL × 1
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
NA SODIUM ION × 2
MPG [(Z)-octadec-9-enyl] (2R)-2,3-bis(oxidanyl)propanoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；0.1 M MES pH6.0,
0.09-0.12 M potassium formate,
24-27% (v/v) PEG500 DME,
0.5 mM zinc chloride,
0.1 M ammonium fluoride
|
Resolution 3.00 Å
R-free 0.275
|
|
7ZI0
Structure of human Smoothened in complex with cholesterol and SAG
Deposited 2022-04-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–127（105 aa）
|
Not recorded
|
V0S 3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-{[3-(pyridin-4-yl)phenyl]methyl}-1-benzothiophene-2-carboxamide × 1
CLR CHOLESTEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；0.1 M MES pH6.0,
0.09-0.12 M potassium formate,
24-27% (v/v) PEG500 DME,
0.5 mM zinc chloride,
0.1 M ammonium fluoride
|
Resolution 3.00 Å
R-free 0.275
|
|
7ZL9
Crystal structure of human GPCR Niacin receptor (HCA2)
Deposited 2022-04-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
OLA OLEIC ACID × 5
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
PEG DI(HYDROXYETHYL)ETHER × 1
UNX UNKNOWN LIGAND × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100mM pH5.4 sodium citrate, 60mM ammonium citrate, 36% PEG400, and 3% Additive 80 (40% PPG)
|
Resolution 2.70 Å
R-free 0.248
|
|
7ZLY
Crystal structure of human GPCR Niacin receptor (HCA2) expressed from Spodoptera frugiperda
Deposited 2022-04-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
OLA OLEIC ACID × 6
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；100mM pH5.4 sodium citrate, 60mM ammonium citrate, 36% PEG400, and 3% Additive 80 (40% PPG)
|
Resolution 2.70 Å
R-free 0.280
|
|
8A2O
Room-temperature structure of the stabilised A2A-Theophylline complex determined by synchrotron serial crystallography
Deposited 2022-06-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：A54L,T88A,R107A,K122A,L202A,L235A,V239A6,S277A,N154A
|
TEP THEOPHYLLINE × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 3
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 4.5；293 K；0.1 M tri-sodium citrate pH 4.5, 0.05 M sodium thiocyanate, 29% (v/v) polyethylene glycol 400, 2% (v/v) 2,5-hexanediol
|
Resolution 3.45 Å
R-free 0.241
|
|
8A2P
Room-temperature structure of the stabilised A2A-LUAA47070 complex determined by synchrotron serial crystallography
Deposited 2022-06-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：A54L,T88A,R107A,K122A,L202A,L235A,V239A6,S277A,N154A
|
9Y2 4-(3,3-dimethylbutanoylamino)-3,5-bis(fluoranyl)-~{N}-(1,3-thiazol-2-yl)benzamide × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 4
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 4.5；293 K；0.1 M tri-sodium citrate pH 4.5, 0.05 M sodium thiocyanate, 29% (v/v) polyethylene glycol 400, 2% (v/v) 2,5-hexanediol
|
Resolution 3.50 Å
R-free 0.247
|
|
8C9W
Crystal structure of the adenosine A2A receptor (construct A2A-PSB2-bRIL) complexed with Etrumadenant at the orthosteric pocket
Deposited 2023-01-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
U30 3-[2-azanyl-6-[1-[[6-(2-oxidanylpropan-2-yl)pyridin-2-yl]methyl]-1,2,3-triazol-4-yl]pyrimidin-4-yl]-2-methyl-benzenecarbonitrile × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 5
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
PEG DI(HYDROXYETHYL)ETHER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.4；293 K；30 % (w/v) PEG400, 7 % (w/v) Tacsimate pH 7.0,100 mM HEPES-Na pH 7.4, 1.8 % (w/v) 2,5-hexandiol, 25 microM Etrumadenant
|
Resolution 2.11 Å
R-free 0.267
|
|
8CIC
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with clinical candidate Etrumadenant
Deposited 2023-02-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：A54L,T88A,K122A,V239A,R107A,L202A,L235A
|
NA SODIUM ION × 1
U30 3-[2-azanyl-6-[1-[[6-(2-oxidanylpropan-2-yl)pyridin-2-yl]methyl]-1,2,3-triazol-4-yl]pyrimidin-4-yl]-2-methyl-benzenecarbonitrile × 1
CLR CHOLESTEROL × 4
OLA OLEIC ACID × 15
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；294 K；0.1 M sodium citrate pH 5.0, 50 mM sodium thiocyanate, 3 % (v/v) 2-methyl-2,4-pentanediol (MPD), 21-32 % (w/v) PEG400, and 2 mM theophylline
|
Resolution 2.10 Å
R-free 0.214
|
|
8CU6
Crystal structure of A2AAR-StaR2-S277-bRIL in complex with a novel A2a antagonist, LJ-4517
Deposited 2022-05-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Mutation：yes
|
OLA OLEIC ACID × 16
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
PEG DI(HYDROXYETHYL)ETHER × 1
LJX (2R,3R,4R)-2-[(8P)-6-amino-2-(hex-1-yn-1-yl)-8-(thiophen-2-yl)-9H-purin-9-yl]oxolane-3,4-diol × 1
CLR CHOLESTEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；0.1 M HEPES, pH 5.3, 0.05 M sodium thiocyanate, 30% PEG400, 2% 2,2,2-trifluoroethanol
|
Resolution 2.80 Å
R-free 0.247
|
|
8CU7
Crystal structure of A2AAR-StaR2-bRIL in complex with a novel A2a antagonist, LJ-4517
Deposited 2022-05-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Mutation：S277A
|
PEG DI(HYDROXYETHYL)ETHER × 4
LJX (2R,3R,4R)-2-[(8P)-6-amino-2-(hex-1-yn-1-yl)-8-(thiophen-2-yl)-9H-purin-9-yl]oxolane-3,4-diol × 1
NA SODIUM ION × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
OLA OLEIC ACID × 23
CLR CHOLESTEROL × 3
ETF TRIFLUOROETHANOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；0.1 M HEPES, pH 5.3, 0.05 M sodium thiocyanate, 30% PEG400, 2% 2,2,2-trifluoroethanol
|
Resolution 2.05 Å
R-free 0.211
|
|
8DEN
Heme-Free Cytochrome Variant ApoCyt
Deposited 2022-06-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；22% PEG 2000, 200 mM MgCl2, 100 mM Tris pH 8.5
|
Resolution 1.69 Å
R-free 0.217
|
|
8DEN
Heme-Free Cytochrome Variant ApoCyt
Deposited 2022-06-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；22% PEG 2000, 200 mM MgCl2, 100 mM Tris pH 8.5
|
Resolution 1.69 Å
R-free 0.217
|
|
8DEP
Cryo-EM structure of the human reduced folate carrier, apo condition
Deposited 2022-06-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
25–127（103 aa）
|
Not recorded
|
AJP Digitonin × 4
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.60 Å
|
|
8DJK
HMGCR-UBIAD1 Complex State 2
Deposited 2022-06-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain C
25–127（103 aa）
|
Not recorded
|
Y01 CHOLESTEROL HEMISUCCINATE × 6
AJP Digitonin × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.33 Å
|
|
8DJM
HMGCR-UBIAD1 Complex State 1
Deposited 2022-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain C
25–127（103 aa）
|
Not recorded
|
Y01 CHOLESTEROL HEMISUCCINATE × 6
AJP Digitonin × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.23 Å
|
|
8DR8
LRRC8A:C conformation 2 (oblong) top mask
Deposited 2022-07-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
PEE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine × 20
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.04 Å
|
|
8DRA
LRRC8A:C conformation 2 (oblong) LRR mask
Deposited 2022-07-20
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.98 Å
|
|
8DRD
Ni(II)-bound B2 dimer (H60/H100/H104)
Deposited 2022-07-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Not recorded
|
HEC HEME C × 2
NI NICKEL (II) ION × 2
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；298 K；MPD 45%, NaCl 200 mM, TRIS-HCl 100 mM
|
Resolution 1.89 Å
R-free 0.215
|
|
8DRE
LRRC8A:C conformation 2 (oblong)
Deposited 2022-07-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
PEE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine × 20
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.18 Å
|
|
8DRF
Zn(II)-bound B2 dimer (H60/H100/H104)
Deposited 2022-07-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
|
Mutation：D60H, A100H, K104H
|
HEC HEME C × 2
ZN ZINC ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6；298 K；PEG3350 7%, (NH4)2SO4 200 mM, MES 100 mM
|
Resolution 1.70 Å
R-free 0.242
|
|
8DRJ
Apo B2 dimer (H60/H100/H104) formed in the presence of Cu(II)
Deposited 2022-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
|
Mutation：D60H, A100H, K104H
Mutation：D60H, A100H, K104H
|
HEC HEME C × 2
SO4 SULFATE ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；298 K；PEG3350 25%, (NH4)2SO4 200 mM, Tris 100 mM, CuCl2 4 mM
|
Resolution 2.40 Å
R-free 0.283
|
|
8DRK
LRRC8A:C conformation 1 (round) top focus
Deposited 2022-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
PEE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine × 21
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.95 Å
|
|
8DRL
Zn(II)-bound B2 dimer (H60/H100/H104) formed in Cu(II)//Zn(II) (M1 // M2) condition
Deposited 2022-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
|
Mutation：D60H, A100H, K104H
|
HEC HEME C × 2
ZN ZINC ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；298 K；PEG3350 24%, CHES 100 mM
|
Resolution 1.65 Å
R-free 0.202
|
|
8DRM
Zn(II)-bound B2 dimer (H60/H100/H104) formed in Zn(II)//Cu(II) (M1 // M2) condition
Deposited 2022-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
HEC HEME C × 2
ZN ZINC ION × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；298 K；PEG3350 25%, CHES 100 mM
|
Resolution 1.55 Å
R-free 0.229
|
|
8DRN
LRRC8A:C conformation 1 (round) LRR focus 1
Deposited 2022-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.12 Å
|
|
8DRO
LRRC8A:C conformation 1 (round) LRR focus 2
Deposited 2022-07-21
|
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.06 Å
|
|
8DRQ
LRRC8A:C conformation 1 (round) LRR focus 3
Deposited 2022-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain E
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.16 Å
|
|
8DS3
LRRC8A:C conformation 1 (round)
Deposited 2022-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
PEE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine × 21
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.07 Å
|
|
8DS9
LRRC8A:C in MSPE3D1 nanodisc top focus
Deposited 2022-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
PEE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine × 4
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.17 Å
|
|
8DSA
LRRC8A:C in MSP1E3D1 nanodisc
Deposited 2022-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
PEE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine × 4
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.48 Å
|
|
8DU3
Crystal structure of A2AAR-StaR2-bRIL in complex with compound 21a
Deposited 2022-07-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：A79L, T113A, R132A, K147A, N179A, L227A, M240W, H335I, R339L, L356A, V360A, S398A
|
TKO (4M)-6-bromo-4-(furan-2-yl)quinazolin-2-amine × 1
CLR CHOLESTEROL × 3
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 4
OLA OLEIC ACID × 17
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 4.5；293 K；Sodium Citrate pH 4.5, sodium thiocyanate, PEG 400, 2,4-hexanediol
|
Resolution 2.50 Å
R-free 0.232
|
|
8F74
LRRC8A(T48D):C conformation 2 top focus
Deposited 2022-11-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
PEE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine × 15
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å
|
|
8F77
LRRC8A(T48D):C conformation 2 top focus
Deposited 2022-11-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Mutation：T48D
Mutation：T48D
Mutation：T48D
Mutation：T48D
Mutation：T48D
|
PEE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine × 15
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.15 Å
|
|
8F79
LRRC8A(T48D):C conformation 2 top focus
Deposited 2022-11-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Mutation：T48D
Mutation：T48D
Mutation：T48D
Mutation：T48D
Mutation：T48D
|
PEE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine × 17
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.15 Å
|
|
8F7B
LRRC8A(T48D):C conformation 2 top focus
Deposited 2022-11-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Mutation：T48D
Mutation：T48D
Mutation：T48D
Mutation：T48D
Mutation：T48D
|
PEE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine × 17
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.15 Å
|
|
8F7C
Cryo-EM structure of human pannexin 2
Deposited 2022-11-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 7
PDB declaration: heptameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
Chain F
23–127（105 aa）
Chain G
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20mM Tris-HCL, 150mM NaCl, 40uM GDN, 1mM Fluorinated Fos-Choline-8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.92 Å
|
|
8F7D
LRRC8A(T48D):C conformation 2 top focus
Deposited 2022-11-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
|
Mutation：T48D
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.20 Å
|
|
8F7E
LRRC8A(T48D):C conformation 2 top focus
Deposited 2022-11-18
|
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
|
Mutation：T48D
Mutation：T48D
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.13 Å
|
|
8F7J
LRRC8A(T48D):C conformation 2 top focus
Deposited 2022-11-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain E
23–127（105 aa）
|
Mutation：T48D
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.32 Å
|
|
8FYN
MicroED structure of A2A from plasma milled lamellae
Deposited 2023-01-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 15
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 5
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
NA SODIUM ION × 1
|
ELECTRON CRYSTALLOGRAPHY
cryo-EM buffer
pH 4.7
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.00 Å
R-free 0.279
|
|
8GNE
Crystal structure of human adenosine A2A receptor in complex with an insurmountable inverse agonist, KW-6356.
Deposited 2022-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：N154Q,M1007W,H1102I,R1106L
|
JQR ~{N}-[4-(furan-2-yl)-5-(oxan-4-ylcarbonyl)-1,3-thiazol-2-yl]-6-methyl-pyridine-3-carboxamide × 1
CLR CHOLESTEROL × 3
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 18
PE4 2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293.15 K；PEG 400, sodium thiocyanate, 2,5-hexanediol, sodium citrate
|
Resolution 2.30 Å
R-free 0.235
|
|
8GY7
Cryo-EM structure of ACTH-bound melanocortin-2 receptor in complex with MRAP1 and Gs protein
Deposited 2022-09-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
CA CALCIUM ION × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å
|
|
8HII
The BRIL-SLC19A1/Fab/Nb ternary complex
Deposited 2022-11-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.57 Å
|
|
8HIJ
The 5-MTHF-bound BRIL-SLC19A1/Fab/Nb ternary complex
Deposited 2022-11-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–127（105 aa）
|
Not recorded
|
THH N-[4-({[(6S)-2-AMINO-4-HYDROXY-5-METHYL-5,6,7,8-TETRAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.54 Å
|
|
8HIK
The TPP-bound BRIL-SLC19A1/Fab/Nb ternary complex
Deposited 2022-11-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–127（105 aa）
|
Not recorded
|
TPP THIAMINE DIPHOSPHATE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.72 Å
|
|
8HJ5
Cryo-EM structure of Gq-coupled MRGPRX1 bound with Compound-16
Deposited 2022-11-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain F
24–128（105 aa）
|
Mutation：M29W,H124I,R128L
|
U2U N-{2-[(1-aminoisoquinolin-6-yl)oxy]-4-methylphenyl}-2-methoxybenzene-1-sulfonamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
8HN8
Cryo-EM structure of ligand histamine-bound Histamine H4 receptor Gi complex
Deposited 2022-12-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
HSM HISTAMINE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
8HNK
CXCR3-DNGi complex activated by CXCL11
Deposited 2022-12-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.01 Å
|
|
8HNL
CXCR3-DNGi complex activated by PS372424
Deposited 2022-12-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
4AI (3S)-N-[(2S)-5-carbamimidamido-1-(cyclohexylmethylamino)-1-oxidanylidene-pentan-2-yl]-2-(4-oxidanylidene-4-phenyl-butanoyl)-3,4-dihydro-1H-isoquinoline-3-carboxamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.98 Å
|
|
8HNM
CXCR3-DNGi complex activated by VUF11222
Deposited 2022-12-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
4IE [4-(2-bromophenyl)phenyl]methyl-[[(1R,5S)-6,6-dimethyl-2-bicyclo[3.1.1]hept-2-enyl]methyl]-dimethyl-azanium × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.94 Å
|
|
8HNN
Structure of CXCR3 complexed with antagonist SCH546738
Deposited 2022-12-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
43I 3-azanyl-6-chloranyl-5-[(3S)-4-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-3-ethyl-piperazin-1-yl]pyrazine-2-carboxamide × 1
CLR CHOLESTEROL × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.60 Å
|
|
8HOC
Cryo-EM structure of ligand histamine-bound Histamine H4 receptor Gi complex
Deposited 2022-12-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
ITF 2-(1~{H}-imidazol-5-yl)ethyl carbamimidothioate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
8HQE
Cryo-EM structure of the apo-GPR132-Gi
Deposited 2022-12-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.97 Å
|
|
8HQM
Activation mechanism of GPR132 by NPGLY
Deposited 2022-12-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
140 N-PALMITOYLGLYCINE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.95 Å
|
|
8HQN
Activation mechanism of GPR132 by 9(S)-HODE
Deposited 2022-12-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
9HO (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
8HS2
Orphan GPR20 in complex with Fab046
Deposited 2022-12-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain R
30–127（98 aa）
|
Mutation：L139W,D293N
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.08 Å
|
|
8HS3
Gi bound orphan GPR20 in ligand-free state
Deposited 2022-12-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
22–127（106 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.14 Å
|
|
8HSC
Gi bound Orphan GPR20 complex with Fab046 in ligand-free state
Deposited 2022-12-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 7
PDB declaration: heptameric
|
Chain R
30–127（98 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.22 Å
|
|
8HVI
Activation mechanism of GPR132 by compound NOX-6-7
Deposited 2022-12-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
30–123（94 aa）
|
Not recorded
|
NFI 3-methyl-5-[(4-oxidanylidene-4-phenyl-butanoyl)amino]-1-benzofuran-2-carboxylic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.04 Å
|
|
8IBU
Cryo-EM structure of the erythromycin-bound motilin receptor-Gq protein complex
Deposited 2023-02-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
ERY ERYTHROMYCIN A × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.51 Å
|
|
8IBV
Cryo-EM structure of the motilin-bound motilin receptor-Gq protein complex
Deposited 2023-02-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.19 Å
|
|
8IHB
Cryo-EM structure of HCA2-Gi complex with GSK256073
Deposited 2023-02-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Mutation：M29W,H124I
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
OKL 8-chloranyl-3-pentyl-7H-purine-2,6-dione × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.85 Å
|
|
8IHF
Cryo-EM structure of HCA2-Gi complex with MK6892
Deposited 2023-02-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Mutation：M29W,H124I
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
FI7 2-[[2,2-dimethyl-3-[3-(5-oxidanylpyridin-2-yl)-1,2,4-oxadiazol-5-yl]propanoyl]amino]cyclohexene-1-carboxylic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.97 Å
|
|
8IHH
Cryo-EM structure of HCA2-Gi complex with LUF6283
Deposited 2023-02-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Mutation：M29W,H124I
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
P8A 5-butyl-1~{H}-pyrazole-3-carboxylic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.06 Å
|
|
8IHI
Cryo-EM structure of HCA2-Gi complex with acifran
Deposited 2023-02-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Mutation：M29W,H124I
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
P9X (5~{S})-5-methyl-4-oxidanylidene-5-phenyl-furan-2-carboxylic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.11 Å
|
|
8IHJ
Cryo-EM structure of HCA3-Gi complex with acifran
Deposited 2023-02-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Mutation：M29W,H124I
|
P9X (5~{S})-5-methyl-4-oxidanylidene-5-phenyl-furan-2-carboxylic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.07 Å
|
|
8IHK
Cryo-EM structure of HCA3-Gi complex with acifran (local)
Deposited 2023-02-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain R
23–127（105 aa）
|
Mutation：M29W,H124I
|
P9X (5~{S})-5-methyl-4-oxidanylidene-5-phenyl-furan-2-carboxylic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.21 Å
|
|
8IKJ
Cryo-EM structure of the inactive CD97
Deposited 2023-02-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain R
21–127（107 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 3
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
8IRS
Dopamine Receptor D2R-Gi-Rotigotine complex
Deposited 2023-03-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
R5F Rotigotine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 3.00 Å
|
|
8IRT
Dopamine Receptor D3R-Gi-Rotigotine complex
Deposited 2023-03-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
R5F Rotigotine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 2.70 Å
|
|
8IRV
Dopamine Receptor D5R-Gs-Rotigotine complex
Deposited 2023-03-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
R5F Rotigotine × 1
CLR CHOLESTEROL × 10
PLM PALMITIC ACID × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 3.10 Å
|
|
8J46
Human Consensus Olfactory Receptor OR52c in apo state, OR52c-bRIL
Deposited 2023-04-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE；blot time 3 seconds
|
Resolution 3.66 Å
|
|
8J7E
Crystal structure of BRIL in complex with 1b3 Fab
Deposited 2023-04-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain F
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIQUID DIFFUSION；295.15 K；0.1 M sodium acetate pH 5.0, 15% (w/v) PEG 6000
|
Resolution 2.80 Å
R-free 0.251
|
|
8J7E
Crystal structure of BRIL in complex with 1b3 Fab
Deposited 2023-04-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain E
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIQUID DIFFUSION；295.15 K；0.1 M sodium acetate pH 5.0, 15% (w/v) PEG 6000
|
Resolution 2.80 Å
R-free 0.251
|
|
8J9O
Cryo-EM structure of inactive FZD1
Deposited 2023-05-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
8JH7
FZD6 in inactive state
Deposited 2023-05-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain D
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
8JHC
FZD3 in inactive state
Deposited 2023-05-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å
|
|
8JJ8
Cryo-EM structure of the beta2AR-mBRIL/1b3 Fab/Glue complex with a partial agonist
Deposited 2023-05-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain F
23–128（106 aa）
|
Not recorded
|
H98 ~{N}-[5-[(1~{R})-2-[[(2~{R})-1-(4-methoxyphenyl)propan-2-yl]amino]-1-oxidanyl-ethyl]-2-oxidanyl-phenyl]methanamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen NITROGEN
|
Resolution 3.20 Å
|
|
8JJL
cryo-EM structure of the beta2-AR-mBRIL/1b3 Fab/Glue complex with a full agonist
Deposited 2023-05-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
DZQ Olodaterol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen NITROGEN
|
Resolution 3.20 Å
|
|
8JLJ
T1AM-bound mTAAR1-Gs protein complex
Deposited 2023-06-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Mutation：M15W,H110I,R114L
|
UJF 4-[4-(2-azanylethyl)-2-iodanyl-phenoxy]phenol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å
|
|
8JLK
Ulotaront(SEP-363856)-bound mTAAR1-Gs protein complex
Deposited 2023-06-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Mutation：M15W,H110I,R114L
|
UJL 1-[(7~{S})-5,7-dihydro-4~{H}-thieno[2,3-c]pyran-7-yl]-~{N}-methyl-methanamine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.22 Å
|
|
8JLN
T1AM-bound hTAAR1-Gs protein complex
Deposited 2023-06-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
|
UJF 4-[4-(2-azanylethyl)-2-iodanyl-phenoxy]phenol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.24 Å
|
|
8JLO
Ulotaront(SEP-363856)-bound hTAAR1-Gs protein complex
Deposited 2023-06-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
|
UJL 1-[(7~{S})-5,7-dihydro-4~{H}-thieno[2,3-c]pyran-7-yl]-~{N}-methyl-methanamine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.52 Å
|
|
8JLP
Ralmitaront(RO-6889450)-bound hTAAR1-Gs protein complex
Deposited 2023-06-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
|
UJU 5-ethyl-4-methyl-~{N}-[4-[(2~{S})-morpholin-2-yl]phenyl]-1~{H}-pyrazole-3-carboxamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.23 Å
|
|
8JLQ
Fenoldopam-bound hTAAR1-Gs protein complex
Deposited 2023-06-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
|
G3C (1R)-6-chloranyl-1-(4-hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.84 Å
|
|
8JLR
A77636-bound hTAAR1-Gs protein complex
Deposited 2023-06-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
|
VRK (1~{S},3~{R})-3-(1-adamantyl)-1-(aminomethyl)-3,4-dihydro-1~{H}-isochromene-5,6-diol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
8JMT
Structure of the adhesion GPCR ADGRL3 in the apo state
Deposited 2023-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
24–65（42 aa）
Chain A
77–128（52 aa）
|
Mutation：T364A/M566W/H654I
Mutation：T364A/M566W/H654I
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen NITROGEN
|
Resolution 3.36 Å
|
|
8JPN
Cryo-EM structure of succinate receptor bound to cis-epoxysuccinic acid coupling to Gi
Deposited 2023-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
U9S (2R,3S)-oxirane-2,3-dicarboxylic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å
|
|
8JPP
Cryo-EM structure of succinate receptor bound to succinate acid coupling MiniGsq
Deposited 2023-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
SIN SUCCINIC ACID × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
8JSO
AMPH-bound hTAAR1-Gs protein complex
Deposited 2023-06-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
|
1WE (2S)-1-phenylpropan-2-amine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
8JT6
5-HT1A-Gi in complex with compound (R)-IHCH-7179
Deposited 2023-06-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 5
PLM PALMITIC ACID × 2
J40 [(2R)-1-[oxidanyl-[(2R,3R,5S,6R)-2,3,5,6-tetrakis(oxidanyl)-4-phosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-3-tetradecanoyloxy-propan-2-yl] (5E,8E)-hexadeca-5,8,11,14-tetraenoate × 1
EZX 1-(4-fluorophenyl)-4-[(7R)-2,5,11-triazatetracyclo[7.6.1.0^2,7.0^12,16]hexadeca-1(15),9,12(16),13-tetraen-5-yl]butan-1-one × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 3.00 Å
|
|
8JT8
Crystal structure of 5-HT2AR in complex with (R)-IHCH-7179
Deposited 2023-06-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–62（40 aa）
Chain A
88–128（41 aa）
|
Mutation：S162K,M164W,M1007W,R1098I,H1102I,R1106G,S372N
Mutation：S162K,M164W,M1007W,R1098I,H1102I,R1106G,S372N
|
MG MAGNESIUM ION × 1
EZX 1-(4-fluorophenyl)-4-[(7R)-2,5,11-triazatetracyclo[7.6.1.0^2,7.0^12,16]hexadeca-1(15),9,12(16),13-tetraen-5-yl]butan-1-one × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 7
CLR CHOLESTEROL × 2
1PE PENTAETHYLENE GLYCOL × 1
PEG DI(HYDROXYETHYL)ETHER × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 8；293.15 K；100 mM Tris/HCl, 160 mM Potassium fluoride, 30% PEG400
|
Resolution 2.70 Å
R-free 0.270
|
|
8K2W
Structure of CXCR3 complexed with antagonist AMG487
Deposited 2023-07-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 1
PCW 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOCHOLINE × 1
LPC [1-MYRISTOYL-GLYCEROL-3-YL]PHOSPHONYLCHOLINE × 1
FI6 N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxidanylidene-pyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluoromethyloxy)phenyl]ethanamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
8K2X
CXCR3-DNGi complex activated by CXCL10
Deposited 2023-07-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
8K4S
CryoEM structure of Gq coupled MRGPRX4 with agonist DCA-3P
Deposited 2023-07-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain E
23–128（106 aa）
|
Not recorded
|
JW0 (4~{R})-4-[(3~{R},5~{R},8~{R},9~{S},10~{S},12~{S},13~{R},14~{S},17~{R})-10,13-dimethyl-12-oxidanyl-3-phosphonooxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1~{H}-cyclopenta[a]phenanthren-17-yl]pentanoic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å
|
|
8K8J
Cannabinoid Receptor 1 bound to Fenofibrate coupling MiniGsq and Nb35 Complex
Deposited 2023-07-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
J3O Fenofibrate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.88 Å
|
|
8K9K
Full agonist-bound mu-type opioid receptor-G protein complex
Deposited 2023-08-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–128（106 aa）
|
Mutation：M7W,H102I,R106L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.98 Å
|
|
8KEX
CryoEM structure of Gq coupled MRGPRX4 with agonist DCA-3P, local
Deposited 2023-08-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain E
23–128（106 aa）
|
Not recorded
|
JW0 (4~{R})-4-[(3~{R},5~{R},8~{R},9~{S},10~{S},12~{S},13~{R},14~{S},17~{R})-10,13-dimethyl-12-oxidanyl-3-phosphonooxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1~{H}-cyclopenta[a]phenanthren-17-yl]pentanoic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
8KIG
Cryo-EM structure of MC3R in complex with SHU9119
Deposited 2023-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CA CALCIUM ION × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å
|
|
8PWN
Structure of A2A adenosine receptor A2AR-StaR2-bRIL, solved at wavelength 2.75 A
Deposited 2023-07-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–123（101 aa）
|
Not recorded
|
TEP THEOPHYLLINE × 1
OLA OLEIC ACID × 12
CLR CHOLESTEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；0.1 M TRI-SODIUM CITRATE PH 5.3-5.4, 0.05 M SODIUM THIOCYANATE, 29-32% PEG400, 2%(V/V) 2,5-HEXANEDIOL
|
Resolution 2.40 Å
R-free 0.261
|
|
8QJ2
Structure of active state MC4R in complex with a potent ligand mimicking nanobody
Deposited 2023-09-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain A
22–127（106 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
8RLN
Crystal structure of human adenosine A2A receptor (construct A2A-PSB2-bRIL) complexed with the partial antagonist LUF5834 at the orthosteric pocket
Deposited 2024-01-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 4
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
PEG DI(HYDROXYETHYL)ETHER × 1
A1H1S 2-azanyl-4-(4-hydroxyphenyl)-6-(1~{H}-imidazol-2-ylmethylsulfanyl)pyridine-3,5-dicarbonitrile × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.2；293 K；23% (w/v) PEG400, 90 mM sodium thiocyanate, 100 mM sodium citrate pH 5.2, and 2% (w/v) 2,5 hexandiol
|
Resolution 2.43 Å
R-free 0.281
|
|
8RQQ
In meso structure of the adenosine A2a G protein-coupled receptor, A2aR, in 7.10 monoacylglycerol
Deposited 2024-01-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
CLR CHOLESTEROL × 3
A1H2K 7.10 monoacylglycerol (S-form) × 8
A1H52 7.10 monoacylglycerol (R-form) × 1
GOL GLYCEROL × 2
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；30-35.5 %(v/v) PEG400, 50 mM sodium thiocyanate, 100 mM sodium citrate at pH 5, 0.2 %(v/v) 2,5-hexanediol, and 0.025 mM ZM241385
|
Resolution 2.37 Å
R-free 0.274
|
|
8RW0
Crystal structure of the adenosine A2A receptor in complex with Istradefylline
Deposited 2024-02-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
JQ9 8-[(~{E})-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methyl-purine-2,6-dione × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 23
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；0.1 M Sodium citrate pH 5, 0.05 M Sodium thiocyanate, 3% (v/v)
2-methyl-2,4-pentanediol, 32% (v/v) PEG 400, 1 mM Theophylline
|
Resolution 1.94 Å
R-free 0.217
|
|
8RW4
Crystal structure of the adenosine A2A receptor in complex with the synthetic photoswitch 'AzoSwitch2
Deposited 2024-02-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1H3L 8-[(~{E})-(3,4-dimethoxyphenyl)diazenyl]-1,3-diethyl-7~{H}-purine-2,6-dione × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 19
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；0.1 M Sodium citrate pH 5, 0.05 M Sodium thiocyanate, 3% (v/v)
2-methyl-2,4-pentanediol, 32% (v/v) PEG 400, 1 mM Theophylline
|
Resolution 2.20 Å
R-free 0.235
|
|
8RW7
Crystal structure of the adenosine A2A receptor in complex with the synthetic photoswitch 'StilSwitch1
Deposited 2024-02-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1H3J 8-[(~{E})-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7~{H}-purine-2,6-dione × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；0.1 M Sodium citrate pH 5, 0.05 M Sodium thiocyanate, 3% (v/v)
2-methyl-2,4-pentanediol, 32% (v/v) PEG 400, 1 mM Theophylline
|
Resolution 2.25 Å
R-free 0.214
|
|
8RWC
Crystal structure of the adenosine A2A receptor in complex with the synthetic photoswitch 'StilSwitch2
Deposited 2024-02-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1H3I 8-[(~{E})-2-[3,4-bis(oxidanyl)phenyl]ethenyl]-1,3-diethyl-7-methyl-purine-2,6-dione × 1
CLR CHOLESTEROL × 4
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 6
OLA OLEIC ACID × 19
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；0.1 M Sodium citrate pH 5, 0.05 M Sodium thiocyanate, 3% (v/v)
2-methyl-2,4-pentanediol, 32% (v/v) PEG 400, 1 mM Theophylline
|
Resolution 2.31 Å
R-free 0.241
|
|
8RWD
Crystal structure of the adenosine A2A receptor in complex with the synthetic photoswitch 'StilSwitch3
Deposited 2024-02-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1H3H 1,3-diethyl-8-[(~{E})-2-(4-methoxy-3-oxidanyl-phenyl)ethenyl]-7-methyl-purine-2,6-dione × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 26
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；0.1 M Sodium citrate pH 5, 0.05 M Sodium thiocyanate, 3% (v/v)
2-methyl-2,4-pentanediol, 32% (v/v) PEG 400, 1 mM Theophylline
|
Resolution 2.05 Å
R-free 0.209
|
|
8RWE
Crystal structure of the adenosine A2A receptor in complex with the synthetic photoswitch 'StilSwitch4
Deposited 2024-02-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1H3K 1,3-diethyl-8-[(~{E})-2-(3-methoxy-4-oxidanyl-phenyl)ethenyl]-7-methyl-purine-2,6-dione × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 23
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 3
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；0.1 M Sodium citrate pH 5, 0.05 M Sodium thiocyanate, 3% (v/v)
2-methyl-2,4-pentanediol, 32% (v/v) PEG 400, 1 mM Theophylline
|
Resolution 2.20 Å
R-free 0.227
|
|
8RWH
Dark structure of the human adenosine A2A receptor bound to synthetic photoswitch 'StilSwitch2' determined by serial synchrotron crystallography
Deposited 2024-02-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1H3I 8-[(~{E})-2-[3,4-bis(oxidanyl)phenyl]ethenyl]-1,3-diethyl-7-methyl-purine-2,6-dione × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 22
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.85；293 K；0.1 M sodium potassium phosphate pH 5.85, 27-30% PEG 500 MME, 0.2 M sodium thiocyanate, 0.4 mM StilSwitch2
|
Resolution 2.45 Å
R-free 0.241
|
|
8RWI
Steady state structure of the human adenosine A2A receptor bound to synthetic photoswitch 'StilSwitch2' determined by serial synchrotron crystallography
Deposited 2024-02-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1H3I 8-[(~{E})-2-[3,4-bis(oxidanyl)phenyl]ethenyl]-1,3-diethyl-7-methyl-purine-2,6-dione × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 17
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.85；293 K；0.1 M sodium potassium phosphate pH 5.85, 27-30% PEG 500 MME, 0.2 M sodium thiocyanate, 0.4 mM StilSwitch2
|
Resolution 2.80 Å
R-free 0.317
|
|
8RWX
Steady state structure of the human adenosine A2A receptor bound to synthetic photoswitch 'StilSwitch3' determined by serial synchrotron crystallography
Deposited 2024-02-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1H3H 1,3-diethyl-8-[(~{E})-2-(4-methoxy-3-oxidanyl-phenyl)ethenyl]-7-methyl-purine-2,6-dione × 1
OLA OLEIC ACID × 16
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5.85；293 K；0.1 M sodium potassium phosphate pH 5.85, 27-30% PEG 500 MME, 0.2 M sodium thiocyanate, 0.4 mM StilSwitch3
|
Resolution 3.05 Å
R-free 0.347
|
|
8T1V
Crystal structure of orphan G protein-coupled receptor 6 with bound inverse agonist 3h
Deposited 2023-06-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
XY8 3-{4-[(2,4-difluorophenyl)methyl]piperazin-1-yl}-7-methyl-N-(propan-2-yl)pyrido[3,4-b]pyrazin-2-amine × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；NaCH3COO, PEG 400, NaCl, PPG P40
|
Resolution 2.60 Å
R-free 0.258
|
|
8T1W
Crystal structure of orphan G protein-coupled receptor 6 with bound CVN424
Deposited 2023-06-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
X7T 1-{2-[4-(2,4-difluorophenoxy)piperidin-1-yl]-3-{[(3R)-oxolan-3-yl]amino}-7,8-dihydropyrido[3,4-b]pyrazin-6(5H)-yl}ethan-1-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；NaCH3COO, PEG 400, NaCl, PPG P40
|
Resolution 3.49 Å
R-free 0.322
|
|
8TB7
Cryo-EM Structure of GPR61-
Deposited 2023-06-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
ZOB 6-{[(3,5-difluoropyridin-4-yl)methyl]amino}-N-(4-ethoxy-6-methylpyrimidin-2-yl)-2-methoxy-N-(2-methoxyethyl)pyridine-3-sulfonamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.94 Å
|
|
8TF5
Crystal structure of orphan G protein-coupled receptor 6, pseudoapo form
Deposited 2023-07-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：C92L,A142P,M232W,H327I,R331L,G342R,S354C,Y383L,C408D
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 5
P15 2,5,8,11,14,17-HEXAOXANONADECAN-19-OL × 2
OLA OLEIC ACID × 12
CLR CHOLESTEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；NaCH3COO, PEG 400, NaCl, PPG P40
|
Resolution 2.10 Å
R-free 0.214
|
|
8TH3
Structure of AT118-H Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor
Deposited 2023-07-13
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
24–127（104 aa）
Chain B
24–127（104 aa）
|
Not recorded
|
Y01 CHOLESTEROL HEMISUCCINATE × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；20 mM HEPES, pH 7.4, 100 mM NaCl, 0.05% GDN, 0.005% CHS
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
8TH4
Structure of AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor and Losartan
Deposited 2023-07-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
24–127（104 aa）
|
Not recorded
|
LSN [2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；20 mM HEPES, pH 7.4, 100 mM NaCl, 0.05% GDN, 0.005% CHS
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å
|
|
8TS1
Cryo-EM structure of human MRS2 with Mg2+
Deposited 2023-08-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
MG MAGNESIUM ION × 7
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris pH 8.0, 150 mM NaCl, 40 mM MgCl2 and 0.04 mM GDN
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.92 Å
|
|
8TS2
Cryo-EM structure of human MRS2 with EDTA
Deposited 2023-08-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–123（101 aa）
Chain B
23–123（101 aa）
Chain C
23–123（101 aa）
Chain D
23–123（101 aa）
Chain E
23–123（101 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris pH 8.0, 150 mM NaCl, 10 mM EDTA and 0.04 mM GDN
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.95 Å
|
|
8TS3
Cryo-EM structure of human MRS2 with Ca2+
Deposited 2023-08-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
CA CALCIUM ION × 7
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8；20 mM Tris pH 8.0, 150 mM NaCl, 10 mM Ca2+ and 0.04 mM GDN
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.11 Å
|
|
8UHB
Cryo-EM Structure of the Ro5256390-bound hTA1-Gs heterotrimer signaling complex
Deposited 2023-10-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–123（101 aa）
|
Mutation：M(-129)W, R(-14)G, Q(-3)E, F112W
|
WV8 (2R,4S)-4-[(2S)-2-phenylbutyl]-1,3-oxazolidin-2-amine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.35 Å
|
|
8UT1
Alpha7-nicotinic acetylcholine receptor bound to epibatidine
Deposited 2023-10-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
CA CALCIUM ION × 5
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 15
9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5
EPJ EPIBATIDINE × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.30 Å
|
|
8UTB
Alpha7-nicotinic acetylcholine receptor bound to epibatidine and NS-1738
Deposited 2023-10-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
XG3 N-(5-chloro-2-hydroxyphenyl)-N'-[2-chloro-5-(trifluoromethyl)phenyl]urea × 5
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
EPJ EPIBATIDINE × 5
9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5
POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.30 Å
|
|
8UZJ
Alpha7-nicotinic acetylcholine receptor bound to epibatidine and ivermectin
Deposited 2023-11-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
CA CALCIUM ION × 5
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5
EPJ EPIBATIDINE × 5
IVM (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17 -oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacy clooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside × 5
POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.30 Å
|
|
8V80
Alpha7-nicotinic acetylcholine receptor bound to epibatidine and (-)-TQS
Deposited 2023-12-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
CA CALCIUM ION × 5
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 10
9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5
EPJ EPIBATIDINE × 5
YLR (3aR,4S,9bS)-4-(naphthalen-1-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.34 Å
|
|
8V82
Alpha7-nicotinic acetylcholine receptor bound to epibatidine and PNU-120596
Deposited 2023-12-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
CA CALCIUM ION × 5
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 15
9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5
EPJ EPIBATIDINE × 5
I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.61 Å
|
|
8V86
Alpha7-nicotinic acetylcholine receptor bound to GAT107
Deposited 2023-12-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 10
9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
YLI (3aR,4S,9bS)-4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.47 Å
|
|
8V88
Alpha7-nicotinic acetylcholine receptor bound to epibatidine and GAT107
Deposited 2023-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
CA CALCIUM ION × 5
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 10
9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5
EPJ EPIBATIDINE × 5
YLI (3aR,4S,9bS)-4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.30 Å
|
|
8V89
Alpha7-nicotinic acetylcholine receptor time resolved resting state
Deposited 2023-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
R16 HEXADECANE × 5
9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5
POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.53 Å
|
|
8V8A
Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 desensitized intermediate state
Deposited 2023-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
CA CALCIUM ION × 5
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
POV (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate × 15
9Z9 (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en × 5
EPJ EPIBATIDINE × 5
I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.19 Å
|
|
8V8C
Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 asymmetric state 1
Deposited 2023-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10
EPJ EPIBATIDINE × 5
I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5
CA CALCIUM ION × 3
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.29 Å
|
|
8V8D
Alpha7-nicotinic acetylcholine receptor time resolved bound to epibatidine and PNU-120596 asymmetric state 2
Deposited 2023-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 10
EPJ EPIBATIDINE × 5
I34 N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea × 5
CA CALCIUM ION × 3
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.31 Å
|
|
8VHF
Cryo-EM structure of GPR119-Gs-Nb35 complex with small molecule agonist MBX-2982
Deposited 2024-01-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
8VP 2-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]-4-[[4-(1,2,3,4-tetrazol-1-yl)phenoxy]methyl]-1,3-thiazole × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.51 Å
|
|
8W77
Human Consensus Olfactory Receptor OR52c in apo state, OR52c only
Deposited 2023-08-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE；blot time 3 seconds
|
Resolution 3.61 Å
|
|
8W8B
Cryo-EM structure of SEP-363856 bounded serotonin 1A (5-HT1A) receptor-Gi protein complex
Deposited 2023-09-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 5
PLM PALMITIC ACID × 1
UJL 1-[(7~{S})-5,7-dihydro-4~{H}-thieno[2,3-c]pyran-7-yl]-~{N}-methyl-methanamine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
8W8Q
Cryo-EM structure of the GPR101-Gs complex
Deposited 2023-09-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain C
23–128（106 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.89 Å
|
|
8W8W
Cryo-EM structure of alpha-MSH-MC3R-Gs_Nb35 complex
Deposited 2023-09-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CA CALCIUM ION × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å
|
|
8W8X
Cryo-EM structure of beta-MSH-MC3R-Gs_Nb35 complex
Deposited 2023-09-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CA CALCIUM ION × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å
|
|
8W8Y
Cryo-EM structure of gamma-MSH-MC3R-Gs_Nb35 complex
Deposited 2023-09-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CA CALCIUM ION × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.90 Å
|
|
8WJX
ADP-bound purinergic receptor 1 in complex with miniGs/q
Deposited 2023-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
ADP ADENOSINE-5'-DIPHOSPHATE × 1
CLR CHOLESTEROL × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
8WRZ
Cry-EM structure of cannabinoid receptor-beta-arrestin-1 complex
Deposited 2023-10-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Mutation：M29W, H124I, T210I, E273K, T283V, R340E
|
8D0 (6~{a}~{R},9~{R},10~{a}~{R})-9-(hydroxymethyl)-3-(8-isothiocyanato-2-methyl-octan-2-yl)-6,6-dimethyl-6~{a},7,8,9,10,10~{a}-hexahydrobenzo[c]chromen-1-ol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.60 Å
|
|
8X2K
OEA bound GPR3-Gs complex structure
Deposited 2023-11-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–127（105 aa）
|
Not recorded
|
5YM (Z)-N-(2-hydroxyethyl)octadec-9-enamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.03 Å
|
|
8X3K
Cryo-EM structure of human VMAT2 in complex with serotonin.
Deposited 2023-11-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Mutation：M8W,H103I
|
SRO SEROTONIN × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.98 Å
|
|
8X5X
CryoEM structure of the histamine H1 receptor in apo-form
Deposited 2023-11-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–127（105 aa）
|
Mutation：M217W,H313I
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen NITROGEN
|
Resolution 3.50 Å
|
|
8X5Y
CryoEM structure of the histamine H1 receptor-BRIL/Anti BRIL Fab complex with astemizole
Deposited 2023-11-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–65（43 aa）
Chain B
77–127（51 aa）
|
Not recorded
|
XB7 1-[(4-fluorophenyl)methyl]-N-{1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}-1H-benzimidazol-2-amine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen NITROGEN
|
Resolution 3.00 Å
|
|
8X63
CryoEM structure of the histamine H1 receptor-BRIL/Anti BRIL Fab complex with mepyramine
Deposited 2023-11-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–65（43 aa）
Chain B
77–127（51 aa）
|
Not recorded
|
Y5E mepyramine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen NITROGEN
|
Resolution 3.20 Å
|
|
8X64
CryoEM structure of the histamine H1 receptor-BRIL/Anti BRIL Fab complex with desloratadine
Deposited 2023-11-20
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–65（43 aa）
Chain B
77–127（51 aa）
|
Not recorded
|
Y5R desloratadine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen NITROGEN
|
Resolution 3.40 Å
|
|
8XML
Cryo-EM structure of the Apo CCR8-Gi complex
Deposited 2023-12-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.58 Å
|
|
8XQE
Cryo-EM structure of human dimeric APJR-Gi complex with apelin-13.
Deposited 2024-01-05
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 7
PDB declaration: heptameric
|
Chain Q
23–127（105 aa）
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.48 Å
|
|
8XQF
Cryo-EM structure of human monomeric APJR-Gi complex with apelin-13.
Deposited 2024-01-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.13 Å
|
|
8XQI
Cryo-EM structure of human dimeric Apelin receptor.
Deposited 2024-01-05
|
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.25 Å
|
|
8XQJ
Cryo-EM structure of human dimeric APJR complex with antagonistic antibody
Deposited 2024-01-05
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 4
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.95 Å
|
|
8XV2
Thiamine-bound human SLC19A3
Deposited 2024-01-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
VIB 3-(4-AMINO-2-METHYL-PYRIMIDIN-5-YLMETHYL)-5-(2-HYDROXY-ETHYL)-4-METHYL-THIAZOL-3-IUM × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.70 Å
|
|
8XV5
Pyridoxamine-bound human SLC19A3
Deposited 2024-01-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
PXM 4-(AMINOMETHYL)-5-(HYDROXYMETHYL)-2-METHYLPYRIDIN-3-OL × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.70 Å
|
|
8XV9
Fedratinib-bound human SLC19A3
Deposited 2024-01-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
2TA N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzenesulfonamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.80 Å
|
|
8XVJ
Cryo-EM structure of ETAR bound with Macitentan
Deposited 2024-01-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1D5I Macitentan × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.26 Å
|
|
8XVK
Cryo-EM structure of ETAR bound with Ambrisentan
Deposited 2024-01-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1D5J Ambrisentan × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.21 Å
|
|
8XVL
Cryo-EM structure of ETAR bound with Zibotentan
Deposited 2024-01-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1D5L Zibotentan × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.22 Å
|
|
8Y6J
The structure of Oryza sativa HKT1;1
Deposited 2024-02-02
|
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.46 Å
|
|
8Y6L
Oryza sativa HKT1;5 salt sensitive variant
Deposited 2024-02-02
|
Different ligand/ion
Different experimental conditions
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
8Y6M
The structure of Oryza sativa HKT2;1
Deposited 2024-02-02
|
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.91 Å
|
|
8Y6N
The structure of Oryza sativa HKT1;5 salt tolerant variant
Deposited 2024-02-02
|
Different ligand/ion
Different experimental conditions
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
8Y6Y
GLPG0974-bound human FFA2
Deposited 2024-02-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1LYD GLPG-0974 × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.36 Å
|
|
8YNS
Cryo-EM structure of SNAP-94847-bound MCHR1, S1 state
Deposited 2024-03-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–65（43 aa）
|
Not recorded
|
A1D6T ~{N}-[3-[1-[[4-[3,4-bis(fluoranyl)phenoxy]phenyl]methyl]piperidin-4-yl]-4-methyl-phenyl]-2-methyl-propanamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.33 Å
|
|
8YNT
Cryo-EM structure of SNAP-94847-bound MCHR1, S2 state
Deposited 2024-03-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–65（43 aa）
|
Not recorded
|
A1D6T ~{N}-[3-[1-[[4-[3,4-bis(fluoranyl)phenoxy]phenyl]methyl]piperidin-4-yl]-4-methyl-phenyl]-2-methyl-propanamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.43 Å
|
|
8YRG
CryoEM structure of fospropofol-bound MRGPRX4-Gq complex
Deposited 2024-03-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1LZU [2,6-di(propan-2-yl)phenoxy]methyl dihydrogen phosphate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 3.14 Å
|
|
8YZK
Orphan receptor GPRC5D in complex with scFv150-18
Deposited 2024-04-07
|
Different construct
Different oligomeric state
Different ligand/ion
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
22–128（107 aa）
Chain B
22–128（107 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
8Z74
Cryo-EM structure of APJR complex with agonistic antibody
Deposited 2024-04-19
|
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.01 Å
|
|
8Z7J
Cryo-EM structure of APJR-Gi complex with agonistic antibody
Deposited 2024-04-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.12 Å
|
|
8ZBB
Cryo-EM structure of outward state Anhydromuropeptide permease (AmpG) G50W/L269W
Deposited 2024-04-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–127（105 aa）
|
Mutation：G50W/L269W
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.11 Å
|
|
8ZBI
Cryo-EM structure of Somatostatin receptor 3 (SSTR3) with Gi1 complex
Deposited 2024-04-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain D
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.79 Å
|
|
8ZBJ
Cryo-EM structure of Somatostatin receptor 5 (SSTR5) with Gi1 complex
Deposited 2024-04-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.94 Å
|
|
8ZFK
Caenorhabditis elegans ACR-23 in betaine and monepantel bound state
Deposited 2024-05-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
A1D8E ~{N}-[(2~{S})-2-cyano-1-[5-cyano-2-(trifluoromethyl)phenoxy]propan-2-yl]-4-(trifluoromethylsulfanyl)benzamide × 5
BET TRIMETHYL GLYCINE × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.64 Å
|
|
8ZFL
Caenorhabditis elegans ACR-23 in apo state
Deposited 2024-05-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.61 Å
|
|
8ZFM
Caenorhabditis elegans ACR-23 in betaine bound state
Deposited 2024-05-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
Chain C
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5
BET TRIMETHYL GLYCINE × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.96 Å
|
|
8ZFZ
cryo-EM structure of Gs-coupled zebrafish GPR4 at pH 6.5
Deposited 2024-05-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
22–128（107 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 6.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.30 Å
|
|
8ZMF
Crystal structure of an inverse agonist antipsychotic drug derivative-bound 5-HT2C
Deposited 2024-05-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M29W,H124I,R128L,C360N
|
A1L10 1-[(4-fluorophenyl)methyl]-1-[(8~{S})-5-methyl-5-azaspiro[2.5]octan-8-yl]-3-[[4-(2-methylpropoxy)phenyl]methyl]urea × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；18-24% PEG300, 40-60 mM ammonium phosphate dibasic
|
Resolution 3.60 Å
R-free 0.285
|
|
8ZMG
Crystal structure of an inverse agonist antipsychotic drug pimavanserin-bound 5-HT2A
Deposited 2024-05-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–62（40 aa）
Chain A
88–128（41 aa）
|
Mutation：S162K,M164W,M29W,H124I,R128L,R315G
Mutation：S162K,M164W,M29W,H124I,R128L,R315G
|
A1L11 Pimavanserin × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；32-38%PEG300, 40-60mM lithium chloride
|
Resolution 3.40 Å
R-free 0.328
|
|
8ZMG
Crystal structure of an inverse agonist antipsychotic drug pimavanserin-bound 5-HT2A
Deposited 2024-05-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–62（40 aa）
Chain B
88–128（41 aa）
|
Mutation：S162K,M164W,M29W,H124I,R128L,R315G
Mutation：S162K,M164W,M29W,H124I,R128L,R315G
|
A1L11 Pimavanserin × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 6；293 K；32-38%PEG300, 40-60mM lithium chloride
|
Resolution 3.40 Å
R-free 0.328
|
|
8ZPL
Cryo-EM strucutre of CXCR4 complexed with antagonist HF51116
Deposited 2024-05-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
A1D8K (2S)-N-[[4-[[3-(cyclohexylamino)propylamino]methyl]phenyl]methyl]-5-(diaminomethylideneamino)-2-(pyridin-2-ylmethylamino)pentanamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.01 Å
|
|
8ZPM
Cryo-EM strucutre of CXCR4 complexed with antagonist AMD070
Deposited 2024-05-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1D8L Mavorixafor × 1
CLR CHOLESTEROL × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
8ZPN
Cryo-EM strucutre of CXCR4 complexed with antagonist AMD3100
Deposited 2024-05-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 1
VH6 Plerixafor × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.31 Å
|
|
8ZRN
Structure of abt
Deposited 2024-06-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
A1D8V 5-[[(2~{S})-azetidin-2-yl]methoxy]-2-chloranyl-pyridine × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.25 Å
|
|
8ZRP
Structure of nico
Deposited 2024-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain B
23–127（105 aa）
Chain D
23–127（105 aa）
Chain E
23–127（105 aa）
|
Not recorded
|
NCT (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.32 Å
|
|
8ZSJ
Cryo-EM structure of the apo hTAAR1-Gs complex
Deposited 2024-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å
|
|
8ZSP
Cryo-EM structure of the LSD-bound hTAAR1-Gs complex
Deposited 2024-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
7LD (8alpha)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.14 Å
|
|
8ZSS
Cryo-EM structure of the RO5263397-bound hTAAR1-Gs complex
Deposited 2024-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1D8X (4~{S})-4-(3-fluoranyl-2-methyl-phenyl)-1,3-oxazolidin-2-amine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.07 Å
|
|
8ZSV
Cryo-EM structure of the RO5263397-bound mTAAR1-Gs complex
Deposited 2024-06-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1D8X (4~{S})-4-(3-fluoranyl-2-methyl-phenyl)-1,3-oxazolidin-2-amine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.96 Å
|
|
8ZVZ
Cryo-EM strcuture of Prostaglandin D2 Receptor DP1 activated by BW245C
Deposited 2024-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–127（107 aa）
|
Not recorded
|
A1AF8 7-{(4S)-3-[(3R)-3-cyclohexyl-3-hydroxypropyl]-2,5-dioxoimidazolidin-4-yl}heptanoic acid × 1
CLR CHOLESTEROL × 5
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.35 Å
|
|
8ZW0
Cryo-EM strcuture of Prostaglandin D2 Receptor DP1 activated by PGD2
Deposited 2024-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain D
21–127（107 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
PG2 PROSTAGLANDIN D2 × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.72 Å
|
|
8ZWF
cryoEM structure of JR14a bound C3aR-BRIL-BAG2 complex
Deposited 2024-06-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–127（105 aa）
|
Mutation：E27Q,M29W,H124I
|
A1D9A (2~{S})-5-[bis(azanyl)methylideneamino]-2-[[5-[bis(4-chlorophenyl)methyl]-3-methyl-thiophen-2-yl]carbonylamino]pentanoic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.3
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
8ZYT
Cryo-EM structure of neurotensin receptor 1 in complex with beta-arrestin1 and SBI-553 (complex 3)
Deposited 2024-06-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
PIO [(2R)-2-octanoyloxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] octanoate × 1
SRW 2-[{2-(1-fluorocyclopropyl)-4-[4-(2-methoxyphenyl)piperidin-1-yl]quinazolin-6-yl}(methyl)amino]ethan-1-ol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.65 Å
|
|
8ZYU
Cryo-EM structure of neurotensin receptor 1 in complex with beta-arrestin1 and SBI-553 (complex 1)
Deposited 2024-06-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
SRW 2-[{2-(1-fluorocyclopropyl)-4-[4-(2-methoxyphenyl)piperidin-1-yl]quinazolin-6-yl}(methyl)amino]ethan-1-ol × 1
PIO [(2R)-2-octanoyloxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] octanoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.65 Å
|
|
8ZYY
Cryo-EM structure of neurotensin receptor 1 in complex with beta-arrestin1 and SBI-553 (complex 2)
Deposited 2024-06-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
PIO [(2R)-2-octanoyloxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] octanoate × 1
SRW 2-[{2-(1-fluorocyclopropyl)-4-[4-(2-methoxyphenyl)piperidin-1-yl]quinazolin-6-yl}(methyl)amino]ethan-1-ol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.83 Å
|
|
9BS9
Local refinement of DRD2 bound to LSD in complex with a mini-GoA and scFv16 obtained by cryo-electron microscopy (cryoEM)
Deposited 2024-05-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
7LD (8alpha)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 2.28 Å
|
|
9BSB
Global reconstruction of DRD2 bound to LSD in complex with a mini-GoA and scFv16 obtained by cryo-electron microscopy (cryoEM)
Deposited 2024-05-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
7LD (8alpha)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 2.32 Å
|
|
9C3F
Cryo-EM structure of E. coli AmpG
Deposited 2024-05-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
LMT DODECYL-BETA-D-MALTOSIDE × 1
PEE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.78 Å
|
|
9CAX
Structure of human SLC2A9 transporter
Deposited 2024-06-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；4 degree cold buffer pH7.5 (300mM NaCl, 50mM Tris and 0.02% GDN)
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.37 Å
|
|
9CBB
Structure of urate bound human SLC2A9 transporter
Deposited 2024-06-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
URC URIC ACID × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；4 degree cold buffer pH7.5 (300mM NaCl, 50mM Tris and 0.02% GDN)
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.15 Å
|
|
9DNG
Structure of rat beta-arrestin 1 by fiducial-assisted cryo-EM
Deposited 2024-09-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
|
Mutation：M29W, H124I, R128L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.52 Å
|
|
9DNM
Structure of rat beta-arrestin 1 bound to allosteric inhibitor
Deposited 2024-09-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
|
Mutation：M29W, H124I, R128L
|
ODN (1beta,6beta,7beta,8alpha,9beta,10alpha,13alpha,14R,16beta)-1,6,7,14-tetrahydroxy-7,20-epoxykauran-15-one × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.47 Å
|
|
9DVB
Thermus thermophilus MreC-MreD complex with an internal MreD BRIL fusion and an anti-BRIL Fab
Deposited 2024-10-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 10
PDB declaration: decameric
|
Chain B
30–119（90 aa）
Fragment：BRIL domain, residues 30-119
Chain N
30–119（90 aa）
Fragment：BRIL domain, residues 30-119
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.60 Å
|
|
9DVC
Thermus thermophilus MreC-MreD complex with a C-terminal MreD BRIL fusion and an anti-BRIL Fab
Deposited 2024-10-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 7
PDB declaration: heptameric
|
Chain B
30–119（90 aa）
Fragment：BRIL domain, residues 30-119
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 7.40 Å
|
|
9DYD
Asenapine-bound serotonin 1A (5-HT1A) receptor-Goa protein complex
Deposited 2024-10-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–128（106 aa）
Fragment：residues 1-25 of the 5-HT receptor deleted
|
Mutation：L125W
|
A1BIR (3aS,12bR)-asenapine × 1
CLR CHOLESTEROL × 3
J40 [(2R)-1-[oxidanyl-[(2R,3R,5S,6R)-2,3,5,6-tetrakis(oxidanyl)-4-phosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-3-tetradecanoyloxy-propan-2-yl] (5E,8E)-hexadeca-5,8,11,14-tetraenoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE；Blot force 3 for 3-5 seconds was used and subsequent grids were screened for ice thickness prior to data collection.
|
Resolution 2.96 Å
|
|
9DYE
Buspirone-bound serotonin 1A (5-HT1A) receptor-Goa protein complex
Deposited 2024-10-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–128（106 aa）
Fragment：residues 1-25 of the 5-HT receptor deleted
|
Mutation：L125W
|
YLX Buspirone × 1
CLR CHOLESTEROL × 2
J40 [(2R)-1-[oxidanyl-[(2R,3R,5S,6R)-2,3,5,6-tetrakis(oxidanyl)-4-phosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-3-tetradecanoyloxy-propan-2-yl] (5E,8E)-hexadeca-5,8,11,14-tetraenoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE；Blot force 3 for 3-5 seconds was used and subsequent grids were screened for ice thickness prior to data collection.
|
Resolution 2.90 Å
|
|
9DYF
Asenapine-bound serotonin 1A (5-HT1A) receptor-Gi1 protein complex
Deposited 2024-10-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–128（106 aa）
Fragment：residues 1-25 of the 5-HT receptor deleted
|
Mutation：L125W
|
A1BIR (3aS,12bR)-asenapine × 1
CLR CHOLESTEROL × 3
J40 [(2R)-1-[oxidanyl-[(2R,3R,5S,6R)-2,3,5,6-tetrakis(oxidanyl)-4-phosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-3-tetradecanoyloxy-propan-2-yl] (5E,8E)-hexadeca-5,8,11,14-tetraenoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE；Blot force 3 for 3-5 seconds was used and subsequent grids were screened for ice thickness prior to data collection.
|
Resolution 2.74 Å
|
|
9EAH
Structure of nanobody AT209 in complex with the olmesartan-bound angiotensin II type I receptor (AT1R)
Deposited 2024-11-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
24–128（105 aa）
Chain B
24–128（105 aa）
|
Mutation：M232W, H327I, R331L
Mutation：M232W, H327I, R331L
|
OLM Olmesartan × 1
CLR CHOLESTEROL × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å
|
|
9EAI
Structure of nanobody AT206 in complex with the losartan-bound angiotensin II type I receptor (AT1R)
Deposited 2024-11-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
24–128（105 aa）
Chain B
24–128（105 aa）
|
Mutation：M232W, H327I, R331L
Mutation：M232W, H327I, R331L
|
LSN [2-butyl-5-chloranyl-3-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol × 1
Y01 CHOLESTEROL HEMISUCCINATE × 2
CLR CHOLESTEROL × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å
|
|
9EAJ
Structure of nanobody AT206 in complex with the angiotensin II type I receptor (AT1R)
Deposited 2024-11-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
24–128（105 aa）
Chain B
24–128（105 aa）
|
Mutation：M232W, H327I, R331L
Mutation：M232W, H327I, R331L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
9EE5
Cryo-EM structure of the ONO2550289-bound prostaglandin D2 receptor (DP1)-bRIL-Fab complex
Deposited 2024-11-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
|
Not recorded
|
A1BIL [2-chloro-5-(2,6-dimethyl-4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}benzamido)phenyl]acetic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.89 Å
|
|
9EI5
Cryo-EM structure of Apo form of prostaglandin D2 receptor (DP1)-bRIL-Fab complex
Deposited 2024-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.84 Å
|
|
9EKH
Cryo-EM structure ONO3030297-bound prostaglandin D2 receptor (DP1)-bRIL-Fab complex
Deposited 2024-12-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
|
Not recorded
|
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
A1BI8 1-[2-chloro-5-(2,6-dimethyl-4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}benzamido)phenyl]cyclopropane-1-carboxylic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.89 Å
|
|
9FUP
Serial microseconds crystallography at ID29 using fixed-target (small foils): A2a adenosine receptor co-crystallised with Istradefylline
Deposited 2024-06-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 11
OLB (2S)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
OLC (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate × 2
JQ9 8-[(~{E})-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-7-methyl-purine-2,6-dione × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；pH 5；293 K；0.1 M tri-sodium citrate pH 5.0, 50 mM sodium thiocyanate, 29-30% (v/v) PEG 400, 1% (v/v) 1,6-hexanediol
|
Resolution 2.50 Å
R-free 0.288
|
|
9GYO
CryoEM structure of Gs-coupled GPBAR with small molecule agonist P395
Deposited 2024-10-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
FWX 2-(ethylamino)-6-[3-(4-propan-2-ylphenyl)propanoyl]-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine-4-carboxamide × 1
CLR CHOLESTEROL × 3
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
|
Resolution 2.50 Å
|
|
9H2X
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 7, a novel nanomolar A2A receptor antagonist from modern hit-finding with structure-guided de novo design
Deposited 2024-10-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 21
A1IR1 4-(furan-2-yl)-6-(6-imidazol-1-ylpyridin-2-yl)-1,3,5-triazin-2-amine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；0.l M tri-sodium citrate pH 5.3-5.4, 0.05 M sodium thiocyanate, 29-32% PEG400, 2% (v/v) 2,5-hexanediol and 0.5 mM theophylline.
|
Resolution 1.75 Å
R-free 0.226
|
|
9H37
Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 9, a novel nanomolar A2A receptor antagonist from modern hit-finding with structure-guided de novo design
Deposited 2024-10-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
NA SODIUM ION × 1
CLR CHOLESTEROL × 3
OLA OLEIC ACID × 21
A1IR0 2-(furan-2-yl)-7-pyridin-4-yl-pyrrolo[2,3-d]pyrimidin-4-amine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
LIPIDIC CUBIC PHASE；293 K；0.1 M tri-sodium citrate pH 5.3-5.4, 0.05 M sodium thiocyanate, 29-32% PEG400, 2% (v/v) 2,5-hexanediol and 0.5 mM theophylline
|
Resolution 1.72 Å
R-free 0.220
|
|
9HAP
Cryo-EM structure of inactive human arginine-vasopressin (AVP) V2 receptor (V2R) with tolvaptan
Deposited 2024-11-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–123（101 aa）
|
Not recorded
|
A1IT8 (R)-Tolvaptan × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.50 Å
|
|
9IP5
Hemichannel sub-structure of Cx36/GJD2 gap junction intercellular channel (FN conformation) in brain polar lipid nanodiscs, treated with a 14-fold molar excess of carbenoxolone
Deposited 2024-07-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
Chain F
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
|
C14 TETRADECANE × 18
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；20mM HEPES(pH 7.5), 150mM KCl, 2mM beta-mercaptoethanol
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.52 Å
|
|
9IPM
Hemichannel sub-structure of Cx36/GJD2 gap junction intercellular channel (FN conformation) in soybean polar lipid nanodiscs, treated with a 20-fold molar excess of carbenoxolone
Deposited 2024-07-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
Chain F
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
|
MC3 1,2-DIMYRISTOYL-RAC-GLYCERO-3-PHOSPHOCHOLINE × 12
C14 TETRADECANE × 6
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；20mM HEPES(pH 7.5), 150mM KCl, 2mM beta-mercaptoethanol
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.56 Å
|
|
9IPN
Hemichannel sub-structure of Cx36/GJD2 gap junction intercellular channel (FN conformation) in soybean polar lipid nanodiscs, treated with a 10-fold molar excess of carbenoxolone and incubated shortly
Deposited 2024-07-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
Chain F
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
|
MC3 1,2-DIMYRISTOYL-RAC-GLYCERO-3-PHOSPHOCHOLINE × 6
C14 TETRADECANE × 6
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；20mM HEPES(pH 7.5), 150mM KCl, 2mM beta-mercaptoethanol
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.46 Å
|
|
9IPO
Hemichannel sub-structure of Cx36/GJD2 gap junction intercellular channel (FN conformation) in soybean polar lipid nanodiscs, treated with a 10-fold molar excess of carbenoxolone
Deposited 2024-07-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 6
PDB declaration: hexameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
Chain F
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
|
MC3 1,2-DIMYRISTOYL-RAC-GLYCERO-3-PHOSPHOCHOLINE × 12
C14 TETRADECANE × 18
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；20mM HEPES(pH 7.5), 150mM KCl, 2mM beta-mercaptoethanol
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.41 Å
|
|
9IPY
Structure of JR14a-bound human C3aR
Deposited 2024-07-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain R
23–127（105 aa）
|
Mutation：M1012W/H1107I
|
A1D9A (2~{S})-5-[bis(azanyl)methylideneamino]-2-[[5-[bis(4-chlorophenyl)methyl]-3-methyl-thiophen-2-yl]carbonylamino]pentanoic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.50 Å
|
|
9ISI
Structure of human C3aR in apo state
Deposited 2024-07-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–127（105 aa）
|
Mutation：M1012W/H1107I
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.56 Å
|
|
9IYA
Cryo-EM structure of GPR55-Fab-Nb-ONO-9710531 complex
Deposited 2024-07-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1L3E 4-(3-bromanyl-5-ethoxy-4-oxidanyl-phenyl)-~{N}-(2-methoxyphenyl)-2-methyl-5-oxidanylidene-4,6,7,8-tetrahydro-1~{H}-quinoline-3-carboxamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.04 Å
|
|
9IZF
Cryo-EM structure of LPA1-Gi complex with LPA
Deposited 2024-08-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
NKP (2R)-2-hydroxy-3-(phosphonooxy)propyl (9E)-octadec-9-enoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.14 Å
|
|
9IZG
Cryo-EM structure of LPA1-Gq complex with LPA
Deposited 2024-08-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
NKP (2R)-2-hydroxy-3-(phosphonooxy)propyl (9E)-octadec-9-enoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.04 Å
|
|
9IZH
Cryo-EM structure of LPA1-G13 complex with LPA
Deposited 2024-08-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
NKP (2R)-2-hydroxy-3-(phosphonooxy)propyl (9E)-octadec-9-enoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.04 Å
|
|
9J05
Apo state purinergic receptor P2Y14-BRIL/PPTN/1B3 Fab-4/9Glue
Deposited 2024-08-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
9J0B
UDP-Glucose bound purinergic receptor P2Y14 in complex with Gi
Deposited 2024-08-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
UPG URIDINE-5'-DIPHOSPHATE-GLUCOSE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
|
Resolution 2.88 Å
|
|
9J0F
NADH bound purinergic receptor P2Y14 in complex with Gi
Deposited 2024-08-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
NAI 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
|
Resolution 2.76 Å
|
|
9J0I
UDP-Glucuronic acid bound purinergic receptor P2Y14 complex with Gi
Deposited 2024-08-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
UGA URIDINE-5'-DIPHOSPHATE-GLUCURONIC ACID × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
|
Resolution 2.76 Å
|
|
9J31
cryo-EM structure of zebrafish GPR4-Gs complex at pH 8.5
Deposited 2024-08-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
22–128（107 aa）
|
Mutation：M29W, H124I, R128L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8.5；20 mM MES (pH 6.5), 100 mM NaCl, 2 mM MgCl2, 0.0025% (w/v) LMNG, and 0.0005% (w/v) CHS.
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.05 Å
|
|
9J9Z
Cryo-EM structure of Outward state Anhydromuropeptide permease (AmpG) complex with GlcNAc-1,6-anhMurNAc
Deposited 2024-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
27–127（101 aa）
|
Mutation：G50W/L269W
|
2YP (2R)-2-[[(1R,2S,3R,4R,5R)-4-acetamido-2-[(2S,3R,4R,5S,6R)-3-acetamido-6-(hydroxymethyl)-4,5-bis(oxidanyl)oxan-2-yl]oxy-6,8-dioxabicyclo[3.2.1]octan-3-yl]oxy]propanoic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.97 Å
|
|
9JFU
Cryo-EM structure of inactive GPR4 with NE52-QQ57
Deposited 2024-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1L1E NE52-QQ57 × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.23 Å
|
|
9JG0
Cryo-EM structure of neuropeptide FF receptor 2 in the ligand-free state with BRIL fusion, anti-BRIL Fab, and nanobody
Deposited 2024-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.91 Å
|
|
9JG1
Cryo-EM structure of Adriforant-bound Histamine receptor 4 H4R at inactive state
Deposited 2024-09-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1EBW Adriforant × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.2
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.62 Å
|
|
9JGK
cryo-EM structure of 5-Hydroxytryptamine 2B Receptor in complex with balovaptan
Deposited 2024-09-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
22–127（106 aa）
|
Not recorded
|
A1EB7 Balovaptan × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.60 Å
|
|
9JKQ
Cryo-EM structure of the METH-bound hTAAR1-Gs complex
Deposited 2024-09-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
B40 (2S)-N-methyl-1-phenylpropan-2-amine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.66 Å
|
|
9JOZ
outward-open hSLC19A1
Deposited 2024-09-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.94 Å
|
|
9JRI
outward-open hSLC19A1 + 5-MTHF
Deposited 2024-09-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
C2F 5-METHYL-5,6,7,8-TETRAHYDROFOLIC ACID × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.43 Å
|
|
9JRK
outward-open hSLC19A1 + MTX
Deposited 2024-09-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
MTX METHOTREXATE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.44 Å
|
|
9JRL
outward-open hSLC19A1 + PT523
Deposited 2024-09-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
COP N-(4-CARBOXY-4-{4-[(2,4-DIAMINO-PTERIDIN-6-YLMETHYL)-AMINO]-BENZOYLAMINO}-BUTYL)-PHTHALAMIC ACID × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.25 Å
|
|
9JRM
outward-open hSLC19A1 + 2'3'-CDAS
Deposited 2024-09-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
GJF (1~{R},3~{S},6~{R},8~{R},9~{R},10~{S},12~{S},15~{R},17~{R},18~{R})-8,17-bis(6-aminopurin-9-yl)-3,12-bis(oxidanylidene)-3,12-bis(sulfanyl)-2,4,7,11,13,16-hexaoxa-3$l^{5},12$l^{5}-diphosphatricyclo[13.2.1.0^{6,10}]octadecane-9,18-diol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.34 Å
|
|
9JRN
outward-open hSLC19A1 + TPP
Deposited 2024-09-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
TPP THIAMINE DIPHOSPHATE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.74 Å
|
|
9JRO
Structural Insights into Selective Antagonism of PF04418948 and EP2 Prostaglandin Receptor
Deposited 2024-09-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1ECS PF-04418948 × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.3
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.50 Å
|
|
9JRT
Structural Insights into Selective Antagonism of TG6-129 and EP2 Prostaglandin Receptor
Deposited 2024-09-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1EC5 ~{N}-[[4-[(5-ethyl-1,3,4-thiadiazol-2-yl)sulfamoyl]phenyl]carbamothioyl]-3-(4-fluorophenyl)propanamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.3
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.28 Å
|
|
9KC9
Cryo-EM structure of docked mouse bestrophin-1 in a partial open state
Deposited 2024-11-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Fragment：BRIL-3X
Chain B
23–128（106 aa）
Fragment：BRIL-3X
Chain C
23–128（106 aa）
Fragment：BRIL-3X
Chain D
23–128（106 aa）
Fragment：BRIL-3X
Chain E
23–128（106 aa）
Fragment：BRIL-3X
|
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
|
CA CALCIUM ION × 5
CL CHLORIDE ION × 10
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å
|
|
9KCA
Cryo-EM structure of docked mouse bestrophin-1 in a closed state
Deposited 2024-11-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Fragment：BRIL-3X
Chain B
23–128（106 aa）
Fragment：BRIL-3X
Chain C
23–128（106 aa）
Fragment：BRIL-3X
Chain D
23–128（106 aa）
Fragment：BRIL-3X
Chain E
23–128（106 aa）
Fragment：BRIL-3X
|
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
Mutation：M29W,H124I,R128L
|
CA CALCIUM ION × 5
CL CHLORIDE ION × 10
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.18 Å
|
|
9KFI
Cryo-EM structure of the human relaxin family peptide receptor 3 in complex with relaxin-3 and G protein
Deposited 2024-11-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 7
PDB declaration: heptameric
|
Chain C
23–128（106 aa）
|
Mutation：M29W, H124I, R128L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.91 Å
|
|
9KFJ
Cryo-EM structure of the compound 4-bound human relaxin family peptide receptor 3 (RXFP3)-Gi complex
Deposited 2024-11-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain C
23–128（106 aa）
|
Mutation：M29W, H124I, R128L
|
IYF 1-[2-(4-chlorophenyl)ethyl]-3-[(7-ethyl-5-oxidanyl-1H-indol-3-yl)methylideneamino]guanidine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å
|
|
9KFK
Cryo-EM structure of the relaxin-3-bound human relaxin family peptide receptor 4 (RXFP4)-Gi complex
Deposited 2024-11-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 7
PDB declaration: heptameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.95 Å
|
|
9KKN
Cryo-EM structure of human VAChT in complex with ACh
Deposited 2024-11-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M8W,H103I,R107L
|
ACH ACETYLCHOLINE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.72 Å
|
|
9KKO
Cryo-EM structure of human VAChT in apo state
Deposited 2024-11-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M8W,H103I,R107L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.25 Å
|
|
9KP6
Cryo-EM structure of mouse bestrophin-1 in a closed state
Deposited 2024-11-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
Chain D
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
CA CALCIUM ION × 5
CL CHLORIDE ION × 10
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.18 Å
|
|
9KQ5
Cryo-EM structure of human VAChT at protonated state
Deposited 2024-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M8W,H103I,R107L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
mmCIF provides none of the parsed conditions
|
Resolution 3.21 Å
|
|
9KQ8
Cryo-EM structure of human VMAT2 in complex with valbenazine
Deposited 2024-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M8W,H103I,R107L
|
XW7 valbenazine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.38 Å
|
|
9KQA
Cryo-EM structure of human VMAT2 in complex with Tetrabenazine
Deposited 2024-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M8W,H103I,R107L
|
EBZ (3S,5R,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.28 Å
|
|
9KQE
Cryo-EM structure of human VMAT2 in complex with dopamine.
Deposited 2024-11-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M8W,H103I,R107L
|
LDP L-DOPAMINE × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
9KQM
Cryo-EM structure of human VAChT in complex with VSM
Deposited 2024-11-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M8W,H103I,R107L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
mmCIF provides none of the parsed conditions
|
Resolution 3.50 Å
|
|
9L3Z
Cryo-EM structure of the inactive chemokine-like receptor 1 (CMKLR1)
Deposited 2024-12-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–127（105 aa）
|
Mutation：F259D
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.90 Å
|
|
9L9O
Cryo-EM structure of apo GPR50 with BRIL fusion, anti-BRIL Fab, and anti-Fab Nb complex
Deposited 2024-12-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
|
Mutation：M29W,H124I,R128L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.98 Å
|
|
9LLG
Cryo-EM structure of D1R in complex with de novo designed negative allosteric GEM targeting TM5/6/7
Deposited 2025-01-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain R
30–120（91 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
A1EKL Flupentixol × 1
PLM PALMITIC ACID × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.77 Å
|
|
9LMO
Cryo-EM structure of human apo inactive GPR4
Deposited 2025-01-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
9LMP
Cryo-EM structure of antagonist-bounded inactive human GPR4
Deposited 2025-01-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1L1E NE52-QQ57 × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.65 Å
|
|
9LRS
The structure of MRGPRX4 with PSB-18061
Deposited 2025-02-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1L7J 4-[7-methyl-2,6-bis(oxidanylidene)-1-prop-2-ynyl-8-[2-[3-(trifluoromethyl)phenyl]ethyl]purin-3-yl]butylphosphonic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 2.83 Å
|
|
9LVB
IAA-free AUX1
Deposited 2025-02-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.97 Å
|
|
9M0D
Cryo-EM structure of neurotensin receptor 1 in complex with beta-arrestin 1
Deposited 2025-02-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.41 Å
|
|
9M8P
GPR3 dimer with antagonist AF64394
Deposited 2025-03-12
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
|
Not recorded
|
5YM (Z)-N-(2-hydroxyethyl)octadec-9-enamide × 2
1DO 1-DODECANOL × 4
A1AJD (4Z)-oct-4-en-1-ol × 4
A1EM2 N-[(4-chloranyl-2-propan-2-yloxy-phenyl)methyl]-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；20mM NaCl, 100mM Hepes, 0.003% LMNG, 0.001% GDN
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.42 Å
|
|
9M8V
dimer-GPR3-Gs complex
Deposited 2025-03-13
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain A
23–128（106 aa）
Chain E
23–128（106 aa）
|
Not recorded
|
A1EM2 N-[(4-chloranyl-2-propan-2-yloxy-phenyl)methyl]-5-phenyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine × 2
1DO 1-DODECANOL × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5；20mM NaCl, 100mM Hepes, 0.003% LMNG, 0.001% GDN
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.83 Å
|
|
9MD1
Buspirone-bound serotonin 1A (5-HT1A) receptor-Gz protein complex
Deposited 2024-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–128（106 aa）
Fragment：residues 1-25 of the 5-HT receptor deleted
|
Mutation：L125W
|
YLX Buspirone × 1
CLR CHOLESTEROL × 4
J40 [(2R)-1-[oxidanyl-[(2R,3R,5S,6R)-2,3,5,6-tetrakis(oxidanyl)-4-phosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-3-tetradecanoyloxy-propan-2-yl] (5E,8E)-hexadeca-5,8,11,14-tetraenoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE；Blot force 3 for 3-5 seconds was used and subsequent grids were screened for ice thickness prior to data collection.
|
Resolution 3.03 Å
|
|
9MD1
Buspirone-bound serotonin 1A (5-HT1A) receptor-Gz protein complex
Deposited 2024-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain C
23–128（106 aa）
Fragment：residues 1-25 of the 5-HT receptor deleted
|
Mutation：L125W
|
YLX Buspirone × 1
CLR CHOLESTEROL × 4
J40 [(2R)-1-[oxidanyl-[(2R,3R,5S,6R)-2,3,5,6-tetrakis(oxidanyl)-4-phosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-3-tetradecanoyloxy-propan-2-yl] (5E,8E)-hexadeca-5,8,11,14-tetraenoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE；Blot force 3 for 3-5 seconds was used and subsequent grids were screened for ice thickness prior to data collection.
|
Resolution 3.03 Å
|
|
9OXA
CryoEM structure of Gi-coupled TAS2R43 with aristolochic acid I
Deposited 2025-06-03
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
GOQ 8-methoxy-6-nitro-naphtho[1,2-e][1,3]benzodioxole-5-carboxylic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE-PROPANE
|
Resolution 2.90 Å
|
|
9P1S
A2AR-BRIL in complex with ZM241385 and PGD2
Deposited 2025-06-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
LMN Lauryl Maltose Neopentyl Glycol × 1
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.34 Å
|
|
9P1T
A2AR-BRIL in complex with ZM241385
Deposited 2025-06-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Not recorded
|
LMN Lauryl Maltose Neopentyl Glycol × 1
ZMA 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.15 Å
|
|
9PNG
Co-bound structure of the H77C variant of TriCyt2
Deposited 2025-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Not recorded
|
CO COBALT (II) ION × 2
CA CALCIUM ION × 3
CL CHLORIDE ION × 6
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；21% PEG 1500, 200 mM CaCl2, 100 mM MES (pH 5.5)
|
Resolution 1.97 Å
R-free 0.223
|
|
9PNH
Ni-bound structure of the H77C variant of TriCyt2
Deposited 2025-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Not recorded
|
NI NICKEL (II) ION × 1
CL CHLORIDE ION × 1
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；25% PEG 1500, 200 mM CaCl2,
100 mM HEPES (pH 8.5)
|
Resolution 1.84 Å
R-free 0.227
|
|
9PPM
Mn-bound structure of the H77C variant of TriCyt2
Deposited 2025-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain C
23–128（106 aa）
Chain H
23–128（106 aa）
|
Not recorded
|
NA SODIUM ION × 1
MN MANGANESE (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；25% PEG 1500, 200 mM NH4OAc, 100 mM HEPES (pH 8.5)
|
Resolution 2.53 Å
R-free 0.291
|
|
9PPM
Mn-bound structure of the H77C variant of TriCyt2
Deposited 2025-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain B
23–128（106 aa）
Chain E
23–128（106 aa）
Chain G
23–128（106 aa）
|
Not recorded
|
MN MANGANESE (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；25% PEG 1500, 200 mM NH4OAc, 100 mM HEPES (pH 8.5)
|
Resolution 2.53 Å
R-free 0.291
|
|
9PPM
Mn-bound structure of the H77C variant of TriCyt2
Deposited 2025-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain D
23–128（106 aa）
Chain F
23–128（106 aa）
Chain K
23–128（106 aa）
|
Not recorded
|
MN MANGANESE (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；25% PEG 1500, 200 mM NH4OAc, 100 mM HEPES (pH 8.5)
|
Resolution 2.53 Å
R-free 0.291
|
|
9PPM
Mn-bound structure of the H77C variant of TriCyt2
Deposited 2025-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain I
23–128（106 aa）
Chain J
23–128（106 aa）
Chain L
23–128（106 aa）
|
Not recorded
|
MN MANGANESE (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；25% PEG 1500, 200 mM NH4OAc, 100 mM HEPES (pH 8.5)
|
Resolution 2.53 Å
R-free 0.291
|
|
9PPN
Cu-bound structure of the H77C variant of TriCyt2
Deposited 2025-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Not recorded
|
CU COPPER (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；21% PEG 1500, 200 mM CaCl2, 100 mM MES (pH 5.5)
|
Resolution 1.87 Å
R-free 0.220
|
|
9PPO
Zn-bound structure of the H77C variant of TriCyt2
Deposited 2025-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Not recorded
|
ZN ZINC ION × 2
CA CALCIUM ION × 4
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；25% PEG 1500, 200 mM CaCl2,
100 mM HEPES (pH 8.5)
|
Resolution 1.62 Å
R-free 0.223
|
|
9PPR
Zn- and Bi-bound structure of the H77C variant of TriCyt2
Deposited 2025-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Not recorded
|
ZN ZINC ION × 2
CL CHLORIDE ION × 5
BS3 Bismuth(III) ION × 1
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；298 K；18% PEG 1500, 200 mM CaCl2,
100 mM HEPES (pH 8.5)
|
Resolution 1.57 Å
R-free 0.225
|
|
9PPS
Co- and Bi-bound structure of the H77C variant of TriCyt2
Deposited 2025-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Not recorded
|
BS3 Bismuth(III) ION × 1
NA SODIUM ION × 1
CO COBALT (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；298 K；25% PEG 1500, 200 mM CaCl2,
100 mM HEPES (pH 6.5)
|
Resolution 2.00 Å
R-free 0.257
|
|
9PPT
Ni- and Bi-bound structure of the H77C variant of TriCyt2
Deposited 2025-07-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Not recorded
|
BS3 Bismuth(III) ION × 1
NI NICKEL (II) ION × 1
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；25% PEG 1500, 200 mM CaCl2, 100 mM MES (pH 5.5)
|
Resolution 1.78 Å
R-free 0.267
|
|
9PQ4
Bi-bound structure of the H77C variant of TriCyt2
Deposited 2025-07-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
Chain B
23–128（106 aa）
Chain C
23–128（106 aa）
|
Not recorded
|
CL CHLORIDE ION × 1
NA SODIUM ION × 2
BS3 Bismuth(III) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；25% PEG 1500, 200 mM CaCl2, 100 mM MES (pH 5.5)
|
Resolution 1.48 Å
R-free 0.218
|
|
9PXU
Inactive-state naloxone-mu opioid receptor nanobody6 complex
Deposited 2025-08-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–123（101 aa）
|
Not recorded
|
A1APV Naloxone × 1
NA SODIUM ION × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
9PXV
Nucleotide-free naloxone-mu opioid receptor Gi1 complex
Deposited 2025-08-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–123（101 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
A1APV Naloxone × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.02 Å
|
|
9PXW
Latent-state naloxone-mu opioid receptor-Gi GDPbS complex (rebound)
Deposited 2025-08-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–123（101 aa）
|
Not recorded
|
VSN 5'-O-[(R)-hydroxy(thiophosphonooxy)phosphoryl]guanosine × 1
A1APV Naloxone × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.80 Å
|
|
9PXX
Unlatched-state naloxone-mu opioid receptor-Gi GDPbS complex (rebound)
Deposited 2025-08-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–123（101 aa）
|
Not recorded
|
VSN 5'-O-[(R)-hydroxy(thiophosphonooxy)phosphoryl]guanosine × 1
CLR CHOLESTEROL × 2
A1APV Naloxone × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å
|
|
9PXY
Primed-state naloxone-mu opioid receptor-Gi GDPbS complex (rebound)
Deposited 2025-08-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
A1APV Naloxone × 1
VSN 5'-O-[(R)-hydroxy(thiophosphonooxy)phosphoryl]guanosine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|
|
9PY2
Engaged-state loperamide-mu opioid receptor-Gi GDPbS complex (rebound)
Deposited 2025-08-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–123（101 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
A1CMV 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide × 1
VSN 5'-O-[(R)-hydroxy(thiophosphonooxy)phosphoryl]guanosine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.16 Å
|
|
9PY3
Unlatched-state loperamide-mu opioid receptor-Gi GDPbS complex (rebound)
Deposited 2025-08-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–123（101 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
A1CMV 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide × 1
VSN 5'-O-[(R)-hydroxy(thiophosphonooxy)phosphoryl]guanosine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
9PY4
Primed-state loperamide-mu opioid receptor-Gi GDPbS complex (rebound)
Deposited 2025-08-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
VSN 5'-O-[(R)-hydroxy(thiophosphonooxy)phosphoryl]guanosine × 1
CLR CHOLESTEROL × 2
A1CMV 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.78 Å
|
|
9R42
Quinpirole-bound Dopamine D3 Receptor - Gi Protein Complex
Deposited 2025-05-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1JDS (4aR,8aR)-5-propyl-1,4,4a,6,7,8,8a,9-octahydropyrazolo[3,4-g]quinoline × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.24 Å
|
|
9TMP
Crystal Structure of Native Cytochrome b562 in complex with the synthetic anti-BRIL antibody BAG2.
Deposited 2025-12-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
1–128（128 aa）
|
Not recorded
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.1M MOPS/HEPES-Na pH 7.5, 0.03M bromide, 0.03M fluoride, 0.03M imidazole, 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 12.5% v/v MPD
|
Resolution 2.65 Å
R-free 0.237
|
|
9U80
Cryo-EM structure of conivaptan-bound human vasopressin V2 receptor complex with Fab
Deposited 2025-03-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1ECE Conivaptan × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.94 Å
|
|
9U81
Cryo-EM structure of tolvaptan-bound human vasopressin V2 receptor complex with Fab
Deposited 2025-03-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1ECF Tolvaptan × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.08 Å
|
|
9UPU
Cryo-EM strucutre of CXCR4 complexed with agonist SDV1a
Deposited 2025-04-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å
|
|
9UPV
Cryo-EM structure of CXCR4 complexed with agonist SDVX1
Deposited 2025-04-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
CLR CHOLESTEROL × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.70 Å
|
|
9UVT
Cryo-EM structure of bradykinin B2 receptor (B2R)-BRIL/anti BRIL SRP2070 Fab antibody complex with icatibant
Deposited 2025-05-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain A
23–128（106 aa）
|
Mutation：M258W/H353I/R357L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
|
Resolution 3.29 Å
|
|
9UVU
Cryo-EM structure of bradykinin B2 receptor (B2R)-BRIL/anti BRIL SRP2070 Fab antibody complex with icatibant, focused on receptor
Deposited 2025-05-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–128（106 aa）
|
Mutation：M258W/H353I/R357L
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
|
Resolution 3.69 Å
|
|
9UVV
Cryo-EM structure of Vasopressin receptor 2 (V2R)-BRIL/anti BRIL SRP2070 Fab antibody complex with tolvaptan
Deposited 2025-05-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
23–128（106 aa）
|
Mutation：M243W/H338I/R342L
|
A1IT8 (R)-Tolvaptan × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
|
Resolution 3.02 Å
|
|
9UVW
Cryo-EM structure of Vasopressin receptor 2 (V2R)-BRIL/anti BRIL SRP2070 Fab antibody complex with tolvaptan, focused on receptor
Deposited 2025-05-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M243W/H338I/R342L
|
A1IT8 (R)-Tolvaptan × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
|
Resolution 2.89 Å
|
|
9UVX
Cryo-EM structure of Vasopressin receptor 2 (V2R)-BRIL/anti BRIL SRP2070 Fab antibody complex with OPC51803, focused on receptor
Deposited 2025-05-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–128（106 aa）
|
Mutation：M243W/H338I/R342L
|
A1L9O 2-[(5~{R})-1-(2-chloranyl-4-pyrrolidin-1-yl-phenyl)carbonyl-2,3,4,5-tetrahydro-1-benzazepin-5-yl]-~{N}-propan-2-yl-ethanamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
|
Resolution 3.31 Å
|
|
9UWD
Cryo-EM structure of inactive-DP1
Deposited 2025-05-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.41 Å
|
|
9UY3
Anamorelin bound growth hormone secretagogue receptor in complex with Gq
Deposited 2025-05-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
A1ESD 2-azanyl-N-[(2R)-1-[(3S)-3-[dimethylamino(methyl)carbamoyl]-3-(phenylmethyl)piperidin-1-yl]-3-(1H-indol-3-yl)-1-oxidanylidene-propan-2-yl]-2-methyl-propanamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.3
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.52 Å
|
|
9V2N
Macimorelin bound growth hormone secretagogue receptor in complex with Gq
Deposited 2025-05-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 6
PDB declaration: hexameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
A1EQV Macimorelin × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.3
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.63 Å
|
|
9V81
cryoEM structure of HEP-50768-bound MRGPRX4-Gq complex
Deposited 2025-05-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1L9Y 5-[2-fluoranyl-3-[(2S)-5-(trifluoromethyl)-2,3-dihydro-1-benzofuran-2-yl]phenyl]-1H-1,2,3,4-tetrazole × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.63 Å
|
|
9V82
Local refine map of HEP-50768-bound MRGPRX4
Deposited 2025-05-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1L9Y 5-[2-fluoranyl-3-[(2S)-5-(trifluoromethyl)-2,3-dihydro-1-benzofuran-2-yl]phenyl]-1H-1,2,3,4-tetrazole × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.56 Å
|
|
9VJ5
Cryo-EM structure of 5-HT1AR-GoA in complex with gepirone
Deposited 2025-06-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
30–127（98 aa）
|
Not recorded
|
A1ESA Gepirone × 1
CLR CHOLESTEROL × 2
T7M (2R)-1-(heptadecanoyloxy)-3-{[(R)-hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,5,6-tetrahydroxy-4-(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.69 Å
|
|
9VJ6
Cryo-EM structure of 5-HT1AR-Gi3 in complex with F-15599
Deposited 2025-06-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
30–127（98 aa）
|
Not recorded
|
A1ESC (3-chloranyl-4-fluoranyl-phenyl)-[4-fluoranyl-4-[[(5-methylpyrimidin-2-yl)methylamino]methyl]piperidin-1-yl]methanone × 1
CLR CHOLESTEROL × 2
T7M (2R)-1-(heptadecanoyloxy)-3-{[(R)-hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,5,6-tetrahydroxy-4-(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.62 Å
|
|
9VJE
Cryo-EM structure of 5-HT1AR-GoA in complex with buspirone
Deposited 2025-06-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
30–127（98 aa）
|
Not recorded
|
YLX Buspirone × 1
CLR CHOLESTEROL × 2
T7M (2R)-1-(heptadecanoyloxy)-3-{[(R)-hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,5,6-tetrahydroxy-4-(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.47 Å
|
|
9VJF
Cryo-EM structure of 5-HT1AR-Gi3 in complex with buspirone
Deposited 2025-06-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
30–127（98 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
T7M (2R)-1-(heptadecanoyloxy)-3-{[(R)-hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,5,6-tetrahydroxy-4-(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate × 1
YLX Buspirone × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.70 Å
|
|
9VJG
Cryo-EM structure of 5-HT1AR-Gz in complex with (R)-8-OH-DPAT
Deposited 2025-06-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
30–127（98 aa）
|
Not recorded
|
CLR CHOLESTEROL × 2
T7M (2R)-1-(heptadecanoyloxy)-3-{[(R)-hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,5,6-tetrahydroxy-4-(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate × 1
A1ESE (7~{R})-7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.67 Å
|
|
9VMY
Cryo-EM structure of 5-HT1AR-GoA in complex with TMU4142
Deposited 2025-06-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
30–127（98 aa）
|
Not recorded
|
A1ES2 8-[3-[[(2~{S})-3-(1~{H}-indol-4-yloxy)-2-oxidanyl-propyl]amino]propyl]-8-azaspiro[4.5]decane-7,9-dione × 1
CLR CHOLESTEROL × 2
T7M (2R)-1-(heptadecanoyloxy)-3-{[(R)-hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,5,6-tetrahydroxy-4-(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.86 Å
|
|
9VNF
Cryo-EM structure of 5-HT1AR-GoA in complex with (S)-pindolol
Deposited 2025-06-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
30–127（98 aa）
|
Not recorded
|
A1ES4 (2~{S})-1-(1~{H}-indol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol × 1
CLR CHOLESTEROL × 2
T7M (2R)-1-(heptadecanoyloxy)-3-{[(R)-hydroxy{[(1R,2R,3R,4R,5S,6R)-2,3,5,6-tetrahydroxy-4-(phosphonooxy)cyclohexyl]oxy}phosphoryl]oxy}propan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.74 Å
|
|
9VNY
Cryo-EM structure of Gi coupled Sphingosine 1-phosphate receptor bound with CYM5442
Deposited 2025-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain F
23–128（106 aa）
|
Not recorded
|
A1L3G 2-[[(1~{R})-4-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1~{H}-inden-1-yl]amino]ethanol × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.69 Å
|
|
9VNZ
Cryo-EM structure of Gi coupled Sphingosine 1-phosphate receptor bound with HY-X-1011
Deposited 2025-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain F
23–128（106 aa）
|
Not recorded
|
A1ESY [(2~{S})-2-azanyl-2-[[4-[5-[4-cyclohexyl-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-2-fluoranyl-phenyl]methyl]-3-oxidanyl-propyl] dihydrogen phosphate × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.79 Å
|
|
9VO0
Cryo-EM structure of Gi coupled Sphingosine 1-phosphate receptor bound with Ponesimod
Deposited 2025-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain F
23–128（106 aa）
|
Not recorded
|
A1ESZ (2~{Z},5~{Z})-5-[[4-[(2~{R})-2,3-bis(oxidanyl)propoxy]-3-chloranyl-phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.79 Å
|
|
9VO1
Cryo-EM structure of Gi coupled Sphingosine 1-phosphate receptor bound with SAR247799
Deposited 2025-07-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain F
23–128（106 aa）
|
Not recorded
|
A1LYQ SAR247799 × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.97 Å
|
|
9W0P
CryoEM structure of T2R14 in complex with chlorhexidine and heterotrimeric G protein complex
Deposited 2025-07-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
XC9 1-[6-[azanylidene-[[azanylidene-[[(4-chlorophenyl)amino]methyl]-$l^{4}-azanyl]methyl]-$l^{4}-azanyl]hexyl]-3-[~{N}-(4-chlorophenyl)carbamimidoyl]guanidine × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE；blot for 1s
|
Resolution 3.60 Å
|
|
9W0Q
Cryo-EM structure of T2R14 in complex with tangeretin and heterotrimeric G protein
Deposited 2025-07-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–128（106 aa）
|
Not recorded
|
A1EUI 5,6,7,8-tetramethoxy-2-(4-methoxyphenyl)chromen-4-one × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE；blot for 1s
|
Resolution 3.20 Å
|
|
9W1Q
Human SLC37A4 lateral dimer
Deposited 2025-07-26
|
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.20 Å
|
|
9W1R
S-4048-bound human SLC37A4 monomer
Deposited 2025-07-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain A
23–127（105 aa）
|
Not recorded
|
A1EUP (1~{S},3~{R},4~{R},5~{R})-1-[[(1~{R},2~{S})-2-(4-chlorophenyl)cyclopropyl]methoxy]-3-[(~{Z})-3-imidazo[4,5-b]pyridin-1-yl-3-phenyl-prop-2-enoyl]oxy-4,5-bis(oxidanyl)cyclohexane-1-carboxylic acid × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
9W32
antagonist 1-bound inactive SSTR5 structure
Deposited 2025-07-28
|
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
|
Not recorded
|
A1EVP 1-[2-[[3,5-diethoxy-4-(4-fluorophenyl)phenyl]methyl]-5-oxa-2,6-diazaspiro[3.4]oct-6-en-7-yl]piperidine-4-carboxylic acid × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.59 Å
|
|
9W33
S5A1-bound inactive SSTR5 structure
Deposited 2025-07-28
|
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
|
Not recorded
|
A1EVQ 4-[8-[(2-cyclopropyl-5-ethoxy-4-methyl-phenyl)methyl]-2-oxidanylidene-1,3,8-triazaspiro[4.5]decan-3-yl]benzoic acid × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.69 Å
|
|
9W6W
5-CT-bound serotonin 5A (5-HT5A) receptor-Gi protein complex
Deposited 2025-08-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 5
PDB declaration: pentameric
|
Chain R
22–127（106 aa）
|
Not recorded
|
8K3 3-(2-azanylethyl)-1H-indole-5-carboxamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.13 Å
|
|
9WYL
CryoEM structure of quinol dependent Nitric Oxide Reductase with BRIL
Deposited 2025-09-27
|
Different ligand/ion
|
Assembly 1
Insufficient information
Homooligomer；Protein × 2
PDB declaration: dimeric
|
Chain A
23–127（105 aa）
Chain B
23–127（105 aa）
|
Not recorded
|
HEM PROTOPORPHYRIN IX CONTAINING FE × 4
FE FE (III) ION × 2
CA CALCIUM ION × 2
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å
|
|
9XZN
Teichoic acid flippase TacF from Streptococcus pneumoniae
Deposited 2025-08-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer；Protein × 1
PDB declaration: monomeric
|
Chain B
23–127（105 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.63 Å
|
|
9YFU
Structure of GPR61 bound to inverse agonist compound 15
Deposited 2025-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 4
PDB declaration: tetrameric
|
Chain R
23–127（105 aa）
|
Not recorded
|
A1CWB N-(5-chloro-4,6-dimethylpyrimidin-2-yl)-6-{[(3,5-difluoropyridin-4-yl)methyl]amino}-2-methylpyridine-3-sulfonamide × 1
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.08 Å
|
|
9ZR7
Cryo-EM structure of NRAS(Q61K)-BRIL fusion in complex with Fab(BAG2) and Monobody(Mb24)
Deposited 2025-12-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer；Protein × 3
PDB declaration: trimeric
|
Chain A
29–125（97 aa）
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
mmCIF provides none of the parsed conditions
|
Resolution 3.28 Å
|
